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Abstract 
Autologous mesenchymal stem cell (MSC) therapies have huge potential in 
addressing clinical challenges for otherwise intractable diseases. Label-free, 
intra-operative separation and enrichment of MSC subpopulations would provide 
a step change in delivery of such therapies. The long term goal of this research 
is to use binding proteins to provide a surface with switchable affinity, coupled 
with microfluidics to selectively bind and subsequently collect released cells. The 
specific aim of this thesis was to take the first steps towards achieving this goal, 
by identifying the most suitable binding proteins for cell capture and release in a 
prototype device and determining the feasibility of cell enrichment from complex 
clinical samples such as bone marrow aspirate. 
A prototype device was developed exploiting the cell surface marker CD271 to 
select for MSCs. Affimer binding proteins and a commercially available antibody 
were investigated for specific cell capture and release. Specificity for CD271+ 
cells was demonstrated via flow cytometry using two different cell types. CD271 
binding proteins were immobilised to a low-fouling substrate in a microfluidic 
channel and known mixtures of the two cell populations used to demonstrate 
specific cell capture. Increased flow rates allowed for bound cells to be released, 
collected and analysed, providing evidence that cells remained viable and 
minimally manipulated after enrichment. Clinical samples of bone marrow 
aspirate were then used in the same way and the results compared to gold 
standard methods of cell sorting.  
Results showed that the percentage of CD271+ cells selected from bone marrow 
mononuclear cell populations using the prototype device was similar to results 
obtained using established cell sorting methodologies. This work demonstrated 
that affinity capture via antibody technology, together with a surface designed to 
provide a controlled release mechanism, offers a high-throughput, minimally 
manipulative approach to select and enrich MSC populations for therapeutic 
applications.  
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Chapter 1: Introduction 
Over the last two decades there has been an overwhelming volume of research 
in respect of mesenchymal stem cells (MSCs) and their therapeutic potential. This 
has led to an increasing number of clinical trials involving MSC therapies 
addressing treatment of clinically intractable diseases such as cardiovascular 
disease, neurodegenerative diseases, spinal cord injury, musculoskeletal 
diseases, immune diseases and autoimmune diseases (1). Although the safety 
of MSC therapies is now widely accepted, their efficacy is still under much debate 
and the translation of MSC therapies to commercial products has been slow.  
One of the reasons for the slow rate of translation, and inconsistent clinical 
results, is the challenge involved in harvesting a therapeutic population of cells 
that are present at very small percentages among other cell types in the body. 
MSCs are reported to be present in the range of 1 in 10,000 to 1 in 100,000 cells 
in bone marrow mononuclear cell populations (BM-MNCs)(2), and 1000s of 
MSCs are thought to be required for effective cell therapies (3-5). Currently MSCs 
are enriched by their adherence to plastic, and culture-expanded to gain a larger 
number of cells for therapeutic use. This results in the use of a heterogeneous 
population of cells with unknown properties (6), and could be the reason that the 
efficacy of MSC-based therapies has been variable and not yet been proven. 
Furthermore, there are risks of contamination and phenotypic changes during cell 
culture (7), as well as the processes being time-consuming and expensive.   
Novel MSC enrichment technologies have the potential to change the way MSC 
therapies are delivered leading to more reliable and reproducible results to 
potentially demonstrate therapeutic efficacy. There is a clinical need to enrich a 
high purity population of cells with known properties, using a high-throughput 
technology and at low cost. Moreover, the cells must be minimally manipulated 
(biological characteristics not altered) during the enrichment process to ensure a 
high level of safety and reduce the regulatory requirements for translation. This 
thesis will describe the development of an MSC enrichment device which takes 
advantage of the beneficial properties of microfluidic technology and uses a high 
resolution affinity-capture based mechanism for cell enrichment. The device has 
been designed for intraoperative use with a patient’s own cells (autologous cells) 
therefore reducing both the risk of bio-contamination and the risk of immune 
rejection. Thus, this device has the potential to overcome the limitations 
associated with current MSC enrichment technologies and provide a high purity 
population of clinically beneficial cells for immediate use in autologous cell 
therapies. 
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This thesis will begin by introducing MSCs and reviewing the most recent clinical 
trials using MSC therapy. The therapeutic mechanisms of MSCs will be discussed 
and the main barriers to translation highlighted in more detail. A review of cell 
enrichment technologies used traditionally will demonstrate the limitations of 
these technologies regarding MSC enrichment, and emerging novel technologies 
will help inform this research project further. Finally, MSC surface antigens will 
be evaluated with regards to their ability to select a clinically beneficial population 
of cells. This  information is required for the affinity-based cell capture in this work.  
Following a review of the literature, the overall project aim and specific objectives 
will be described in Chapter 3, as well as chapter outlines for the subsequent 
chapters.  
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Chapter 2: Literature review 
2.1 Introduction to MSCs 
MSCs were first reported by Friedenstein and colleagues in 1970 (8), who 
demonstrated the isolation of clonogenic, proliferating fibroblastic cells from bone 
marrow and their ability to differentiate into bones and osteocytes. Their work was 
expanded upon in the next two decades and in 1999, Pittenger et al. (2) described 
the isolation, expansion and characterisation of multipotent human MSCs 
establishing chondrogenic, adipogenic and osteogenic lineages. Since then 
MSCs have been shown to differentiate into many other cell types including 
cardiomyocytes (9), endothelial cells (10), pancreatic islet cells (11) and neuron-
like cells (12) and this multipotency was thought of as the basis of their 
therapeutic potential. However as the field of MSC research progresses, it has 
been found that the differentiation potential of MSCs is likely to have minimal 
impact on tissue regeneration and the more prominent therapeutic mechanisms 
are related to the paracrine mechanisms and immunomodulatory properties of 
MSCs (1, 13-15)(Section 2.3). 
The regenerative properties of MSCs have been demonstrated when applied to 
a wide range of clinically intractable diseases through in vitro and in vivo pre-
clinical studies (1). This has led to an increasing number of clinical trials for MSC 
therapies over the last 15 years (Figure 2.1). Adult MSCs are an attractive cell 
source for therapies since they avoid the ethical and safety issues associated 
with embryonic and induced pluripotent stem cells. Moreover, they are relatively 
easy to harvest from many different tissues in the body through minimally invasive 
techniques. The therapeutic potential of MSCs is potentially wide-reaching, which 
is reflected in the broad range of disease areas where MSC therapies are being 
investigated. Section 2.2 reviews the latest results from clinical trials in some of 
the most widely investigated conditions. 
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Figure 2.1 The increasing number of registered clinical trials using MSCs  
A search of ClinicalTrials.gov from 01/01/2004 to 01/01/2019 using the 
search term of ‘mesenchymal stem cells’ was used to extract the above data 
which represents registered clinical trials globally. 
 
2.2 The therapeutic potential of MSCs 
A brief review of the current status of MSC therapies is included in this section, 
with a particular focus on the processing of MSCs prior to treatment, and the 
different treatment strategies that have been employed. Figure 2.2 shows a 
summary of some of the conditions where MSCs have the potential to provide 
therapeutic intervention.  
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Figure 2.2 The potential therapeutic applications of MSCs 
Examples of the different conditions where MSC therapies have been 
applied. This diagram was created with BioRender.com. 
 
2.2.1 Musculoskeletal applications of MSC therapies 
Approximately one in three people worldwide live with a chronic, painful 
musculoskeletal condition (16), accounting for the greatest proportion of 
persistent pain across all geographies and ages (17). Although musculoskeletal 
conditions affect people of all ages, the prevalence of conditions increases with 
age (16) and by 2050, the number of people aged 65 and over is expected to 
reach nearly 2.1 billion (18). There are huge concerns for the social and economic 
impact of an ageing population and therefore new treatments for age-related 
conditions is a global priority. Musculoskeletal diseases have therefore become 
one of the primary focuses for MSC therapy and Sections 2.2.1.1 and 2.2.1.2 
discuss the progress of MSC therapies for bone and cartilage regeneration 
respectively – two of the leading areas of research. 
2.2.1.1 MSC therapy for bone regeneration 
MSCs have been widely investigated for the treatment of non-union bone 
fractures due to the important role of MSCs in the natural bone healing process 
(13). In the normal bone healing process, resident stromal, stem and progenitor 
cells work together with pro-inflammatory and anti-inflammatory immune cells as 
well as circulating blood cells to coordinate complex cell signalling which leads to 
the regeneration of new bone (19). However, where injuries result in large bone 
defects, the normal bone healing process may not be sufficient and therapeutic 
intervention is required.   
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Various MSC-based strategies have been explored for this purpose, including 
systemic injection of MSCs (20), direct injection to the injury site (21, 22) and 
injection with pre-fabricated or injectable scaffold materials (23-25). Horwitz et al. 
(1999)(26) reported positive outcomes for the treatment of osteogenesis 
imperfecta by intravenous injection of un-manipulated bone marrow in three 
children, including an increase in total body bone mineral content due to the 
increased growth velocity and lower frequency of bone fractures. Despite this, 
there are reservations regarding the intravenous injection of MSCs since it has 
been reported that many of the cells become trapped in the lungs (27). 
Alternatively, MSCs have been injected by arterial delivery and there are studies 
which show this is a more effective route of administration (28-30). Unfortunately, 
there are still safety concerns surrounding the dose and velocity of injections due 
to changes in cerebral blood flow which increase the risk of stroke development 
(31). 
More favourably, local injection of MSCs overcomes some of the drawbacks 
discussed above. This method was first introduced over 20 years ago where 
Connolly et al. (1991)(32) used autologous bone marrow injection to stimulate 
healing in 18 out of 20 non-union tibial fracture patients. However little was known 
about the number or concentration of cells required for bone union. More recently 
this knowledge gap was addressed by Hernigou et al. (2005)(3), who related the 
number of MSCs in concentrated aspirate samples to the clinical healing of non-
union tibial fractures. It was found that bone union was achieved in 53 out of 60 
patients and where bone union had not occurred, the number of MSCs injected 
had been significantly lower than where treatment had been successful. They 
proposed that a graft requires more than 1000 MSCs per mL in order to be 
successful, with approximately 20 mL of bone marrow graft injected into each 
fracture site. This in turn suggests concentration of aspirate is essential since 
they found that there were on average only 600 MSCs per mL in bone marrow 
aspirate samples that were not concentrated.  
Finally, tissue engineering approaches utilising a variety of natural and synthetic 
biomaterials have been investigated for their therapeutic potential. These 
methods have the advantage of controlling the delivery of MSCs and the potential 
to enhance bone regeneration via the co-delivery of osteoinductive growth factors 
(13). Park et al. (2011)(23) highlighted the benefits of using a calcium phosphate 
cement mixed with alginate to increase cell viability, proliferation and osteogenic 
differentiation of MSCs in vitro, whilst Kim et al. (2007)(25) used a scaffold made 
from acrylated hyaluronic acid to deliver MSCs and bone morphogenic protein-2 
to rat calvarial defects in vivo. They found that there was the most mature bone 
formation in this treatment group compared to four control groups.  
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Although many pre-clinical studies have claimed to show the efficacy of MSC 
therapy for bone regeneration, published results from registered national and 
international clinical trials are lacking (13). A review carried out by Oryan et al. 
(2017)(13) stated that of 16 registered trials to treat long bone defects with MSCs, 
three treatment categories could be established; trials that used direct injection 
of MSCs without in vitro expansion (4 in total), trials that used direct injection of 
expanded MSCs (5 in total) and trials that used MSCs with bone substitutes (8 in 
total). However, of all of these trials only one trial in the last category had 
published results. Here, Liebergall et al. (2013)(33) used immunoselected MSCs 
(see Section 2.5.1.4) combined with platelet-rich plasma and demineralised bone 
matrix to treat 24 patients with tibial fractures. It was found that the treatment 
reduced the healing period by approximately 40 days compared to no 
intervention, however it was not possible to elucidate which factor/factors of the 
combined treatment contributed to the improved outcome.  
There are more published results available for the treatment of oral and 
craniofacial bone repair using MSCs - the majority of which report positive 
outcomes (34-38). Three of these studies use MSCs concentrated by a ‘bone 
marrow aspirate concentration’ system (BMAC-Kit; Harvest Technologies 
Corporation)(36-38)(see Section 2.5.1.2), one used bone marrow aspirate with 
no concentration (35) and the final study used cells enriched for MSCs in a 
bioreactor (34). The only study to report no difference between MSC treatment 
and control treatments was carried out using cells expanded in normal tissue 
culture conditions (39). 
At this point it is deemed too soon to advocate MSC therapy for bone 
regeneration due to the lack of published clinical trials and controversies in results 
(13). The major barriers to translation are reported to be the limited number of 
MSCs available for implantation (therefore often requiring in vitro expansion), the 
heterogeneity in the quality of MSCs from different donors and the lack of 
standardisation in procedures (40).  
 
2.2.1.2 MSC therapy for cartilage regeneration 
Unlike bone defects, cartilage defects have very limited ability to self-repair due 
to the avascular and aneural nature of cartilage tissue (41, 42). Cartilage loss can 
occur as a consequence of traumatic injury or through chronic degeneration 
which eventually leads to decreased mobility and can frequently progress to 
osteoarthritis – one of the most common musculoskeletal disorders and the 11th 
cause of disability in the world (43, 44). Current surgical interventions for cartilage 
damage include bone marrow stimulation, mosaicplasty and autologous 
- 8 - 
chondrocyte implantation, however there are inherent complications with such 
procedures, for example; donor site morbidity, high costs and the need for two 
operations (41, 45). Furthermore, for the treatment of osteoarthritis these 
interventions are restricted to the repair of focal defects and there are no 
treatments available for the global pathology of osteoarthritis (46). The innate 
ability of MSCs to differentiate into chondrocytes, as well as their 
immunomodulatory and inflammatory properties, provides an alternative 
therapeutic approach for the treatment of cartilage defects as well as related 
diseases such as osteoarthritis. 
Similarly to bone regeneration strategies, both cell therapy (direct injection of 
MSCs) and tissue engineering approaches (cell-scaffold combinations) have 
been investigated for cartilage repair. A systematic review of all in vitro, pre-
clinical and clinical studies of MSC therapy for cartilage repair was carried out by 
Goldberg and colleagues (2017)(42), who found that the majority of pre-clinical 
studies (85%) used tissue engineering approaches rather than direct injection. In 
clinical trials, MSCs were delivered in a suspension with various different co-
stimulators either through arthroscopic implantation, open surgery or intra-
articular injection. The review concluded that there was a lack of continuity 
between in vitro, pre-clinical and clinical studies and that the efficacy of MSC 
treatments was yet to be established.  
In a review of MSC therapy for the treatment of osteoarthritis, Freitag et al. 
(2016)(46) highlighted the clinical results from two methods of therapy – MSC 
scaffold transplantation techniques and MSC injectable techniques. Using a 
scaffold transplantation technique, Wakitani et al. (1994)(47) demonstrated that 
culture-expanded adherent MSCs embedded in a collagen gel and transplanted 
into rabbit knee articular cartilage defects resulted in some hyaline-like cartilage 
formation, however there was no significant difference between the cell-
transplanted group and the cell-free control group. Nejadnik et al. (2010)(48) 
compared autologous chondrocyte repair to the use of autologous MSCs (both 
cell types expanded in culture prior to transplantation) in 72 age-matched patients 
and found that BMSCs were as effective as chondrocytes for articular cartilage 
repair and had the advantages of one less knee surgery, reduced costs and 
minimised donor-site morbidity. Using an injectable technique, Emadedin et al. 
(2012)(49) used intra-articular injection of passage-2 MSCs to treat six patients 
with osteoarthritis of the knee. They found that six months post-injection, pain 
was reduced and walking distance was improved, however they proposed that 
repeat injections may have been more beneficial.  
Whilst the methods of treatment vary, so does the cell dosage in each case. In 
an in vitro study, it was found that hyaluronic acid hydrogels with higher cell 
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seeding density (60 million cells/mL) produced constructs with improved 
biomechanical properties compared to lower cell seeding densities (20 million 
cells/mL)(50). In a pre-clinical study, MSCs embedded in a collagen gel were 
transplanted into cartilage defects in rabbit knees and it was found that a cell 
seeding density of 50 million cells/mL resulted in significantly more cartilage 
matrix production than a cell seeding density of 1 million cells/mL (51). However, 
there is a need for caution in using high cell seeding densities associated with 
higher metabolic demands and the limited capacity for oxygen, carbon dioxide 
and other nutrients to diffuse within a graft (52). 
Whilst the safety of MSC treatment appears promising, the efficacy of treatments 
remains unclear due to the myriad of different strategies explored. What is clear, 
is the need for a single-stage procedure to avoid expensive, time-consuming and 
potentially harmful in vitro expansion of cells requiring a two stage procedure (42).  
2.2.2 MSC therapy for cardiovascular diseases 
Cardiovascular diseases are a leading cause of death in the world and are 
formally recognised by the United Nations as a major concern for global health 
(53). In 2015, there were an estimated 422.7 million cases of cardiovascular 
disease globally and 17.92 million deaths (53). As with musculoskeletal diseases, 
the risk of cardiovascular disease increases with age and therefore the 
implications of an ageing population must be addressed. Adult heart tissue has 
an inability to replace cells lost due to disease and MSC therapy has the potential 
to promote regeneration. Although cardiac cell-based therapies have shown 
limited cardiomyocyte differentiation capacity and poor long-term engraftment in 
vivo (14), there has been therapeutic benefit established via their paracrine 
mechanisms (see Section 2.3.3).  
Evidence to support the safety and efficacy of MSC therapy for cardiac 
regeneration has been collected via a number of independent clinical studies (54-
58). A randomised placebo-controlled trial showed that intra-myocardial 
injections of culture-expanded MSCs improved myocardial function in patients 
with ischaemic heart failure compared to phosphate buffered saline injections 
(54). Another clinical trial investigated the use of in vitro lineage-directed 
cardiopoietic stem cells derived from MSCs (and obtained from bone marrow 
aspirate) to treat advanced heart failure (55). It was found that intra-myocardial 
injection of cardiopoietic stem cells led to left ventricular reverse modelling – a 
marker of improved outcome in patients with advanced heart failure.  
Interestingly, a phase I and phase II randomised, blinded and placebo-controlled 
trial with 65 patients with ischaemic cardiomyopathy compared both culture-
expanded MSCs and MSCs derived from the concentration of whole bone 
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marrow, with placebo controls (58). It was found that trans-endocardial stem cell 
injection with MSCs derived from either method were safe and both resulted in 
some improved outcomes compared to placebo controls. However there were 
some measured outcomes that were only significantly improved for culture-
expanded MSCs rather than MSCs concentrated from bone marrow aspirate 
suggesting MSCs isolated by density gradient centrifugation (see Section 2.5.1.2) 
were inferior to culture-expanded MSCs (see Section 2.5.1.1). 
The majority of MSC therapies used in clinical studies for cardiac regeneration 
appear to utilise culture-expanded MSCs. Although these have provided a 
promising outlook, the expansion of cells in vitro requires expensive and time-
consuming procedures which more sophisticated isolation methods could avoid.  
2.2.3 MSC therapy for neurological diseases  
Neurological disorders are a large cause of disability and death worldwide. A 
systematic analysis for the Global Burden of Disease Study 2015 showed that 
the burden of neurological diseases had increased substantially over the previous 
25 years due to population ageing (59). It is predicted that the number of patients 
who will need neurological care will continue to grow in the coming decades. In 
addition, spinal cord injury (SCI) caused by traumatic events causes a substantial 
financial burden on health care systems due to the need for high-level acute care 
in the short term and associated secondary complications in the long term (60). 
Traffic accidents have been found to be the most common cause of SCI however 
falls in the elderly population are the second most common cause. 
For neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s 
disease, Huntingdon’s disease, amyotrophic lateral sclerosis (ALS) and multiple 
system atrophy, cumulative data has suggested common cellular and molecular 
pathological mechanisms (61). MSC transplantation in models of these diseases 
has improved survival rates, reduced pathology and rescued cognitive function 
decline. The proposed mechanisms for improvement include neuroprotection by 
secretion of neurotrophic factors, induction of neurogenesis, modulation of 
inflammation and prevention of misfolded protein aggregation (61).  
In terms of clinical trials, the majority reported to date have been early phase trials 
focussing on the demonstration of safety. For the treatment of multiple sclerosis 
and ALS, Karussis et al. (2010)(62) reported that intrathecal and intravenous 
injections of culture-expanded MSCs in 34 patients had no major adverse effects 
and elicited immunomodulatory effects. Similar trials for the treatment of ALS also 
confirmed the safety and possible benefits of MSC injections with pending phase 
II results (63-65). For the treatment of ischaemic stroke Lee et al. (2010)(66) 
carried out a long-term (5-year) assessment of 16 patients receiving intravenous 
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injection of culture-expanded MSCs compared to a control group. It was 
concluded that the MSC therapy was safe with no significant side effects whilst 
also showing some clinical improvement. In a randomised trial including 33 
patients with multiple system atrophy, the intra-arterial and intravenous injection 
of culture-expanded MSCs (2 doses of 40 million cells) reported no serious 
adverse effects and led to decreased deterioration compared to a placebo group 
(67).  
Similarly, the secretion of neuroprotective cytokines such as vascular endothelial 
growth factor, glial-cell-line-derived neurotrophic factor and brain-derived 
neurotrophic factor can increase neural regeneration, strengthen axon growth 
and revive damaged neurons in SCI (68). A systematic review carried out by Xu 
et al. (2019)(68) assessed the safety and efficacy of MSCs in treating SCI 
patients and found 11 studies that met the inclusion criteria. Meta-analysis of the 
11 studies showed that some sensory functions were significantly improved by 
MSC transplantation, however, there was no significant difference found in motor 
functions. In contrast, locomotor improvements have been reported in animal 
models using MSC transplantation (69, 70). There were no serious or permanent 
adverse effects reported from the 11 studies.  
MSC therapy for neurological diseases and SCI is in the early stages of clinical 
assessment but has so far been shown to be safe and has demonstrated some 
therapeutic effect. Similar to MSC therapies explored for cardiovascular disease, 
MSCs have been expanded in vitro in many of the clinical trials to date.  
2.2.4 MSC therapy for other diseases  
Although the main disease areas being targeted for potential treatment with 
MSCs have been discussed above, there are many other examples of where 
stem cell therapy has produced encouraging results in clinical studies. For 
example, in the treatment of graft versus host disease (GvHD), a prominent case 
study in 2004 showed donor MSCs expanded in culture and injected 
intravenously into a patient with acute GvHD (and unresponsive to all other 
therapy) had a rapid healing effect. This case study sparked the quick succession 
of numerous other studies including two large multicentre phase II trials also 
demonstrating remarkable efficacy (71, 72). MSC therapy has also been found to 
be safe and effective for digestive system disorders including liver disease (73), 
inflammatory bowel diseases (Crohn’s disease (74) and ulcerative colitis (75)) 
and coeliac disease (76). In particular, a related illness of Crohn’s disease - 
perianal fistulas - was successfully addressed by Dietz et al. (2017)(77), where 
83% of patients had complete clinical healing six months after implantation of 
MSCs in a bioabsorbable matrix.   
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2.2.5 Summary of MSC therapeutic potential demonstrated in 
clinical trials to date 
In conclusion, in the last two decades there has been a vast amount of in vitro, 
pre-clinical and clinical research into the safety and efficacy of MSC therapies. 
This brief review has focussed on the results of registered clinical trials in some 
of the most prevalent disease areas. The safety of MSCs has been confirmed 
with no serious or permanent adverse effects reported in any of the clinical trials 
reviewed. However, there appears to be controversial results regarding the 
efficacy of MSCs across the majority of conditions investigated. Although the 
outlook remains promising it is clear that there are limitations to current 
methodologies. These limitations and challenges are discussed in more detail in 
Section 2.4 - including the clinical need for the development of novel cell 
enrichment technologies. In addition, although the therapeutic mechanisms of 
MSCs are not completely understood, some key themes have been recognised 
which are outlined in Section 2.3. Isolation of MSC subpopulations with higher 
purities would help elucidate these specific mechanisms further and provides 
another motivation for the development of novel enrichment technologies. 
 
2.3 Potential therapeutic mechanisms of MSCs 
It is thought unlikely that there is a uniform MSC therapeutic mechanism for all 
disease states, however, there are common attributes that have been identified 
in many in vitro and in vivo studies that are likely to contribute to the beneficial 
effects of MSC therapies. The identified mechanisms are described below and 
summarised in Figure 2.3. 
 1
3
 
 
Figure 2.3 The proposed therapeutic mechanisms of MSCs 
The differentiation potential, homing capabilities, paracrine effects and immunomodulatory behaviour of MSCs have been identified 
as therapeutic mechanisms in in vitro and in vivo studies. This diagram was created with BioRender.com and adapted from (78).
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2.3.1 Homing efficiency of MSCs 
When MSCs are injected systemically they have the ability to home to damaged 
tissues exhibiting inflammation (79, 80). This homing mechanism has been 
shown to involve important cell trafficking-related molecules such as chemokines, 
adhesion molecules and matrix metalloproteinases (MMPs)(1). Of these, some 
key mediators have been identified; the stromal-derived factor 1 (SDF-1)/C-X-C 
chemokine receptor type 4 (CXCR4) axis and the hepatocyte growth factor 
(HGF)/MET proto-oncogene (c-MET) receptor tyrosine kinase axis (81, 82). SDF-
1 and HGF are upregulated at sites of tissue damage and the results of an in vitro 
study carried out by Bo-Ra Son et al. (2006)(81) indicated that these factors along 
with MMPs could be involved in the migration of MSCs. Further in vivo evidence 
was reported by Kitaori et al. (2009)(83), where it was shown that SDF-1/CXCR4 
signalling was crucial for the recruitment of MSCs to a fracture site in a mouse 
model. 
In order for MSCs to reach damaged tissue, they must be able to transmigrate 
the endothelial barrier (84). Schmidt et al. (2006)(84) found that by direct cell-cell 
contacts, MSCs integrated into the endothelial wall of capillary vessels and could 
fully pass the endothelial barrier within 30 minutes of perfusion in an isolated 
heart. It was found by Rüster et al. (2006)(85) that the ability to interact with 
endothelial cells involved MSCs engaging vascular cell adhesion molecule-1 
(VCAM-1) and very late antigen-4 (VLA-4). It has also been demonstrated that 
inflammatory cytokines such as transforming growth factor β1, interleukin 1β and 
tumour necrosis factor-α (TNF- α) promoted invasion and migration of MSCs 
through the extracellular matrix by up-regulation of MMP activity (86).  
The molecules described above are proposed to drive the migration of MSCs 
however the precise mechanisms are not fully understood (78). Moreover, many 
intravenously administered MSCs become trapped in the lungs and do not reach 
the damaged tissue (87, 88). 
2.3.2 Differentiation potential of MSCs 
While the multipotent potential of MSCs has been largely documented in vitro and 
in vivo, there is accumulating evidence that their contribution to tissue 
regeneration is largely via indirect mechanisms rather than the direct replacement 
of lost tissue (1, 13, 78). Nevertheless, there are reports that describe the 
differentiation of transplanted MSCs in models of injury; Sasaki et al. (2008)(89) 
injected MSCs derived from green fluorescent protein (GFP) transgenic mice 
intravenously into back skin-injured mice and found GFP-positive cells 
associated with specific markers for keratinocytes, endothelial cells and pericytes 
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at the site of the wound – demonstrating the transdifferentation of injected MSCs 
as well as their homing efficiency. Li et al. (2010)(90) investigated the 
differentiation characteristics of MSCs transplanted into a mouse model of renal 
tubular injury. They reported that MSCs were able to differentiate toward renal 
tubular epithelium and contributed to the maintenance of structural integrity 
during the repair process. In contrast, Oryan et al. (2017)(13) suggested that 
MSCs indirectly contribute to cell differentiation (in the case of bone regeneration) 
via an MSC-mediated reduction in TNF-α, which inhibits osteoblast differentiation 
(91). 
It has been proposed that in order to benefit from MSC differentiation, local 
administration of cells or administration with a scaffold material is the preferred 
method (78). This is due to reports that systemically injected MSCs are likely to 
be trapped in the lungs and other tissues (88, 92) as discussed in Section 2.3.1.  
2.3.3  Paracrine effects of MSCs 
It is becoming more widely acknowledged that the therapeutic effects of MSCs 
are largely attributable to their ability to secrete a wide variety of cytokines, 
chemokines and growth factors (78). Once MSCs have migrated to damaged 
tissues, they interact with local stimuli such as inflammatory cytokines, ligands of 
Toll-like receptors and hypoxia, which signals MSCs to secrete molecules 
mediating processes such as angiogenesis and the prevention of cell apoptosis 
(1). It was found that the release of vascular endothelial growth factor and 
fibroblast growth factor 2 – both promotors of angiogenesis -  was increased when 
MSCs were exposed to the stimulants TNF-α, endotoxin and hypoxia (93). An 
increase in angiogenic factors could improve regional blood flow at a site of injury 
as well as stimulating autocrine mechanisms (93). Xu et al. (2007)(94) found that 
MSCs exhibited an anti-apoptotic effect mediated by the release of interleukin-6 
when in direct contact with lymphocytes.  
A multitude of other proteins that are upregulated by MSC paracrine mechanisms 
have been identified, including; Toll-like receptor 2/6 (95), transforming growth 
factor-β1 (96), interleukin-8, monocyte chemotactic protein-1, MMPs, pentraxin 3 
and cathepsin L (97), however, the majority of studies have been carried out in 
vitro. It is therefore necessary to systematically examine the MSC secretome in 
vivo to further inform MSC therapies (98).  
2.3.4 Immunomodulatory behaviour of MSCs 
The unique immunomodulatory behaviour of MSCs was first shown by Liechty et 
al. (2000)(99) when human MSCs were transplanted into foetal sheep early in 
gestation before and after the expected development of immunological 
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competence. They found that there was long-term engraftment of MSCs even 
after the development of immunological competence. It has since been found that 
MSCs have the ability to inhibit the activation and proliferation of T cells,  B cells, 
dendritic cells, macrophages and natural killer cells (100, 101). The underlying 
mechanisms of suppression are linked with inflammatory stimuli such as nitric 
oxide, indoleamine 2,3, dioxygenase, prostaglandin E2, tumour necrosis factor-
inducible gene 6 protein, chemokine ligand 2 and programmed death ligand 1 via 
stimulation of inflammatory cytokines such as interferon-γ, TNF-α and interleukin-
1 (1). 
As well as the inhibition of immune cells, MSCs also preferentially activate T-cell 
subsets with regulatory activity (Tregs) and maintain the capability of Tregs to 
suppress self-reactive T-effector responses (78, 102). This means that even 
short-lived MSCs could have long lasting effects on immunoregulation. These 
immunomodulatory properties have important implications for the treatment of 
autoimmune diseases and GvHD (Section 2.2.4).  
Furthermore, it has emerged that not only can MSCs negatively modulate a high-
inflammation environment but if the levels of inflammatory cytokines are low, 
MSCs stimulate cells of the immune system to release proinflammatory 
molecules and promote host defence (98). Monocytes arriving at an inflammatory 
environment can develop into M1 macrophages or M2 macrophages depending 
on microenvironmental cues (103). The M1 macrophages release 
proinflammatory cytokines stimulating local inflammation. This demonstrates that 
MSCs and macrophages have dynamic regulatory feedback and can switch 
between proinflammatory and anti-inflammatory activities to create a loop that 
prevents excessive tissue damage and promotes repair (103). 
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2.4 Clinical challenges of MSC therapy 
The large amount of research into MSCs and their therapeutic mechanisms has 
led to an increasing number of clinical trials using MSCs over the last 15 years 
(see Figure 2.1). However, there are still only a handful of therapies available 
commercially for clinical use and none are FDA-approved (104). Osiris 
Therapeutics (United States) completed the first major industry-sponsored phase 
III trial of allogeneic bone marrow-derived MSCs for treatment of GvHD in 2009 
(105). The product – Prochymal – did not result in a significantly different benefit 
compared to a placebo treatment. However, subset analysis revealed that 
children were more responsive than adults and this led to market approval for 
Prochymal in Canada to treat children with acute GvHD. A similar allogeneic MSC 
product for treatment of GvHD is approved for use in Japan (TEMCELL). 
The first MSC-based product approved for use in Europe was in 2018 to treat 
Crohn’s-related anal fistulas (105). The product - Alofisel - contains expanded 
human allogeneic MSCs extracted from adipose tissue. Two further MSC-based 
products are CARTISTEM and HeartSheet approved for use in Japan and South 
Korea respectively (104). CARTISTEM uses allogeneic umbilical cord-derived 
MSCs for the treatment of knee cartilage defects and HeartSheet uses cultured 
autologous skeletal myoblast cells for treatment of severe heart failure. Currently 
these are the only commercially available MSC-based products. 
This slow rate of translation is also reflected in the data used to create Figure 2.1. 
If the number of clinical trials is categorised by study phase, it becomes clear that 
the majority of studies are in early phase I/phase I or phase II, and that this trend 
has not changed over the past 15 years (Figure 2.4). There has been a slight 
increase in the percentage of clinical trials in Phase I in the last 15 years but a 
slight decline in the number of clinical trials in Phase II/Phase III. A small number 
of clinical trials have reached Phase IV in the last five years compared with none 
in the first 10 years. Altogether this data confirms that there is a hurdle between 
demonstrating the safety of MSC therapies and demonstrating the efficacy. Some 
of the key barriers to translation are discussed in Sections 2.4.1 and 2.4.2. 
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Figure 2.4 The percentage of registered clinical trials involving MSCs in 
each study phase  
This global data was extracted from ClinicalTrials.gov using a search term 
of ‘mesenchymal stem cells’ and filtered by year and phase of study. 
 
2.4.1 The lack of standardisation in MSC pre-clinical research and 
clinical trials for MSC therapy  
One of the reasons that efficacy has not yet been proven for many MSC therapies 
is the lack of standardisation between clinical trials and different research groups 
in the field. Following a review of published results from clinical trials (Section 
2.2), it is evident that there is no clear consensus on the most appropriate 
therapeutic strategy for MSCs, including the source of MSCs, the delivery method 
and what constitutes a beneficial dose of cells. This means that there is a lack of 
evidence behind each individual strategy. Although these limitations are common 
across all disease areas, it is likely that these factors will ultimately be application-
specific and there must be a concerted effort to design more large, multicentre 
studies using standardised protocols.  
In terms of sources of MSCs, bone marrow-derived MSCs (BM-MSCs) have been 
most commonly used (106), however, MSCs are found throughout the body and 
the best source for therapies remains unclear (46). Bone marrow has been 
traditionally used since it can be relatively easily accessed using already available 
tools (from bone marrow transplantation procedures) however, adipose tissue-
derived MSCs (AT-MSCs) and umbilical cord-derived MSCs (UC-MSCs) have 
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been found to be promising alternative sources that can be harvested through 
less invasive procedures (107). In a comparison of all three sources, Kern et al. 
(2006)(107) found that UC-MSCs had a higher proliferation capacity whereas AT-
MSCs contained the highest frequency of MSCs. Despite this, UC-MSCs were 
not as reliably sourced as AT-MSCs and BM-MSCs. MSCs have also been 
isolated from dental pulp tissue (108), skeletal muscle tissue (109), and amniotic 
fluid (110). 
A further debate concerns whether MSCs should be allogeneic or autologous for 
clinical therapies. MSCs are immunosuppressive with low immunogenicity and 
thus can avoid eliciting immune responses in recipients (111)(Section 2.3.4). 
They also have the advantage of being available as ‘off-the-shelf’ products which 
is favourable in terms of time, cost and quality assurance. It is noted that of the 
handful of commercially available products, all but one utilises allogeneic MSCs. 
Despite this, there are reports that allogeneic MSCs are not fully immune 
privileged and without immunosuppressive therapy can cause an immune 
response and graft rejection (112-114). A safer approach to MSC therapy is to 
use autologous cells where there is no possibility of immune rejection and no 
need for immunosuppressive therapies. Perhaps the reason that autologous cell 
therapies are lagging behind allogeneic cell therapies, is due to the lack of 
adequate technology available for autologous cell processing – the focus of this 
research project.  
 
2.4.2 Inadequate isolation methods for MSCs 
In the majority of clinical trials to date, the processing of cells prior to therapy has 
been via MSC isolation methods which have a number of limitations. In almost all 
of the clinical trials reviewed, cells were expanded in vitro to enrich a therapeutic 
population with sufficient cell numbers. There are a number of issues associated 
with the in vitro expansion of cells; first and foremost, the enrichment of MSCs 
based on their adherence to tissue-culture plastic yields a highly heterogeneous 
population (6). This means that large cell numbers are required since not all cells 
will be therapeutic in nature. Moreover, it could be the reason why the efficacy of 
treatments in clinical trials has been inconsistent - different culture methods yield 
different populations of cells with unknown properties. In addition, in vitro 
expansion requires Good Manufacturing Practices (115), is time-consuming 
(often taking weeks to acquire sufficient cell numbers) and costly. Finally, it has 
been shown that culturing MSCs in vitro – with growth factors - can change their 
characteristics, such as their becoming more susceptible to apoptosis and loss 
of clonogenic potential (7).  
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Enrichment of MSC populations for therapies is necessary since MSCs are 
present at 0.001–0.01% of mononuclear cells in bone marrow aspirates (2). 
Enriching MSCs by their adherence to tissue-culture plastic has been the most 
commonly adopted method, however techniques have also been used to 
concentrate the mononuclear cell fraction of bone marrow aspirate using density 
gradient centrifugation (Section 2.5.1.2). Unfortunately these methods also yield 
a heterogeneous population of cells, with low numbers of MSCs, resulting in 
many of the same limitations as culture-expanded cells. In one clinical trial, MSCs 
were isolated by immunoselection (33)(Section 2.5.1.4) providing a population of 
MSCs with higher purity. However no comparison was made with MSCs isolated 
by alternative techniques and therefore this study did not confirm whether this 
technique resulted in a greater therapeutic effect. There are also concerns with 
the safety of current immunoselection procedures (discussed in Section 2.5.1.4) 
and controversy over the specific identity of MSCs (discussed in Section 2.6.1) 
which further limit this study.  
There are inherent issues with the isolation techniques currently available for 
MSC processing prior to therapeutic applications and both Diogo et al. (2012)(6), 
and Zhu et al. (2013)(116), described the development of novel stem cell isolation 
and bioprocessing techniques as a crucial factor for the success of stem cell 
therapies. In Section 2.5, current MSC enrichment methods are reviewed in more 
detail as well as some of the emerging methods which have informed this 
research project. 
 
2.5 Introduction to cell sorting methods for MSC enrichment 
In this section, conventional methods of cell sorting will be discussed as well as 
their limitations in respect of MSC therapies. Following this there will be a review 
of the most promising future directions in this field. 
 
2.5.1 Traditional cell sorting methods for MSC enrichment 
2.5.1.1 Cell-culture based enrichment of MSCs  
MSCs can be enriched from different tissues in the body based on their 
preferential adherence to plastic. This mainly eliminates haematopoietic cells 
since they are non-adherent and can be discarded during medium exchange (6, 
117). However, some non-mesenchymal stem cells (stromal cells which do not 
conform to the current formal criteria – see Section 2.6.1) also adhere to the 
tissue culture plastic leading to a heterogeneous and undefined population of 
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cells. Steps have been taken to increase the purity of MSC populations during in 
vitro expansion, for example, using differential trypsinization and selective 
medium during cell culture; differential trypsinization is where MSCs are released 
from the tissue culture plastic during short incubation times but other cell types 
are not (117), and using different compositions of cell culture medium can favour 
the proliferation of various stem cells over other cell types (116). Unfortunately, 
there is no standardised conditioned medium for MSC culture due to the lack of 
a comprehensive list of conditioned medium components (118). Factors such as 
the glucose concentration, serum concentration, amino acids, inorganic salts and 
vitamins can affect the proliferation, morphology, clonogenicity and differentiation 
potential of isolated cells (118, 119). Although these techniques may increase the 
homogeneity of populations, enrichment by preferential adherence is unlikely to 
produce a pure population of MSCs for cell therapies.   
Moreover, there are several additional issues associated with the in vitro 
expansion of MSCs which are discussed in Section 2.4.2. Namely the 
requirement for Good Manufacturing Practices, the timely processes involved, 
the risk of contamination during cell culture and the high costs associated. The 
logistical aspects for large-scale manufacturing of cell therapies which require in 
vitro expansion are a huge challenge and barrier to translation.  
 
2.5.1.2 Density gradient centrifugation (DGC) for MSC enrichment 
Density gradient centrifugation (DGC) is one of the simplest methods of cell 
enrichment. A density gradient is established longitudinally in a test tube and the 
cell sample is added to the top (116). When the solution is centrifuged, cells with 
higher density cross the interface between the two layers and sediment at the 
bottom whilst cells that have a lower density settle at the interface (6).  
This method is commonly used to isolate mononuclear cells from bone marrow 
using a Ficoll-Paque density gradient (6)(Figure 2.5), however this technique has 
extremely low resolution and yields low numbers of MSCs (106). The resulting 
population is heterogeneous consisting of differentially matured B-cells, T-cells 
and monocytes as well as the more rare progenitor cells which includes 
haematopoietic stem cells and MSCs (120). DGC can be used as a preparative 
step for a higher resolution technique such as magnetic-activated cell sorting 
(MACS) or fluorescent-activated cell sorting (FACS)(Sections 2.5.1.3 and 
2.5.1.4), although this has also been found to considerably reduce the yield of 
bone marrow mononuclear cells (BM-MNCs) and therefore MSCs, with nearly 
75% loss of mononuclear cells using Ficoll-Paque DGC (120). In a separate 
study, it was found that red blood cell lysis of 6 mL of bone marrow aspirate 
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yielded the same number of MSCs as Ficoll-Paque DGC of 60 mL of bone marrow 
aspirate, suggesting that red blood cell lysis is a superior method to isolate 
mononuclear cells (121), although the higher volume of aspirate could also affect 
the mononuclear cell count independently from the isolation method. 
 
 
Figure 2.5 Density gradient centrifugation (DGC) for the isolation of 
mononuclear cells from bone marrow aspirate 
Bone marrow mononuclear cells are commonly isolated from bone marrow 
aspirate using a Ficoll-Paque density gradient. The left-hand side shows the 
density gradient solution and cell sample before centrifugation, and the 
right-hand side shows the solutions after centrifugation where the cells have 
been separated according to their density. This diagram was created with 
BioRender.com. 
 
An intraoperative bone marrow aspirate concentrate (BMAC) device 
(SmartPReP®2) has been developed which concentrates bone marrow total 
nucleated cells (122). The BMAC device was found to have a superior 
performance to other bone marrow aspirate concentration systems (BioCUE® 
and MAGELLAN®) in terms of the number and concentration of MSCs after 
centrifugation (123), and cells isolated from the BMAC device were also shown 
to have comparable functional activity to Ficoll-Paque DGC isolated cells and 
achieved a greater yield (122). However, no comparison to higher resolution 
techniques such as immunoselected cells has been made.  
Furthermore, it was found that contaminating cells in heterogeneous populations 
isolated by DGC compromised the therapeutic effect of MSCs (124, 125), and 
factors such as the centrifugation speed and washing buffers could impair the 
functionality and recovery of mononuclear cells (126). Mouquet et al. (2011)(125) 
found that 37% of rabbit BM-MNCs were apoptotic after Ficoll-Paque DGC and 
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the presence of apoptotic cells among mononuclear cells reduced the efficacy of 
cardiac cell therapy after myocardial infarction. Assmus et al. (2010)(124) 
reported how contaminating red blood cells affected the functionality of BM-
MNCs in a dose-dependent manner and the degree of contamination was a 
determining factor of the extent of recovery in patients with acute myocardial 
infarction. Finally, van Beem et al. (2008)(126) studied the effects of different 
DGC protocols and found that lower centrifugation speeds resulted in lower 
mononuclear cell recovery, and washing buffer without human serum albumin 
and heparin resulted in lower mononuclear cell recovery and impaired function 
measured by clonogenic capacity.  
DGC has a number of associated issues and although a simple method of 
enrichment, it is far from an ideal method. To attain high purity MSC populations, 
higher resolution techniques have been developed based on antibody labelling 
of specific antigens – described in Sections 2.5.1.3 and 2.5.1.4. 
 
2.5.1.3 Fluorescence activated cell sorting (FACS) for MSC enrichment 
Fluorescence-activated cell sorting (FACS or flow cytometry) relies on the 
specific labelling of antigen markers with fluorescently tagged monoclonal 
antibodies (6). Cells are labelled in a mixed suspension and analysed using a 
flow cytometer; inside the flow cytometer cells are drawn into a stream created 
by a surrounding sheath of isotonic fluid that creates laminar flow (127). This 
allows single cell analysis and is the basis of the high resolution of this technique. 
At an ‘interrogation point’, a laser is used to excite the fluorescent molecules to a 
higher energy state and upon returning to their resting states, the fluorochromes 
emit light energy at higher wavelengths. The use of multiple fluorochromes with 
similar excitation wavelengths but different emission wavelengths, allows several 
cell antigens to be detected simultaneously (127). The light signals are detected 
by photomultiplier tubes and converted to digital outputs for analysis.  
To sort cells using this technique, after laser excitation the single cells are 
separated into small droplets using mechanical vibration (6). The droplets pass 
through an electrical charging ring where a charge is placed on the droplet 
according to the fluorescence of the cell inside. The droplets then flow parallel to 
electromagnets and are deflected into collection tubes according to their charge 
(Figure 2.6).  
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Figure 2.6 Fluorescence-activated cell sorting (FACS) 
A sheath fluid creates laminar flow so that cells pass individually through a 
laser beam. Fluorescently labelled cells are excited by the laser and the 
emitted light is detected. Mechanical vibration then causes the flow to 
separate into small droplets which become charged according to the 
fluorescence of the cell inside. Droplets are then deflected by 
electromagnets into separate collection tubes based on their different 
charges. This diagram was created with BioRender.com. 
 
There is no doubt that FACS results in high purity cell separations due to the 
highly specific nature of monoclonal antibodies and the single cell analysis 
employed, however, this technique has limited capacity for point-of-care clinical 
applications and is much more widely used as an analytical and diagnostics tool. 
The reasons for this are as follows; firstly, the technique is limited by the time 
taken for high purity separations, although the single cell analysis has a relatively 
high throughput (5000 – 25,000 cells per second (128)), a large number of cells 
must be analysed for rare populations, and processing times are typically 
between three and six hours including pre-processing steps for immunostaining 
(6). The fact the cells are labelled with an antibody conjugated to a fluorophore is 
also undesirable for clinical applications since the labels remain attached to the 
cells post-separation. In addition, the cells are at risk of contamination during 
processing and experience high shear stress during the procedure which could 
lead to cell damage (6, 128). Finally, the equipment is large, very expensive, and 
requires skilled technicians to operate. 
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2.5.1.4 Magnetic activated cell sorting (MACS) for MSC enrichment 
Magnetic-activated cell sorting (MACS) is a trademark name (Miltenyi Biotec, 
Germany) for immunoselection using magnetic nanoparticles conjugated to 
monoclonal antibodies (6). The nanoparticles are approximately 50 nm in 
diameter and are biologically (as far as we know) and optically inert which has 
led to MACS beads becoming the gold standard for magnetic cell separation 
(129). The beads are mixed with cells in suspension, then passed through a 
column in a magnetic field. Cells bound to the antibody binders - conjugated to 
the magnetic beads - are retained in the column whilst unbound cells are eluted. 
The magnet is then removed so that bound cells can be collected (Figure 2.7). 
The columns are filled with a matrix of ferromagnetic steel-wool or iron-spheres 
which focus the magnetic field lines towards their surface inducing strong 
magnetic field gradients (129). Once the magnetic field is removed, the 
ferromagnetic matrix can no longer retain the bound cells and labelled cells can 
be collected.  
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Figure 2.7 Magnetic-activated cell sorting (MACS) 
Magnetic nanoparticles (MACS beads) conjugated to antibodies that 
recognise specific antigens on the surface of the desired cells, are incubated 
with a cell suspension prior to their application to a MACS column in a strong 
magnetic field. The unlabelled cells elute from the column and are collected. 
The magnetic field is then removed enabling the labelled cells to be 
collected. This diagram was created with BioRender.com 
 
Compared to FACS, MACS is easier to use, achieves higher throughput and 
comparable purity (after two consecutive cycles)(6, 130). Despite this, the 
throughput and purity depends on a number of factors including the starting 
population of cells and the particular MACS instrument and reagents used. 
Instruments are available for automatic processing of up to eight samples 
simultaneously (autoMACS™ Pro) and a closed and automated CE-certified 
system (CliniMACS® Plus) has been developed to process up to 1.2 x 1011 cells 
in one sterile run. However, the CliniMACS system is only approved for limited 
therapeutic applications and many of the reagents are intended for in vitro use 
only (129, 131). Multiple parameter MACS is possible by the enzymatic removal 
of magnetic beads after the initial step of isolation (MACS-MultiSort)(128), 
however this would inherently lead to longer processing times and higher costs. 
For MSC enrichment, the clinical-scale isolation of a subset of MSCs (CD271+) 
has been demonstrated using CliniMACS CD271 GMP MicroBeads (132), 
however this product is for research use and in vitro cell processing only. One of 
the reasons for this could be the major concern of interference caused by 
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magnetic beads in the purified population (116). Moreover the equipment and 
reagents are expensive and there is no information regarding the length of the 
full procedure. Although MACS is currently leading the way on cell enrichment, 
the main drawback is the fact that cells are labelled with magnetic nanoparticles 
and monoclonal antibodies which remain attached to the cell surface or are 
internalised through endocytosis after enrichment. This limitation is the motivation 
for developing minimally manipulative and intraoperative cell enrichment 
technologies for autologous MSC therapies.  
An additional limitation of both MACS and FACS for MSC enrichment is the lack 
of consensus on the most appropriate biomarkers for MSC isolation. A review of 
MSC surface markers used to enrich therapeutic populations of MSCs is included 
in Section 2.6, however it is believed that there is no single marker for the isolation 
of a pure population of MSCs.  
 
2.5.2 Emerging cell sorting methods for MSC enrichment 
The most frequently used cell sorting methods for MSC enrichment in clinical 
trials and/or used as standard practice for research purposes have been 
discussed in Section 2.5.1. In this section, methods that are currently being 
developed for MSC enrichment are reviewed including some of the most 
pioneering work to date.  
 
2.5.2.1 Microfluidic methods for MSC enrichment 
There has been a methodological shift away from macroscale technologies 
towards microscale technologies due to a number of beneficial properties these 
systems encompass, including; laminar flow, easy integration with mechanical, 
electrical and optical systems and low-cost fabrication (133). In addition, 
microfluidic systems can be under continuous operation in a closed system to 
prevent contamination. With regard to an intraoperative cell enrichment 
technology, a microfluidic device would have further benefits such as a small size 
- increasing portability, and the relatively low cost of fabrication would be 
favourable for a single use device essential for clinical applications. 
As a result of advances in microfluidic technologies, traditional macroscale 
methods of cell sorting such as FACS and MACS have been developed as 
microscale technologies (µFACS and µMACS). A µMACS device was developed 
by Adams et al. (2008)(134) with multi-target capabilities. The device 
incorporated microfabricated ferromagnetic strips to generate large magnetic 
field gradients within a microchannel. Two different magnetic tags had distinct 
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magnetisation and radius properties which caused labelled targets to be 
deflected at the corresponding ferromagnetic strips into different outlets. The net 
amplitude and direction of the force experienced by the target was governed by 
the sum of the fluidic drag and the magnetophoretic force. For successful 
deflection, the magnetophoretic force was required to exceed the fluidic drag 
component and since the balance of the forces has a non-linear dependence on 
the radius, the different magnetisation and radius of the magnetic tags allowed 
for multitarget sorting.  
This method achieved high purity and high throughput separations but was only 
capable of isolating targets such as bacteria, viruses and molecules with sizes 
smaller or comparable to the magnetic tag. This is because for larger targets 
(such as mammalian cells), the net amplitude and direction of the 
magnetophoretic force would no longer exceed the fluidic drag component and 
therefore additional adaptions to the method would be required. As well as this, 
this method still has many of the same limitations as macroscale MACS – 
including the requirement of labelling which is still present post-separation. 
Droplet microfluidics was used to analyse periosteal cells containing MSCs at 
different stages of osteogenic lineage commitment in a µFACS style device (135). 
Using fluorescent-conjugated antibodies against alkaline phosphatase and 
STRO-1 (prospective markers of MSCs – see Section 2.6.2), three distinct cell 
phenotypes were identified and enumerated using a microfluidic channel and 
optical detection system. At this stage the device was not able to sort the cells 
based on their signal and was used for identification and analysis purposes only. 
Baret et al. (2009)(136) achieved cell sorting in a µFACS device using a pulse of 
high-voltage alternating current to cause chosen droplets to deflect into a 
separate outlet by dielectrophoresis. This device was however limited to a low 
throughput of 2000 droplets per second and has not yet demonstrated separation 
using mammalian cells.   
Although harnessing some of the more advantageous aspects of microfluidics, 
the inherent issue of cell labelling remains relevant to these microfluidic 
technologies. To overcome these, an effort has been made to develop label-free 
microfluidic techniques using dielectrophoresis and field flow fractionation - 
described in Sections 2.5.2.2 and 2.5.2.3 respectively.   
 
2.5.2.2 Dielectrophoresis (DEP) for MSC enrichment 
Dielectophoresis (DEP) has the ability to sort cells based on their polarisability, 
which is determined by properties such as their size and shape, membrane 
integrity and morphology, cytoplasm conductivity and nucleus-cytoplasm volume 
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ratio (137). Cells exposed to an electric field experience mechanical forces due 
to the induced electric charges at interfaces such as the cell membrane and 
structural components inside the cell. The induced charges are small however, 
and since they are non-uniform in nature they produce an electric dipole moment 
in the cell. In a non-uniform electric field, the polarised cell experiences an electric 
field gradient causing the cell to move relative to its surroundings. Depending on 
the polarity of the induced dipole moment, the cell will either move towards 
regions of high electric field gradient (positive DEP) or regions of low electric field 
gradient (negative DEP)(Figure 2.8). The highest field gradients occur at the 
electrode edges which results in the trapping of cells experiencing positive DEP 
whilst the cells experiencing negative DEP can be removed using fluid flow.  
 
 
Figure 2.8 Dielectrophoresis (DEP) for cell separation 
Cells experience positive or negative dielectrophoresis according to the 
polarity of the induced dipole moment in a non-uniform electric field. If a cell 
is more polarisable than the surrounding medium, it will move towards 
regions of high electric field gradient (at the electrodes) and if a cell is less 
polarisable than the surrounding medium it will move to regions of low 
electric field gradient (away from the electrodes). Cells that are not trapped 
at the electrodes can be washed away using fluid flow. This diagram was 
created with BioRender.com. 
 
The DEP force experienced by a cell is dependent upon the Clausius-Mossotti 
factor which in turn is frequency dependent (138). Where the direction of the DEP 
force is independent of the applied voltage, the relative polarisability of the cells 
and the suspending medium can be manipulated by controlling the frequency of 
the applied electric field. For cell separation, the key is to find an operating 
frequency where the desired cell type experiences a different DEP force to the 
undesired cell types. This has been demonstrated a handful of times using cell 
lines derived from bone marrow stem cells (139), and to separate MSCs from 
differentiated cells (140, 141), however these studies use a maximum of three 
different cell types and separation from native BM-MNC populations has yet to 
be achieved. It is therefore unknown whether the dielectric properties of MSCs 
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will be sufficiently different to distinguish MSCs from all the other cell types 
present in BM-MNCs. 
Furthermore, the purities of cell populations enriched using DEP are often low 
and contaminated with unwanted cell types (116). Song et al. (2015)(141) used 
a DEP device to separate MSCs from differentiated osteoblasts and reported that 
purity could be increased from 50 % to ~80 %, however, this was at a low flow 
rate (1.8 µL/min) and did not use clinically relevant populations. Yoshioka et al. 
(2018)(139) used a DEP device to separate two bone marrow-derived cell lines 
with distinct DEP properties and observed similar purities (~80 %), however, 
there was very low cell recovery (~30 %) which would not be appropriate for 
capturing rare MSC populations.  
Currently DEP technologies are not sophisticated enough to enrich MSC 
populations from clinical samples with high purity. Moreover, cell damage is 
unavoidable for cells experiencing positive DEP (118) and problems can arise 
due to electrode fouling. In addition, when cells are kept in physiologically 
relevant medium with high conductivity, DEP can cause joule heating and 
electrochemical reactions to occur causing further concerns for cell viability.  
 
2.5.2.3 Field flow fractionation (FFF) for MSC enrichment 
Another cell separation method based only on physical parameters is field flow 
fractionation (FFF). This method relies on differences in cell morphology and 
biophysical differences such as cell mass, charge, size, density, shape and 
rigidity (6). Separation is achieved by combining laminar flow with an external 
perpendicular field applied to the channel (142)(Figure 2.9). Different fields have 
been applied to FFF including gravitational, centrifugal sedimentation and 
dielectrophoretic which in turn determines the distinguishing properties used for 
separation. According to the particular physical property or properties, cells are 
distributed differently in the flow profile leading to different elution times.  
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Figure 2.9 A field flow fractionation (FFF) device 
FFF combines laminar flow with an external field applied perpendicular to a 
channel and cells elute from the channel in different fractions based on their 
physical properties. The type of external field applied determines which cell 
properties the elution times depend upon. Different external fields have 
been used in FFF including gravitational, centrifugal sedimentation and 
dielectrophoretic. This diagram was created with BioRender.com and 
adapted from (143). 
 
There are only two examples of where FFF has been applied for the enrichment 
of MSCs; one using gravitational FFF (144) and another using DEP-FFF (145). 
The simpler device of the two - which uses gravitational FFF - was able to isolate 
populations of cells with MSC morphology from different sources, as well as 
enrich adipogenic progenitor cells from adipose tissue (144). However the purity 
of populations were not reported nor any further analysis of the cells post-
enrichment. The second example used a more sophisticated DEP-FFF device 
and enriched NG2-postive cells (a marker for stromal/pericyte cells) from a 
starting population of less than 2% in adipose tissue to 28% after enrichment in 
the device, achieving a 14-fold enrichment but still a relatively low overall purity 
(145).  
Similarly to the previously discussed physical-based methods, FFF has low 
resolution leading to low purity populations. Another limitation of FFF is the 
inherently low throughput of the technique, typically processing less than one 
million cells per run (146). 
 
2.5.2.4 Other microfluidic label-free cell sorting techniques for MSC 
enrichment 
There are a handful of examples where label-free microfluidic methods have been 
applied for MSC enrichment based simply on the different sizes of cells. Lee et 
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al. (2018)(147) used a spiral-shaped inertial microfluidic sorter to isolate MSCs 
from mouse bone marrow samples based on their larger size compared to other 
mouse bone marrow-derived cells. This method accomplished reasonable 
recoveries and enrichment but with low purities (~13%). Wu et al. (2009)(148) 
used a louver-array microstructure to enrich human amniotic fluid stem cells in 
which the smaller sized stem cells could flow through the gaps in the array 
whereas larger endothelial cells could not. High separation efficiencies were 
reported at 97% for two consecutive separations or 83% for one separation, 
however this was at low flow rates and no analysis was carried out on the cells 
post-enrichment. Finally, Jung et al. (2015)(149) used hydrodynamic filtration to 
isolate three subpopulations of human MSCs based on their different sizes. The 
smallest sized cells (<25 µM) were separated with the highest purity (reported at 
100%) and demonstrated specific surface markers of MSCs, however the 
throughput of the device was not described.  
There are a number of other microfluidic cell sorting techniques based on: 
microscale filters, deterministic lateral displacement, magnetophoresis, 
acoustophoresis and aqueous two-phase systems (150), however none of these 
have yet been applied for MSC enrichment. This is likely to be due to the fact that 
these label-free techniques potentially lack the specificity and high resolution 
required to enrich high purity populations. In light of this, the next section will 
introduce alternative affinity-capture based techniques for MSC enrichment. 
 
2.5.3 Affinity-capture based systems for MSC enrichment 
Affinity-capture based methods have the advantage of high specificity whilst 
avoiding external labelling of target cells. The principle of affinity-capture based 
methods is the use of highly specific binding molecules attached to a solid 
substrate to allow for specific cell capture and release. The most traditional 
binding molecule is an antibody – previously discussed in Sections 2.5.1.3 and 
2.5.1.4, where their use in FACS and MACS allows for high resolution cell 
separations via solution-based methods. However, over the past 30 years 
alternative non-antibody binding molecules (referred to as aptamers) have been 
developed which can hold some advantages over conventional antibody 
technology. Binding molecules that have the potential to be used as specific 
capture molecules in a cell enrichment device are reviewed in the following 
sections.  
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2.5.3.1 Aptamers as cell capture molecules for MSC enrichment 
RNA, DNA or peptide molecules with high specificity and binding affinity towards 
a target molecule are described as aptamers (151). Aptamers are selected using 
in vitro screening techniques such as the systematic evolution of ligands by 
exponential enrichment (SELEX) and phage display. 
SELEX is a technique used to screen large libraries of combinatorial RNA or 
ssDNA against a target molecule. RNA or ssDNA binders are eluted from the 
target molecule and reverse transcription polymerase chain reaction (RT-PCR) 
or PCR amplification is used to enrich a pool of target-specific binders. The 
process is repeated multiple times to result in highly specific aptamers which can 
be used for therapeutic applications (Figure 2.10). Phage display is an analogous 
technique to screen large libraries of peptide aptamers and is described in more 
detail in Chapter 5: Section 5.1.1. 
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Figure 2.10 Systematic evolution of ligands by exponential enrichment 
(SELEX) 
A ssDNA or RNA library is incubated with a target cell and unbound 
aptamers are washed away. Bound aptamers are eluted and can be further 
enriched with negative selection with non-target cells. Enriched aptamers 
are amplified using polymerase chain reaction (PCR)(or reverse 
transcription-PCR in the case of RNA) and the process is repeated multiple 
times to identify highly specific aptamers for target cells. This diagram was 
created with BioRender.com and adapted from (118). 
 
Aptamers are proposed to have advantages over antibodies for affinity-based cell 
capture, for example; they have uniform activity independent from batch 
synthesis, unlimited shelf-life and reversible heat-induced aptamer denaturation 
(151). Furthermore, there is opportunity to modify aptamers post-selection to 
enhance binding affinity and reduce non-specific binding. 
The therapeutic use of aptamers has been explored for a wide variety of 
applications with some treatments already FDA-approved (152). On the other 
hand, there has been limited investigation of the therapeutic use of aptamers for 
MSC enrichment, and the only example is presented by Guo et al. (2006)(153) 
who explored the use of DNA aptamers for the isolation and surface 
immobilisation of MSCs from porcine bone marrow. Using SELEX, and 
monitoring the enrichment of specific cell-binding aptamers using flow cytometry, 
36 clones were obtained and analysed. After initial analysis, one clone was 
- 35 - 
chosen for further characterisation demonstrating specific binding to porcine 
MSCs compared to human MSCs and a mouse cell line. The aptamer was 
biotinylated which enabled bound cells to be ‘fished out’ by anti-biotin microbeads 
and characterised post-enrichment. Aptamer-sorted cells proliferated and 
showed adipogenic and osteogenic differentiation whereas cells isolated by 
plastic adherence and cultured in the same conditions did not. Finally, biotinylated 
aptamer could be immobilised onto a surface and was shown to trap MSCs from 
an agitated cell suspension.  
This pioneering work demonstrates the efficacy of aptamers for cell enrichment 
applications, however, it requires further development to become a feasible 
platform for intraoperative clinical application. For example, aptamers must be 
isolated against human MSCs rather than porcine MSCs and the cells must be 
able to be released from the aptamer coated surface. In this case, the groups 
long term goal was to create an aptamer-coated scaffold for bone tissue 
engineering and therefore cell release would not have been a priority.  
In more recent work, a DNA aptamer was selected that was specific for human 
embryonic stem cells (hESCs) and could enrich hESCs from a mixture of human 
foreskin fibroblasts using biotinylated aptamer and streptavidin-labelled magnetic 
beads (154). The authors were also able to identify that the aptamer was binding 
to alkaline phosphatase expressed on the cells. This aptamer was then later 
implemented in a tissue engineering approach for osteochondral defect repair 
demonstrating the ability to recruit a higher number of MSCs to a scaffold with 
aptamer incorporated compared to a scaffold with no aptamer (155). Moreover, 
the aptamer scaffold was used in a full thickness rat osteochondral defect and 
displayed superior healing to a scaffold without aptamer. This study 
demonstrates the efficacy of aptamers in regenerative medicine and presents the 
opportunity for their implementation in an MSC enrichment technology.  
 
2.5.3.2 Affimers as cell capture molecules for MSC enrichment  
Peptide aptamers - “Affimers” - were first introduced as “Adhirons” in 2014 by the 
BioScreening Technology Group (BSTG) at the University of Leeds (156), and 
later referred to as Affimer proteins. Affimer proteins have the potential to be used 
as binding molecules in an affinity-capture based device with some advantages 
over traditional antibodies. For example, Affimers are easy to express in E. coli - 
therefore avoiding the use of animals and mammalian cell culture, and they do 
not contain cysteine residues - allowing the site-directed introduction of a cysteine 
for site-specific coupling of biotin/fluorescent labels to enhance their utility. 
Furthermore, for use as a binding molecule in an affinity-capture based device, 
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they have the advantage of being approximately ten times smaller than antibodies 
allowing increased packing density on a solid substrate, and they have tuneable 
affinity due to the ability to change the properties of selected Affimers via affinity 
maturation or mutagenesis. The affinity of binding molecules is a critical factor in 
this application since the cells need to be released from the solid substrate after 
capture. 
Peptide aptamers such as Affimers consist of a short amino acid sequence 
embedded within a small and very stable protein backbone referred to as a 
scaffold (157). The conformational constraint applied by the scaffold stabilises 
the insert loop and can increase the binding affinity to a specific ligand by as 
much as 1000 times compared to free peptide (157). In search of a highly stable 
protein scaffold for Affimer proteins, the consensus design concept was used to 
generate a scaffold based on a consensus sequence of plant-derived 
phytocystatins. This ensured that a scaffold with desirable properties such as a 
small size, monomeric, high solubility, and high stability - without the need for 
disulphide bonds and glycosylation - was generated for aptamer peptide 
presentation. Within the protein scaffold two loops of nine randomised amino acid 
positions were introduced to create an Affimer phage display library comprising 
of 1.3 x 1010 clones. The X-ray crystal structure of the Affimer scaffold is shown 
in Figure 2.11.  
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Figure 2.11 X-ray crystal structure of the Affimer scaffold  
The Affimer scaffold has a single alpha helix, four anti-parallel β strands and 
two loops of nine randomised amino acid positions (insertion sites) for library 
production. Residues 1-10 and 90-92 are not visible in the structure and are 
presumed to be disordered. The X-ray crystal structure is shown here at 
1.75 Å resolution. This image was taken from (156).  
 
In 2017, Tiede et al. (158) presented some of the outcomes of over 350 
successful screens of the Affimer library, including; Affimer binders selected 
against homologous protein family members – with the purpose to increase the 
understanding of intracellular signalling pathways, Affimers used as affinity histo-
chemistry reagents with high sensitivity, Affimers capable of blocking the 
biological function of specific receptors, and Affimers for in vivo rapid imaging of 
tumours. Moreover, in 2016 Sharma et al. (159) reported the use of Affimers in 
an electrochemical impedance biosensor for detection of human interleukin-8 (IL-
8). This application is the most relevant to this thesis since the biosensor 
consisted of Affimer proteins immobilised to a solid substrate used as capture 
molecules – the same intention as binding cell surface molecules in this work, 
however for whole cell capture.  
 
2.5.3.3 Antibodies as cell capture molecules for MSC enrichment 
Despite aptamers presenting a promising opportunity for use as specific cell 
capture molecules, the concept relies on the selection and identification of 
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suitable aptamers during in vitro screening of a target. In the case that an 
appropriate binding molecule cannot be identified for the intended application, 
antibodies provide a long-established method of specific antigen binding which 
could be utilised in an affinity-capture based device and are commercially 
available.  
Antibodies specific to a particular antigen are produced by mature B lymphocytes 
when an antigen is recognised as being foreign (160). The antibodies are 
released into the bloodstream and specifically bind with the foreign molecule 
allowing the immune system to eliminate the molecule from the system. 
Antibodies are immunoglobulins (Igs) which in their monomeric form are 
glycoproteins with a molecular weight of approximately 150 kDa (160). The basic 
structure of the monomer is a Y-shape which consists of four polypeptide chains 
– two heavy chains and two light chains connected by disulphide bonds (Figure 
2.12).  
Antibodies have dual functions, antigen binding and biological activity mediation. 
The different functions are carried out by different parts of the antibody; the 
fragment antigen binding (Fab fragment) contains the antigen binding site and 
the fragment crystallisable region (Fc region) can activate the immune system. 
The Fc region contains protein sequences common to all Igs as well as 
determinants unique to the individual classes (IgA, IgD, IgE, IgM and IgG), and 
are referred to as constant regions since they do not vary significantly among 
different Ig molecules within the same class. The Fab portion contains both heavy 
and light chains where one heavy and one light chain combine to form the specific 
antigen binding site of the antibody. The two heavy chains and the two light 
chains are identical in any given antibody meaning there are two identical antigen 
binding sites.  
Antibody technology has been successfully employed for MSC enrichment using 
solution-based methods - FACS and MACS (Sections 2.5.1.3 and 2.5.1.4), and 
could provide a suitable capture molecule in an affinity-capture based method of 
cell enrichment.  
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Figure 2.12 Structure of an antibody binding molecule 
An antibody has a Y-shaped structure which consists of four polypeptide 
chains – two heavy chains and two light chains connected by disulphide 
bonds. The Fc fragment is known as the constant region since it does not 
significantly vary between immunoglobulin molecules within the same 
immunoglobulin class. The Fab fragment is made up of light chains and 
heavy chains, and one light chain and one heavy chain combine to make a 
specific antigen binding site. CH=heavy chain constant region, VH=heavy 
chain variable region, CL=light chain constant region, VL=light chain 
variable region. This diagram was created with Biorender.com and adapted 
from (160). 
 
2.5.4 Summary of cell sorting methods for MSC enrichment 
In reviewing the limitations of conventional cell enrichment technologies, as well 
as evaluating the most promising technologies currently in development, the work 
to be carried out in this thesis will investigate the use of an affinity-capture based 
microfluidic device to enrich a subset of MSCs with therapeutic potential. By 
taking the advantageous aspects of microfluidic technologies and combining 
these with the high resolution of an affinity-capture based approach - without the 
need for extrinsic labelling, this project will develop a novel MSC enrichment 
device. Furthermore, alternative binding molecules (Affimers - Section 2.5.3.2) as 
well as commercially available antibodies (Section 2.5.3.3) will be explored as 
binding molecules to optimise cell capture and release in the device. In order to 
exploit specific antigen binding technology, an appropriate MSC surface molecule 
(antigen) must be identified and utilised. In the next section, the specific criteria 
and nomenclature for MSCs will be discussed, and the most promising surface 
markers for MSC enrichment reviewed.  
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2.6 MSC surface antigens for affinity-based cell capture  
In advance of reviewing the different MSC surface antigens, it is first necessary 
to discuss MSC nomenclature and the impact that differing MSC terminology has 
had on stem cell research - including attempts to standardise definitions and 
criteria such as specific surface molecule (antigen) expression.  
 
2.6.1  MSC nomenclature and specific surface antigen criteria 
MSCs were officially named as mesenchymal stem cells over 25 years ago by 
US biologist Arnold Caplan (161). This was based on their capacity to be induced 
to form a variety of mesodermal phenotypes and tissues in vitro (162). The term 
has since been used in over 700 clinical trials (see Figure 2.1) and in more than 
32,000 Medline-indexed articles (163). Despite this, MSCs have also been 
described in numerous other ways, for example; marrow stromal cells, 
multipotent stromal cells, mesodermal stem cells and mesenchymal stromal cells. 
The lack of a clear definition has resulted in inconsistencies and ambiguities in 
stem cell research (163, 164).  
Prompted by this, in 2005, the International Society for Cellular Therapy (ISCT) 
published a position statement for clarification of the nomenclature of MSCs 
(165). Here it was advised that the term “multipotent mesenchymal stromal cell” 
should be used for plastic-adherent cells and the term “mesenchymal stem cell” 
should be reserved for cells that demonstrate stem cell activity defined by clearly 
stated criteria. The ISCT criteria for MSCs was published in 2006 as follows (164): 
• Adherence to plastic 
• Specific surface antigen expression (see Table 2.1) 
• Multipotent differentiation potential  
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Table 2.1 ISCT minimal criteria for the specific surface antigen expression 
of MSCs 
 
POSITIVE (≥ 95%) NEGATIVE (≤ 2%) 
CD105 CD45 
CD73 CD34 
CD90 CD14 or CD11b 
 CD79α or CD19 
 HLA-DR 
 
The specific antigen expression criteria ensures there is a lack of expression of 
haematopoietic antigen that would likely be found in MSC cultures. This includes 
markers for leukocytes, haematopoietic progenitors, endothelial cells, monocytes 
and macrophages. The multipotent differentiation potential refers to trilineage 
differentiation to osteoblasts, adipocytes and chondroblasts under standard in 
vitro differentiating conditions.  
Despite these recommendations, the term mesenchymal stem cell is still widely 
used without observation of the criteria and assays commonly used to evaluate 
a cell’s ‘stemness’ can be easily misinterpreted (163). Furthermore, as the 
number of MSC sources increases it has been shown that the gene expression 
patterns, proteome and functionality of MSCs differs in accordance with their 
source and no general assumptions can be made between different populations 
(166).  
To date, misperception still exists and in 2017, Caplan suggested that his original 
nomenclature was misleading and a term such as medicinal signalling cell would 
be more appropriate (162). He proposed that since the main in vivo function of 
MSCs is not their multipotency, they should not be deemed a stem cell. However 
this shift in nomenclature is disputed by others in the field concerned that it could 
heighten assumptions of broad therapeutic use that have not yet been proven 
(163). It has been suggested that in order to make important advancements in 
the field of stem cell research, it will be crucial to rigorously control the use of the 
term MSC and stop its use as an umbrella term for multiple different cell types 
(163).  
With respect to the work carried out in this thesis, one specific cell surface antigen 
will be used to demonstrate the proof-of-concept of an affinity-capture based 
microfluidic device to enrich a subset of cells with therapeutic potential. It is noted 
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that the surface antigens defined by the ISCT do not uniquely identify MSCs and 
were proposed alongside the functional criteria to best recognise MSCs in line 
with current knowledge (164). However, these markers are also expressed on 
many other stromal cells including fibroblasts (166), meaning that they would not 
be suitable candidates for use as a single MSC marker in this project. Alternative 
MSC surface molecules have been proposed which could provide a more suitable 
candidate marker. The efficacy of these markers to be used to enrich a 
therapeutic population of cells is reviewed in the following section.  
 
2.6.2 Alternative MSC surface molecules (antigens) 
In 2014, Lv et al. (167) published a review of human MSC surface markers in 
which four molecules were highlighted as the most commonly used markers to 
select for MSCs. These four markers are the focus of this next section.  
 
2.6.2.1  STRO-1 selection of MSCs 
In 1991, Simmons et al. (168) described the generation and specificity of a murine 
IgM monoclonal antibody termed STRO-1 according to its reactivity with bone 
marrow stromal elements in vitro and in vivo. They found that STRO-
1+/glycophorin A- cells were enriched 100-fold for colony-forming unit-fibroblast 
(CFU-F) – an assay used to determine the clonogenic potential of cells and 
therefore assess the proportion of MSCs in a population. Glycophorin A is a 
marker associated with erythroid cells and since the majority of STRO-1+ cells 
co-expressed glycophorin A, they found it was necessary to deplete glycophorin 
A+ cells to enrich CFU-F. 
Psaltis et al. (2010)(169) used STRO-1 as a single marker for MSC isolation 
(without depletion of glycophorin A) and compared the activity of STRO-1+ 
immunoselected mesenchymal precursor cells (STRO-1-MPC) to cells isolated 
by plastic adherence (PA-MSC). They found that STRO-1-MPC had greater 
clonogenicity, proliferative capacity, multilineage differentiation potential and 
mRNA expression of MSC-related transcripts than PA-MSC. Furthermore, 
conditioned medium from STRO-1-MPC had greater paracrine activity with 
respect to cardiac cell proliferation and migration, and endothelial migration and 
tube formation – demonstrating the cardiovascular regenerative potential of 
STRO-1-MPC.  
Gronthos et al. (2003)(170) reported a CFU-F enrichment factor of approximately 
5000-fold using STRO-1 in combination with vascular cell adhesion molecule-1 
(VCAM-1/CD106) to isolate a minor subpopulation of STRO-1+ selected cells 
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(1.4 ± 0.3%) which equated to 0.02% of the total BM-MNC population. Cells 
immunoselected for STRO-1+/VCAM-1+ were also used by Martens et al. 
(2006)(171), in an athymic rat model of acute myocardial infarction which resulted 
in a dose-dependent induction of arteriogenesis and vascular network formation.  
Despite the fact that STRO-1 has been recognised as the ‘best-known MSC 
marker’ (172, 173), the molecular identity of the antigen remains elusive (174). It 
has been suggested that STRO-1 is an endothelial antigen and that its expression 
in MSCs is induced during in vitro culture only (175). This finding is supported by 
Lee et al. (2009)(176) who found that STRO-1 expression increased over 9 days 
in culture with no initial analysis of an un-cultured population. However it has also 
been proposed that STRO-1 binds to cell surface heat shock cognate 70 
(HSC70/HSPA8) and that additional investigation of this molecule could provide 
further insight into MSC biology (174).  
The practicality of using STRO-1 as an MSC marker for therapeutic applications 
is limited; it has been found that STRO-1 is not universally expressed in all MSC 
sources (167), for example there was no expression found in MSCs derived from 
adipose tissue (177) and umbilical cord matrix (178) - two promising alternative 
MSC sources to bone marrow. Moreover, the use of STRO-1 as a sole marker 
would yield an erythroid-contaminated population due to the high percentage 
(>95%) of STRO-1 cells which co-express glycophorin A (167, 168). 
2.6.2.2 CD271 selection of MSCs 
CD271 - also named low-affinity nerve growth factor receptor (LNGFR) - is a 
receptor for neurotrophins which stimulate neuronal cells to survive and 
differentiate (167). In 2002, Quirici et al. (179) found that positive selection using 
anti-CD271 antibodies isolated a homogenous and multipotent population of 
cells. They found that CFU-F for CD271+ cells were increased more than 60-fold 
compared with cells isolated by density gradient centrifugation and no residual 
CFU-F activity was observed in the CD271- fraction of cells. Furthermore, the 
CD271+ cells had greater capacity to give rise to adipocyte colonies and 
displayed increased calcium accumulation in their extracellular matrices after 
osteogenic differentiation compared to cells isolated by plastic adherence or 
negative selection of CD45-/glycophorin A- cells.  
Since then, Jones et al. (2002-2019)(180-186) have published a considerable 
amount of work regarding a subset of MSCs with phenotype 
CD271bright/CD45low i.e. high expression of the CD271 antigen and low 
expression of the CD45 antigen. They demonstrated that there was a significant 
correlation between the frequency of CFU-F and CD271bright/CD45low cells 
(180, 184), and that these cells expressed other classic markers of MSCs 
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including CD73, CD105, CD90, CD106 and alkaline phosphatase (184, 185). 
They suggested that the enumeration of cells of this phenotype could be used as 
an indicator of bone marrow sample quality (181) and would be suitable for intra-
operative quality control of bone marrow aspirates (180). The work of Jones and 
colleagues has focused on the identification of MSCs in vivo and has found that 
CD271 is the most differentially expressed marker on MSCs compared to other 
marrow cell populations (186).  
Further evidence supports the concept that CD271+ cells are a therapeutic cell 
population; Kuci et al. (2010)(187) reported their immunosuppressive and 
haematopoietic engraftment-promoting properties of immunoselected CD271+ 
cells and Hermida-Gómez et al. (2011)(188) reported the involvement of 
immunoselected CD271+ cells in spontaneous cartilage repair, and the superior 
quality of chondral repair using this subset of cells. Flores-Torales et al. 
(2010)(189) proposed CD271 as a sole marker for isolating MSCs from fresh 
samples of bone marrow. In their study, it was found that the percentage of 
CD271+ cells from 25 donors was significantly correlated with the percentage of 
CD90+/CD105+/CD45-/CD34-/CD79- cells, markers defined by the ISCT criteria 
though not inclusive of all specified markers (Section 2.6.1) 
Altogether these observations have resulted in the commercialisation of CD271 
as a preferred marker for the purification of a homogenous population of cells that 
contains all bone marrow MSC activity (186, 190). Despite this, similar to STRO-
1, CD271 is not a universal marker for MSCs and although CD271+ cells can be 
isolated from bone marrow and adipose tissue (191), expression was absent in 
umbilical cord matrix (192) and other sources (167). Furthermore, the necessity 
to exclude hematopoietic cells (CD34+ and CD45+ cells) prevents CD271 alone 
from being used to isolate a pure population of therapeutic cells (179, 193).  
 
2.6.2.3  CD146 selection of MSCs 
CD146 – also named melanoma cell adhesion molecule (MCAM) - is a cell 
adhesion protein involved in vascular endothelial cell activity and angiogenesis 
(167). CD146 expression on MSCs has been correlated to an increased capacity 
for multipotent differentiation (194), where Russell and colleagues (2010) 
determined that the tripotent clones expressed higher levels of CD146 than their 
unipotent counterparts. In addition to this, Sacchetti et al. (2007)(195) found that 
CD146 distinguished bone marrow MSCs from other osteogenic cell strains and 
was expressed at high levels on CFU-F but was expressed at decreased levels 
in non-clonal cultures, where mature osteoblastic cells were present. 
Furthermore, when CD45- cells were selected for CD146 by FACS, CFU-Fs were 
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enriched more than 800-fold from BM-MNC and ~80 % of CFU-F were recovered 
in this fraction.  
In addition to the clonogenic and multipotent potential of CD146+ cells, Sacchetti 
et al. (2007)(195) demonstrated that CD146+ cells were capable of transferring 
the haematopoietic microenvironment (HME) to heterotopic sites in vivo – 
revealing functional relationships between the establishment of the HME, 
progenitor cells in bone marrow and angiogenesis. Before this, relatively little was 
known about the role that BM-MSCs play in the HME, which is crucial for the 
regulation and maintenance of haematopoiesis (193). Tormin et al. (2011)(193) 
were then able to provide a greater insight into these relationships with their 
analysis of co-stained CD146 and CD271 BM-MNCs. In this study it was found 
that all assayable CFU-Fs were highly and exclusively enriched not only in the 
CD146+/CD271+ fractions of lineage-depleted cells but also in the CD146-
/CD271+ fraction of cells. They found that the differences in CD146 expression 
correlated with in situ localisation of cells and were able to identify a CD146-
/CD271+ phenotype for bone-lining cells and a CD146+/CD271+ phenotype for 
cells located in perivascular regions.  
Following this work, Maijenbrug et al. (2012)(196) investigated the effects of 
ageing on these two subpopulations – CD146+/CD271+ and CD146-/CD271+. 
They found that CD146 expression decreased with age and the main population 
in adults was CD146-/CD271+ and the main population in paediatric and foetal 
bone marrow was CD146+/CD271+. This is important to note when considering 
the application of cell therapies; patients requiring cell therapies could be of any 
age and therefore a marker that decreases in expression with age would not be 
suitable unless the relationship was consistent and well defined. 
  
2.6.2.4  Stage-specific embryonic antigen-4 (SSEA-4) selection of MSCs 
Stage-specific embryonic antigen-4 (SSEA-4) is an early embryonic glycolipid 
antigen commonly used as a marker for undifferentiated pluripotent human 
embryonic stem cells. In 2007, Gang et al. (197) proposed that SSEA-4 could 
also identify an adult mesenchymal stem cell population. They found that 
approximately 2–4% of human bone marrow cells expressed SSEA-4 and that its 
expression gradually increased in culture. They also found that when SSEA-4 
was used for the prospective isolation of MSCs, SSEA-4+ cells adhered to plastic 
and formed a homogenous cell monolayer whereas SSEA-4- cells failed to grow. 
SSEA-4+ cells demonstrated trilineage differentiation potential however no 
assessment of their clonogenic capacity was reported. 
- 46 - 
Beyond this work there is little evidence to support SSEA-4 as a reliable MSC 
surface marker. Zeddou et al. (2010)(192) reported the expression of SSEA-4 on 
MSCs cultured from bone marrow but not umbilical cord matrix, whereas others 
have reported no SSEA-4 expression on bone marrow cells (193, 198). Notably, 
there has been no direct comparison of the multipotency and clonogenicity of 
SSEA-4+ cells compared to cells isolated by plastic adherence or by other 
molecules (167). 
 
2.6.2.5 Other proposed markers for the selection of MSCs 
In addition to the markers discussed above, there have been various other 
markers used to isolate clonogenic MSCs from BM; including α6-integrin (CD49f) 
in combination with podocalyxin-like protein (PODXL)(199), stage specific 
antigen-3 (SSEA-3) in combination with CD105 (200) and CD200 (201). 
Furthermore, in search of unique MSC markers, research groups have reported 
molecules that are expressed only on MSCs compared to other marrow cells, 
such as the neural ganglioside GD2 (202). In further support of the perivascular 
niche of bone marrow derived MSCs, the pericyte marker 3G5 has been found to 
be expressed on adherent colony-forming cells (203) and STRO-1 selected cells 
(204). 
Various research has highlighted alternative or additional markers associated 
with the CD271+ subpopulation of MSCs; Sivasubramaniyan et al. (2013)(205) 
found that the type I integral membrane protein Sushi domain containing 2 
(SUSD2) was exclusively expressed on CD271+/CD45- cells and isolation of 
SUSD2+ cells enriched CFU-F approximately 70-fold. They propose that the 
W5C5 antibody - which reacts with SUSD2 - could provide a highly specific 
method for the isolation of BM-MSCs.  
Using CD56-specific 39D5 and MSCA-1-specific W8B2 monoclonal antibodies, 
Battula et al. (2009)(206) showed that these reagents were selectively expressed 
on CD271+ cells and no other bone marrow cells. CD271+/CD56+ and 
CD271+/MSCA-1+ subpopulations co-expressed established MSC markers and 
gave rise to CFU-F providing a more specific subset of cells for autologous cell 
therapies. It must also be noted that the MSCA-1 antigen has been found to be 
identical to tissue non-specific alkaline phosphatase (TNAP)(207) and TNAP is 
also thought of as a marker of MSCs. TNAP has been long known as a marker 
for mineralising cells, however it has also been found that TNAP activity within 
progenitor cells induces adipocyte and neuron differentiation as well as 
immunomodulation (208). 
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2.6.2.6 Summary of alternative MSC surface antigens for MSC selection 
Similarly to other properties of MSC, the determination of their specific surface 
antigen expression has been confounded by a lack of standardisation in the field. 
Analysis of surface markers has often been acquired after in vitro culture which 
can change the expression of markers according to the cell culture reagents (209) 
and confluence of cells (176). In addition, different cell sources have been used 
which further confuse the literature.  
While it is still considered that there is no consensus on a single surface molecule 
to identify MSCs (167), this thesis will focus on the utility of the CD271 antigen 
as a marker to enrich a therapeutic subpopulation of MSCs from bone marrow 
aspirate. There has been independent evidence from several research groups 
that CD271 antibodies can isolate a population of cells from bone marrow which 
are enriched for CFU-F and demonstrate trilineage differentiation potential. 
Moreover, CD271 has been shown to be expressed on freshly isolated bone 
marrow cells which is of crucial concern for this project since the aim is to develop 
a cell enrichment technology for intraoperative use with no in vitro expansion of 
cells prior to therapy. Finally, unlike STRO-1, the CD271 antigen has been 
identified, which means CD271 recombinant protein is available to buy – a factor 
that must be considered for the experiments carried out in this project.  
 
2.7  Summary and considerations for proposed research 
In consideration of all the literature, this research project proposes to design and 
fabricate a microfluidics-based device, with a cell capture surface based on 
affinity capture, to enrich a subset of CD271+ MSCs from clinical samples of bone 
marrow aspirate. Controlled flow will allow unbound cells to be washed away 
resulting in an enriched population of cells for potential use in autologous cell 
therapies. Mechanisms to release and collect the enriched cells will be explored 
including investigating pH change and increased fluid flow. In Section 2.5.3.1, the 
advantages of aptamers for use in specific cell capture were briefly discussed, 
and in Section 2.5.3.2 peptide aptamers named Affimers were introduced as 
alternative non-antibody binding proteins. Affimers, as well as commercially 
available antibodies, will be explored as capture molecules for CD271-expressing 
cells in the proposed microfluidic device. 
 
  
- 48 - 
Chapter 3: Introduction to research project 
This chapter will describe the specific research aim and objectives of this project 
and outline the results reported in each of the following chapters of work.  
 
3.1 Research aim 
The long-term goal of this research is to produce a cell sorting device that will 
enrich specific cells from clinically relevant samples within intraoperative times 
and without the need for extrinsic labelling. This would therefore be 
commensurate with the criteria for minimal manipulation for use in autologous 
cell therapies. The aim of the research described in this thesis was to develop a 
prototype microfluidic device for affinity-based capture of CD271+ cells and 
assess the feasibility of using the device for enriching cells from clinical bone 
marrow aspirates.  
 
3.2 Research objectives 
3.2.1 Objective 1 
To screen Affimer libraries in order to identify CD271-specific binding proteins 
and to investigate their potential use as capture molecules for CD271+ cells 
The efficacy of CD271 as a biomarker to be used in order to enrich a therapeutic 
population of MSCs was described in Section 2.6.2.2. The use of novel peptide 
aptamers (“Affimers”) as non-antibody protein binding proteins was described in 
Section 2.5.3.2. The first objective of this research project was to use the in vitro 
screening technique of phage display to select for CD271-specific binding 
proteins from the Affimer libraries. The specificity of selected Affimers to CD271 
would then be investigated and compared to commercially available antibodies 
with the intention of immobilising the most appropriate binding protein to a solid 
substrate in a microfluidic channel for specific cell capture (Objective 2). 
 
3.2.2 Objective 2 
To design and fabricate a prototype microfluidic device capable of specific 
capture and release of CD271+ cells 
The clinical need for novel MSC enrichment methods was described in Section 
2.4.2. The benefits of microfluidic technologies were described in Section 2.5.2.1. 
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The second objective of this research project was to design and fabricate a 
prototype microfluidic device with affinity-based capture of CD271+ cells. The 
device would be designed to overcome the limitations of current MSC enrichment 
technologies to achieve enrichment with: high specificity, minimal manipulation, 
no extrinsic labelling of cells and within intraoperative timeframes. 
 
3.2.3 Objective 3 
To evaluate the feasibility of specific capture of CD271+ cells from clinical 
samples of bone marrow aspirate using a prototype microfluidic device 
The third objective of this research project was to investigate the CD271+ 
population of cells in clinical samples of bone marrow aspirate and evaluate the 
feasibility of enriching the CD271+ subpopulation using the prototype microfluidic 
device. The efficacy of the device will be compared to current ‘gold standard’ cell 
sorting methods - MACS and FACS - and assessed against the required criteria 
for novel MSC enrichment technologies. 
 
3.3 Chapter outlines 
3.3.1 Chapter 4 
Chapter 4 describes the materials and methods common to all chapters in this 
thesis, whereas materials and methods exclusive to one chapter are described 
in the relevant chapter.  
3.3.2 Chapter 5 
Chapter 5 describes the results from phage display screening of human 
recombinant CD271 protein. Three candidate Affimer proteins from the phage 
display screening were produced and purified and their binding to CD271 
recombinant protein characterised using enzyme linked immunosorbent assays 
and surface plasmon resonance. One Affimer protein was investigated for 
specific capture of CD271+ cells from dental pulp stromal cells and a CD271+ 
cell line, assessed via flow cytometry. The specificity of Affimer proteins was 
compared to a commercially available CD271 antibody and the most suitable 
binding protein investigated for specific cell capture in a prototype microfluidic 
device. 
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3.3.3 Chapter 6 
Chapter 6 describes the design, fabrication and optimisation of a prototype 
microfluidic device. The device was fabricated using soft lithography techniques 
and specific cell capture and release optimised using a CD271+ cell line and 
CD271- cells. Analysis of the cells post-enrichment was carried out to assess the 
viability, proliferation and manipulation (in terms of cell labelling) of enriched cells 
compared to control cells which had not been enriched in the microfluidic device. 
The device was also compared to current methods of MSC enrichment – MACS 
and FACS – in terms of specificity and cell recovery. 
 
3.3.4 Chapter 7 
Chapter 7 describes the use of conventional cell enrichment technologies (MACS 
and FACS) to enrich and characterise a subpopulation of CD271+ cells from 
clinical samples containing BM-MNCs. Once critical information such as the 
percentage and number of CD271+ cells was established, the enrichment of 
CD271+ cells from clinical samples using the prototype device was assessed. 
The performance of the device was compared to MACS and FACS and evaluated 
against the criteria required for a novel MSC enrichment technology. 
 
3.3.5 Chapter 8 
Chapter 8 discusses the different factors that must be considered for future 
work and summarises the thesis conclusions.  
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Chapter 4: Material and Methods 
This Chapter will detail the general materials and methods used throughout this 
thesis. Materials and methods that are specific to only one chapter are detailed 
in the appropriate chapter of work. 
 
4.1 Cell culture 
Cell culture refers to the in vitro expansion of cells either harvested directly from 
the tissue or derived from an established cell line. Cells harvested directly from 
tissue are known as primary cells, they are cultured until they reach confluence 
(i.e. occupy all available space in a tissue culture flask) and then subcultured (i.e. 
passaged) into a new tissue culture flask to allow more room for growth. Cells 
derived from primary sources have a finite life span before they lose their ability 
to proliferate. Established cell lines are immortalised through a process called 
transformation, these cells have the ability to proliferate indefinitely and are 
known as continuous cell lines (210). 
Different cell types require different culture conditions, however, the culture 
vessel will inevitably contain; a medium that supplies essential nutrients, 
antibiotics to prevent infection and serum (usually foetal bovine serum, FBS) that 
provides various hormones, growth and adhesion factors, lipids and minerals 
(211). Culture vessels are usually kept at 37 °C and at pH 7.4. The growth 
medium controls the pH by incorporating a bicarbonate based buffer system and 
the percentage of CO2 in air is controlled exogenously. All cell culture is 
maintained in a sterile environment and handled using aseptic technique.  
 
4.1.1 Dental pulp stromal cell (DPSC) culture 
Dental pulp stromal cells (DPSCs) were used for flow cytometry experiments to 
assess whether Affimer proteins bound to CD271+ cells. DPSCs were harvested 
from extracted third molars obtained with consent through the Leeds School of 
Dentistry Skeletal Tissues Research Tissue Bank (Dental Research Ethics 
Committee approval 160916/AP/211). Cells were received cryopreserved at 
passage 2. 
Cells were thawed and resuspended in Minimum Essential Medium (MEM) - 
Alpha Eagle with Earle’s BSS (Lonza, BE12-169F) supplemented with 10% FBS 
(Sigma Aldrich, F7524), 1% L-glutamine (200 mM, Sigma, G7513) and 1% 
penicillin streptomycin solution (P/S, Sigma, P4458). Cultures were incubated at 
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37 °C, 5% CO2 and passaged when 80-90% confluent. Cells were detached from 
culture flasks by addition of 3-5 mL trypsin-EDTA solution (Sigma, T4049). Cells 
from passages 3 to 5 were used for all experiments.  
 
4.1.2 SH-SY5Y cell culture 
SH-SY5Y neuroblastoma cells, which constitutively express CD271, were used 
to assess whether Affimer proteins bound to CD271+ cells and to optimise cell 
capture and release in a prototype microfluidic device. SH-SY5Y cells were kindly 
donated by the Faculty of Biological Sciences (University of Leeds) and received 
cryopreserved at passage 13. The cells were originally provided to the Faculty of 
Biological Sciences by Dr. J. A. Sim (University of Manchester, Manchester, UK). 
Cells were thawed and resuspended in Dulbecco’s Modified Eagle Medium:F12 
(DMEM:F12, Lonza, BE12-719F) supplemented with 10% FBS and 1% P/S 
solution. Cultures were incubated at 37 °C, 5% CO2 and passaged when 80-90% 
confluent. Cells were detached from culture flasks by addition of 3-5 mL trypsin-
EDTA solution. Cells were used up to passage 30.  
 
4.1.3 Fibroblast cell culture 
Human fibroblast cells were used as CD271- cells during the optimisation of 
specific cell capture in a prototype microfluidic device. Primary dermal fibroblasts 
from normal adults were purchased from ATCC (PCS-201-012). The cells were 
thawed and re-suspended in DMEM - high glucose cell culture medium (Sigma, 
D5671) supplemented with 10% FBS (Sigma Aldrich,  F7524), 1% L-Glutamine 
(200 mM, Sigma, G7513) and 1% P/S solution (Sigma, P4458). Cultures were 
incubated at 37 °C, 5% CO2 and passaged when 80-90% confluent. Cells were 
detached from culture flasks by addition of 3-5 mL trypsin-EDTA solution (Sigma, 
T4049). Cells were used up to passage 10. 
 
4.2 Surface plasmon resonance (SPR) 
Surface plasmon resonance (SPR) is a label-free, non-destructive method to 
characterise ligand binding. The technique involves immobilising a ligand to a 
metal film (usually gold) which is placed at the interface of two dielectric media 
(212)(Figure 4.1). Medium 1 is a prism which has a higher refractive index (n1), 
and medium 2 is the analyte solution which has a lower refractive index (n2). 
When a plane-polarised light beam hits the prism, the light is bent towards the 
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plane of the interface when moving from medium 1 to medium 2. Total internal 
reflection can be achieved by adjusting the incident angle (θ) so it is greater than 
the critical angle (θC)(where sin(θC)=n2/n1). Under total internal reflection 
conditions, evanescent waves are formed in the lower refractive index medium 
(n2).  
Surface plasmons are electromagnetic waves confined to the metal-dielectric 
interface. The surface plasmons can be excited by the evanescent wave and this 
phenomenon is termed surface plasmon resonance (SPR). The magnitude of the 
wave is related to the dielectric constant of medium 2 and when surface plasmon 
resonance occurs, the intensity of the reflected light decreases sharply. 
Adsorption and desorption on the gold surface i.e. analyte association and 
dissociation, changes the refractive index of medium 2 near the metal-dielectric 
interface therefore changing the angle required for resonance. 
 
 
 
Figure 4.1 Surface plasmon resonance (SPR) schematic 
Total internal reflection occurs when the incident angle (θ) is greater than 
the critical angle (θC)(where sin(θC)=n2/n1). This causes evanescent waves 
to form in the analyte solution which has a lower refractive index than the 
prism (n1 > n2). Evanescent waves cause surface plasmons at the interface 
to become excited, termed surface plasmon resonance (SPR). Association 
and dissociation of analyte causes a change in the refractive index of the 
analyte solution (n2)  which changes the angle required for SPR. 
 
SPR is an analogous system to the desired method of cell capture within a 
microfluidic cell enrichment device, making it an ideal method to assess CD271 
protein binding to selected Affimer proteins (Section 5.2.10). SPR analysis was 
also used during the development of the prototype device to assess whole cell 
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binding to a functionalised surface (Section 6.2.2). The specific protocols for 
these experiments are described in the respective sections.  
 
4.3 Self-assembled monolayers (SAMs) 
Self-assembled monolayers (SAMs) contain a head group, a backbone and a 
specific terminal group (213). The head group guides the self-assembly process 
linking the hydrocarbon chain to the surface through a strong bond. The 
hydrocarbon chains form a packed monolayer through inter-molecular 
interactions such as van der Waals, and the specific terminal group allows 
different molecules such as proteins to be anchored to the monolayer.  
To create a non-fouling surface for specific cell capture in this work, a 
polyethylene glycol (PEG) monolayer terminated with a carboxylic acid group 
(HS-C11-(EG)6-OCH2-COOH, ProChima Surfaces TH 003-m11.n6) was formed 
on gold-coated surfaces (used for specific cell capture) prior to functionalisation. 
A non-fouling surface was required to help prevent non-specific adsorption of 
unwanted cell types in the device, and PEG monolayers are commonly used for 
this purpose (214).  
 
4.4 Crosslinking chemistry for the immobilisation of proteins to 
a solid surface 
For the work in this thesis, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide).HCl 
(EDC) and N-hydroxysuccinimide (NHS) crosslinking chemistry was used to 
immobilise proteins to various different surfaces, including; a CM5 substrate (GE 
Healthcare, Chapter 5: Section 5.2.10), a gold-coated glass disk (Xantec 
Bioanalytics, Chapter 6: Section 6.2.2) - both for SPR analysis - and a gold-
coated substrate in the prototype microfluidic device (Chapter 6: Section 6.2.3 
and 6.2.5). A CM5 substrate has a carboxymethylated dextran matrix attached to 
a gold surface, whereas the gold-coated substrates were first coated with a SAM 
terminated with a carboxylic acid group. Carbodiimide compounds are commonly 
used for labelling or crosslinking to carboxylic acids, and EDC is water soluble so 
allows for aqueous crosslinking (215). 
The crosslinking reaction mechanism is summarised as follows; EDC reacts with 
carboxylic acid groups on the surface to create an unstable intermediate, NHS is 
added to form a stable amine-reactive ester which allows for efficient conjugation 
of primary amines at a physiological pH (Figure 4.2). 
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Figure 4.2 EDC crosslinking reaction mechanism 
EDC reacts with carboxylic acid groups to form an unstable intermediate. 
NHS is added to form a more stable amine-reactive ester which reacts with 
primary amines at physiological pH. This diagram was created with 
BioRender.com.  
 
4.5 Analysis of flow cytometry data using CytExpert software  
CytExpert software was used to analyse all flow cytometry data recorded in this 
thesis. With the exception of viability testing (Chapter 6: Section 6.3.6), single 
cells were gated on the occasion of each analysis in order to exclude cellular 
debris and doublets which could lead to false positive results. An example of the 
gating strategy is shown in Figure 4.3 for the analysis of SH-SY5Y cells used 
during the optimisation of cell capture and release in a prototype microfluidic 
device (Chapter 6: Section 6.3.2). 
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Figure 4.3 Flow cytometry gating strategy for single cells 
For all flow cytometry data excluding viability testing, single cells were gated; 
first, intact cells were gated to exclude cellular debris (top left panel), then 
single cells were gated to exclude doublets (top right panel). The bottom 
panels show a comparison of intact cells (bottom left panel) and single cells 
(bottom right panel) on a forward scatter area against forward scatter height 
contour plot. Contour plots indicate the density of cells using contour lines 
and different colours; in CytExpert software, red indicates the area of highest 
cell density in the centre of the plot and dark blue indicates the areas of 
lower cell density at the edges of the plot. This example shows the gating of 
SH-SY5Y single cells used during the optimisation of cell capture and 
release in a prototype microfluidic device.   
 
4.6 Statistical analysis 
All statistical analysis was carried out using IBM SPSS Statistics 25 software. The 
Shapiro Wilk test of normality was used to assess the distribution of replicates, 
and if the replicates were normally distributed an independent samples t-test was 
- 57 - 
used to compare means. If the replicates were not normally distributed, a Mann 
Whitney U test was used to compare means. For the experiments carried out in 
Chapter 5, the n value represents the number of technical replicates carried out 
in each experiment. In Chapters 6 and 7, a minimum of three biological replicates 
were carried out for each experiment (each replicate carried out on a different 
day using a different device). In addition, in Chapter 7 where donor samples are 
used, bone marrow mononuclear cells from multiple donors were combined for 
each experiment and the n value represents the number of replicates carried out 
on different days with different donor samples (unless otherwise specified).  
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Chapter 5:  
Identification of suitable binding proteins for the capture of 
CD271+ cells  
5.1 Introduction 
To address Objective 1 (Section 3.2.1), this chapter of work aimed to identify a 
suitable binding protein for the capture of CD271+ cells in a cell enrichment 
device.  
Affimer proteins were selected against human CD271 recombinant protein using 
phage display (Section 5.3.1), and target-specific clones identified by phage 
enzyme-linked immunosorbent assay (phage ELISA, Section 5.3.1.4) and DNA 
sequencing (Section 5.3.1.5). Once target-specific clones were identified, the 
unique insert sequences were sub-cloned into an E. coli expression vector and 
produced in E. coli cells (Section 5.3.2). Affimer proteins were purified and their 
binding to CD271 protein assessed using ELISA and SPR (Section 5.3.3). Finally, 
Affimer proteins displaying specific binding to CD271 recombinant protein were 
investigated for their specific binding to CD271+ cells present in DPSC 
populations and SH-SY5Y neuroblastoma cells (CD271+ cell line)(Section 5.3.4).  
The following sections will detail the processes involved in phage display 
selection of target-specific Affimers and the production and purification of Affimer 
proteins.  
 
5.1.1 Phage display 
Phage display is a powerful in vitro screening technique used to identify ligands 
for proteins and other macromolecules (216). A filamentous bacteriophage can 
display polypeptide or protein sequences as fusion coat proteins on the phage 
surface. This can be used to create libraries of up to 1010 different variants (217). 
The phage phenotype and genotype are physically linked such that the gene 
encoding the displayed molecule is packed within the same virion as a single-
stranded DNA, meaning that identical phage particles will be obtained from the 
same E Coli. clone.  
Phage display was used in this work to identify potential ligands for CD271 protein 
expressed on MSCs. The phage display library was created by the BioScreening 
and Technology Group (BSTG) at the University of Leeds, and is based on a 
consensus phytocystatin sequence, modified and truncated for use as a non-
antibody protein scaffold now referred to as an Affimer (formerly an “Adhiron”)  
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(156). Briefly, the coding region of the Affimer scaffold was cloned between NheI 
and NotI restriction sites in a phagemid vector which allowed the production of an 
Affimer/truncated-pIII fusion coat protein in ER2738 suppressor cells for phage 
display. The library was constructed by splice overlap extension of two PCR 
products to introduce two nine-amino acid variable regions (see Chapter 2: 
Section 2.5.3.2, Figure 2.11), estimated to contain ~1.3 x 1010 independent 
clones. A small subsection of the library contained only one variable loop region 
(158). 
Phage display relies on multiple cycles of biopanning to select highly specific 
ligands against target molecules. Figure 5.1 shows a typical biopanning cycle; 
the target protein is immobilized on a solid substrate, the phage display library is 
incubated with the immobilized target, unbound phage are washed away and 
bound phage are eluted and amplified in bacteria ready for the next selection 
round. In this work, the target protein was biotinylated prior to phage display 
biopanning facilitating immobilisation to biotin-binding solid substrates. In each 
biopanning round the biotin-binding substrate was changed to minimise non-
specific binding. After three biopanning rounds, the binding activity of bound 
phage was tested in a phage ELISA (see Section 5.1.2).   
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Figure 5.1 Schematic illustrating phage display biopanning  
The phage library is incubated with an immobilised target and unbound 
phage are washed away. Bound phage are eluted and amplified in E. coli 
cells ready for the next biopanning round. Typically three or four rounds of 
biopanning are carried out in order to enrich target-specific ligands with the 
desired binding behaviour. This diagram was created with BioRender.com. 
 
5.1.2 Enzyme-linked immunosorbent assay (ELISA) 
An enzyme-linked immunosorbent assay (ELISA) is a plate-based assay which 
enables the quantification of substances such as proteins, peptides and 
hormones (218). There are various formats an ELISA can be carried out in 
however the principle remains the same - an antigen is immobilised to a plate 
and recognised by, and then complexed with, an antigen-specific antibody 
conjugated to an enzyme. The enzyme activity can be detected by reaction with 
a substrate that produces a measurable product. The enzyme used for detection 
in this work was horseradish peroxidase (HRP) which reacts with 3,3',5,5'-
tetramethylbenzidine (TMB) substrate to produce a soluble blue product 
measured at 620 nm. ELISAs were used in this study for two purposes; to check 
that proteins were successfully biotinylated, and to assess the binding activity of 
different clones isolated by phage display. The different ELISA formats used in 
the work in this chapter are outlined below. 
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5.1.2.1 Direct ELISA to check for biotinylation 
The ELISA format used to check the successful biotinylation of proteins was a 
direct ELISA. The biotinylated protein was directly adsorbed onto the well plate 
and a streptavidin-HRP conjugate was used for detection (Figure 5.2). This 
detection strategy takes advantage of the well-known avidin-biotin interaction, 
which is the strongest non-covalent interaction known (219). A streptavidin 
molecule can bind up to four biotin molecules making it an ideal approach for the 
detection of bound molecules.  
 
 
Figure 5.2 Direct ELISA format for detecting biotinylated protein 
In the direct ELISA format, a protein is directly adsorbed onto a solid 
substrate and complexed with a primary antibody conjugated to an enzyme. 
In this case, the protein is biotinylated and streptavidin is used instead of a 
primary antibody, which is conjugated to HRP and detected via reaction with 
TMB substrate. This diagram was created with BioRender.com. 
 
5.1.2.2 Sandwich ELISA to assess binding behaviour of individual clones 
A phage ELISA was carried out to assess the binding behaviour of clones 
selected by phage display biopanning. The format of the phage ELISA was a 
“sandwich” ELISA with indirect detection. The wells were coated with streptavidin 
as a capture molecule for the biotinylated target protein and bound phage was 
detected via an anti-phage-HRP antibody (Figure 5.3).  
Sandwich ELISAs were also carried out to assess the binding behaviour of 
purified Affimer proteins - streptavidin was again used as a capture molecule and 
HRP-conjugated secondary antibodies were used as detection molecules.  
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Figure 5.3 Sandwich ELISA format for assessing phage binding behaviour 
to target protein 
In a sandwich ELISA, a capture molecule is used to immobilise the antigen 
to a solid substrate. In this case, streptavidin was used to capture 
biotinylated proteins. Bound phage was detected via an anti-phage-HRP 
secondary antibody and HRP activity measured using TMB substrate. This 
diagram was created with BioRender.com 
 
5.1.3 DNA sequencing 
DNA sequencing is the process of determining the nucleotide sequence of a 
piece of DNA. This is commonly carried out by Sanger sequencing, where the 
target DNA is first copied many times making fragments of different lengths. At 
the end of each fragment is a dideoxy nucleotide which terminates the chain and 
is marked with a particular colour of dye depending on the nucleic base (A, T, C 
or G)(220). The dye at the end of each fragment can be detected and produces 
a chromatogram where the DNA sequence can be read from the peaks. 
To identify the phage display clones responsible for specific binding in the phage 
ELISA, clones were sent to an external facility for DNA sequencing. DNA 
sequencing was also carried out after DNA sub-cloning (Section 5.1.4.2) to 
confirm the correct Affimer sequence had been cloned.  
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5.1.4 Recombinant protein production and purification methods 
Recombinant proteins are widely used throughout biological and biomedical 
sciences and the technology of their production and purification is now relatively 
simple (221). Despite this, different proteins require different protocols and these 
must be optimised for each individual protein. The strategy used for Affimer 
protein production and purification has been previously optimised by the BSTG 
and is outlined in Figure 5.4. In the following section, the individual techniques 
involved are described.  
 
 
Figure 5.4 Affimer protein production and purification overview 
 
5.1.4.1 Polymerase Chain Reaction (PCR) 
Affimer insert sequences are amplified prior to DNA sub-cloning using the 
polymerase chain reaction (PCR). PCR is based on the ability of DNA polymerase 
to synthesize DNA complementary to a template strand (222).  
Briefly, a DNA template that contains the target sequence is heated to a high 
temperature to denature the DNA strands. A primer sequence (complementary 
to the target sequence) is required to provide the starting point for DNA 
polymerase and nucleotide bases are added to provide the ‘building blocks’ for 
1. Affimer DNA sequence cloned into an E. coli
expression vector 
(Section 5.1.4.2 and 5.2.6)
2. Protein expressed in BL21 Star™ (DE3) E. coli 
cells with IPTG induction
(Section 5.1.4.3 and 5.2.7)
3. Cells lysed and Ni-NTA resin used to purify the 
soluble His-tagged Affimer protein
(Section 5.1.4.4 and 5.2.7)
4. Gel electrophoresis used to check the efficiency 
and purity of Affimer proteins
(Section 5.1.4.5 and 5.2.7)
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new DNA strands. The temperature is lowered to enable the DNA primers to 
attach to the template DNA, then raised again for the polymerase to make new 
strands of DNA. Through repeated cycles, thousands to millions of DNA copies 
are generated (223). 
 
5.1.4.2 DNA sub-cloning 
Recombinant DNA technology is the process of joining two or more DNA 
segments to generate a single molecule capable of autonomous replication in a 
given host (224). In the case of DNA sub-cloning, a previously cloned DNA 
segment is the insert sequence, cloned into a plasmid or bacteriophage cloning 
vector. 
Figure 5.5 shows a schematic of a basic sub-cloning protocol; both insert DNA 
and vector DNA are treated with restriction endonucleases and purified using 
agarose or polyacrylamide gel electrophoresis (Section 5.1.4.5). The digested 
components are combined and treated with DNA ligase, then introduced into 
competent E. coli cells. An antibiotic resistance gene in the plasmid allows 
transformants to be identified by using the appropriate antibiotic in cell cultures.  
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Figure 5.5 DNA sub-cloning schematic 
A basic protocol for DNA sub-cloning involves digesting both donor 
plasmid and recipient plasmid with restriction endonucleases and ligating 
the digested products. An antibiotic resistance gene is included so that 
transformants can be selected. This diagram was created with 
BioRender.com 
 
5.1.4.3 Protein expression in E. coli cells 
E. coli as an expression host is fast, inexpensive and useful in many cases of 
protein production (221). For Affimer protein production, the BL21 Star™ (DE3) 
E. coli strain is commonly used which is compatible with the T7 lacO promoter 
system. Affimer proteins are produced as fusions to an N-terminal hexahistidine 
affinity tag which enables purification via immobilised metal affinity 
chromatography (Section 5.1.4.4).  
Using a T7 system, protein expression is induced using isopropyl-β-D-
thiogalactoside (IPTG) which triggers transcription of the lac operon. Cells are 
grown to high densities and IPTG is added at mid-to-late log phase of growth to 
achieve maximal yields. A low temperature (25 °C) is used during induction so 
that recombinant proteins remain soluble.  
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5.1.4.4 Protein purification using immobilised metal affinity 
chromatography (IMAC) 
Once the recombinant protein has been expressed in E. coli cells, it is extracted 
by cell lysis. The lysis buffer contains a cocktail of enzymes and protease 
inhibitors to break down the cell wall, and has a relatively high ionic strength to 
promote protein solubility and stability. The soluble protein can then be purified 
using immobilised metal affinity chromatography (IMAC). This process uses a 
resin such as nickel-nitrilotriacetic acid (Ni-NTA)(for His-tagged proteins) where 
the histidine residues bind to the nickel ions whilst other proteins can be washed 
away. The His-tagged protein can be eluted using an elution buffer with a high 
concentration of imidazole (300 mM) which competes for binding to the nickel 
resin. Wash buffers contain a low concentration of imidazole (20 mM) to elute 
weakly bound contaminants.  
 
5.1.4.5 Polyacrylamide and agarose gel electrophoresis 
Gel electrophoresis is a method used to separate mixtures of DNA, RNA or 
proteins according to their molecular size (225). An electrical field is applied such 
that one end of the gel is positively charged and the other is negatively charged. 
Molecules move through the gel according to their size and charge with smaller 
molecules travelling at a faster speed. DNA and RNA are negatively charged 
molecules and are therefore pulled towards the positive end of the gel. However 
proteins may not carry an appropriate negative charge and are mixed with a 
detergent – sodium dodecyl sulphate (SDS) - beforehand. This causes the 
proteins to unfold and have a negative charge proportional to the polypeptide 
chain length.    
Typically DNA and RNA fragments are separated on agarose gels and proteins 
on SDS polyacrylamide (SDS-PAGE) gels. A DNA-binding dye is used in the 
agarose gel solution which can be visualised under UV light. Coomassie blue is 
used to stain SDS-PAGE gels where the intensity of the bands is usually 
proportional to the amount of protein, providing a semi-quantitative method. 
 
5.1.5 Mass spectrometry 
Mass spectrometry measures the mass to charge ratio (m/z) of ions and can be 
used for a number of applications including proteomics. For this work, mass 
spectrometry was used to determine the mass of an Affimer protein before and 
after reaction with biotin-maleimide (Section 5.2.9).  
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In mass spectrometry, samples are loaded into a mass spectrometer, vaporised, 
and ionised by an ion source. The mass spectrometer used in this case was an 
ion mobility enabled mass spectrometer (IMEMS) which uses Travelling Wave 
Ion Mobility. In an IMEMS, ions move through a buffer-filled guide where their 
charge determines the magnitude of the interaction with the buffer gas, which 
affects the mobility of the ions (226). The ions are therefore separated, and then 
detected. 
 
5.2 Materials and Methods 
5.2.1 Biotinylation of phage display target: CD271-His recombinant 
protein 
The target protein was biotinylated prior to phage display biopanning to facilitate 
immobilisation to biotin-binding substrates. 
Human CD271-His recombinant protein was purchased from Sino Biological 
(13184-H08H) and biotinylated according to a protocol previously optimised by 
the BSTG. Protocols optimised by the BSTG were used throughout phage display 
screening (Section 5.2.3), for DNA sub-cloning (Section 5.2.6), and for Affimer 
protein production and purification (Section 5.2.7).  
A 10 mM solution of EZ-Link® NHS-SS biotin (Thermo Scientific, 21441) in 
dimethylsulphoxide (DMSO, Sigma-Aldrich,  D8418) was prepared and 0.64 µL 
incubated with CD271-His recombinant protein (0.2 mg/mL, 130 µL) for 1 h at RT. 
The amount of biotin solution used was proportional to the molecular weight of 
the protein (45-60 kDa). To remove excess biotin, Zeba Spin Desalting Columns, 
7K MWCO (Thermo Scientific, 89882) were used according to the manufacturer’s 
instructions. An equal volume of 80% glycerol was added to the biotinylated 
protein and stored at -20 °C. 
 
5.2.2 Direct ELISA to determine biotinylation of target protein 
A direct ELISA (Section 5.1.2.1) was carried out to check that the target protein 
had been successfully biotinylated. 
Phosphate-buffered saline (PBS) was aliquoted into Nunc-Immuno™ 
MaxiSorp™ strips (Thermo Scientific, 469949, 50 µL per well) and biotinylated 
CD271-His protein was added in different volumes (1 µL and 0.01 µL) to two 
wells. Two additional wells contained PBS only. The wells were incubated at 4 °C 
overnight then washed 3x with 300 µL PBST (PBS containing 0.1% Tween 20) 
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on a plate washer (TECAN HydroFlex). Wells were blocked with 10x Blocking 
Buffer (Sigma, B6429, 250 µL per well) and incubated for 3 h at 37 °C before 
washing was repeated (3x 300 µL PBST). High sensitivity streptavidin-HRP 
(Thermo Scientific, 21130) was diluted 1:1000 in 2x Blocking Buffer (10x Blocking 
Buffer diluted in PBST) and 50 µL was added to each well. After 1 h incubation 
on a vibrating platform shaker (Heidolph VIBRAMAX 100; speed setting 3) the 
plate was washed 6x (300 µL PBST) and 50 µL TMB substrate (SeramunBlau® 
fast TMB substrate solution, Seramun,  S-001-TMB) added per well. The colour 
was allowed to develop for 5 min and the absorbance was measured at 620 nm.  
 
5.2.3 Phage display screening of target protein: biotinylated CD271-
His recombinant protein 
Two phage display screens of biotinylated CD271-His protein were carried out 
using two slightly different protocols. The first protocol included overnight 
washing with the aim to wash away any weakly bound or non-specifically bound 
phage (protocol 1). The second protocol eliminated the overnight washing steps 
in order to capture clones with weaker affinity to the target protein (protocol 2). 
The second protocol also eluted bound phage to investigate change in pH as a 
possible release mechanism in the final cell enrichment application.  
In the first phage display screen, a yeast small ubiquitin-like modifier (ySUMO) 
protein was screened alongside CD271-His protein as a positive control known 
to produce hits from the Affimer library (156). In the second phage display screen, 
a tubulin protein was used as a positive control (158). In both screens, the first 
biopanning round was carried out on streptavidin-coated wells, the second on 
streptavidin-coated magnetic beads, and the third on NeutrAvidin-coated wells. 
The solid substrate was changed in each biopanning round to reduce non-specific 
binding. 
5.2.3.1 First biopanning round 
Streptavidin coated (high binding capacity) 8-well strips (Thermo Scientific,  
15501) were blocked with 2x Blocking Buffer (250 μL per well) and incubated 
overnight at 37 °C. The phage display library (40 µL) was diluted 1 in 10 with 2x 
Blocking Buffer and pre-panned in the pre-blocked wells for 2 h on a vibrating 
platform shaker at RT. The phage were moved to a new pre-blocked well every 
40 min. Pre-panning was carried out to reduce non-specific binding to the 
streptavidin-coated wells. At the same time, biotinylated target was immobilised 
to a pre-blocked streptavidin-coated well by incubating for 2 h on a vibrating 
platform shaker at RT. 
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Immobilised target protein was washed 3x with PBST (300 µL per well) on a plate 
washer. The pre-panned phage was added to the target wells and incubated for 
2 h on a shaker (125 rpm). The plate was washed 27x with PBST (300 µL per 
well) to wash away unbound phage. Bound phage were eluted by addition of 
glycine-HCl (0.2 M, 100 µL, pH 2.2) for 10 min at RT, then neutralised with tris-
HCl (1 M, 15 µL, pH 9.1) and incubated with ER2738 E. coli cells in 2TY media1 
(8 mL, A600 ~0.6). Any bound phage remaining in the target well was eluted with 
addition of triethylamine (Sigma-Aldrich, T0886, 1 mM in PBS, 100 µL, pH 10.75) 
for 6 min at RT, neutralised with tris-HCl (1 M, 50 µL, pH 7) and added to the 
ER2738 E. coli cell culture.  
The cell culture was incubated for 1 h at 37 °C shaking at low speed (90 rpm). 
Phage-infected ER2738 cells (1 μL – representing 100 - 250 colony forming units) 
were plated on a LB carb plate (lysogeny broth agar plates containing 100 μg/mL 
carbenicillin) and incubated overnight at 37 °C. The remaining cells were 
centrifuged at 3000 g for 5 min then plated on a LB carb plate and incubated 
overnight at 37 °C. 
Colonies on the 1 μL plate were counted and the total number of colony forming 
units per 8 mL cell culture was calculated. The plate containing the remaining 
cells was scraped and diluted in 2TY carb (2TY media containing 100 μg/mL 
carbenicillin) to make 8 mL cultures (A600=0.2). Cell cultures were incubated for 
1 h at 37 °C, 230 rpm. M13K07 helper phage (0.32 μL, titre ca. 1014/mL) was 
added and incubated for a further 30 min at 37 °C, 90 rpm. Kanamycin (25 mg/mL, 
16 μL) was added and incubated overnight at 25 °C, 170 rpm.  
The phage-infected cultures were centrifuged at 3500 g for 10 min. The phage-
containing supernatant was transferred to a fresh tube and a small aliquot was 
taken for the second biopanning round. Polyethylene glycol-sodium chloride 
(PEG-NaCl) precipitation solution (2 mL, 20% (w/v) PEG 8000, 2.5 M NaCl) was 
added to the remaining supernatant and incubated overnight at 4 °C. The 
precipitated phage was centrifuged at 4,816 g for 30 min, the pellet resuspended 
in TE buffer2 (320 μL) and stored at 4 °C. 
5.2.3.2 Second biopanning round 
Streptavidin beads (Dynabeads® MyOne™ streptavidin T1, 10 mg/mL, 
Invitrogen, 656.01/656.02, 20 μL) were washed 2x in PBST and blocked using 2x 
Blocking Buffer (100 μL) overnight on a Stuart SB2 fixed speed rotator (20 rpm). 
The beads were centrifuged at 800 g for 1 min and immobilised on a magnet. The 
 
1 2TY media (per litre): 10 g yeast extract, 16 g tryptone, 5 g sodium chloride  
2 TE buffer: 10 mM Tris, 1 mM EDTA, pH 8.0 
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phage-containing supernatant from the first biopanning round was blocked with 
10x Blocking Buffer (60 μL) and pre-panned on the pre-blocked streptavidin 
beads for 2 h on the fixed speed rotator. At the same time, biotinylated target (10 
μL) was added to pre-blocked beads with 2x Blocking Buffer (300 μL) and 
incubated for 2 h on the rotator to immobilise the target protein.  
The beads with immobilised protein were centrifuged at 1000 g for 1 min, placed 
on a magnet and washed 3x in 2x Blocking Buffer (1 mL). The beads with pre-
panned phage were centrifuged at 1000 g for 1 min and placed on a magnet so 
that the supernatant containing the pre-panned phage could be removed and 
added to the immobilised target. The pre-panned phage and the beads with 
immobilised target were mixed and transferred to pre-blocked wells of a deep well 
96 plate (Thermo Scientific, 95040450). 
For protocol 1: A pre-programmed protocol “Phage_Display_Competition” (see 
Appendix A: KingFisher Flex Protocol “Phage_Display_Competition”) was used 
on the KingFisher Flex (an automated system for handling magnetic beads). At 
the end of the protocol, the beads were released into PBS (100 μL) and 
transferred into Protein LoBind Tubes. The wells were washed with PBST with 
20% glycerol (200 μL) and added to the tubes to a total volume of 1 mL. The 
tubes were incubated for 24 h on a rotator with 1x buffer change. The samples 
were centrifuged at 800 g for 30 s then transferred to a pre-blocked deep well 96 
well plate. A second pre-programmed protocol “Phage_Display_Wash_Elute” 
(see Appendix B: KingFisher Flex Protocol "Phage_Display_Wash_Elute") was 
used on the Kingfisher Flex to elute the phage into glycine-HCl and triethylamine 
as in the first biopanning round.  
For protocol 2: A pre-programmed protocol “Phage_Display_Standard” (see 
Appendix C: KingFisher Flex Protocol “Phage_Display_Standard”) was used on 
the KingFisher Flex. At the end of the protocol the beads were released into 
glycine-HCl, then triethylamine, and neutralised with tris-HCl as in the first 
biopanning round. No overnight washing was carried out.  
For both protocols, once the bound phage had been eluted, samples were treated 
in the same way as the first biopanning round; incubation with ER2738 E. coli 
cells (8 mL cultures), plated on LB carb plates overnight and phage prepared for 
the third biopanning round using M13K07 helper phage.  
5.2.3.3 Third biopanning round  
NeutrAvidin Coated (HBC) 8-well strips (Thermo Scientific, 15508) were blocked 
with 2x Blocking Buffer (250 μL) and incubated overnight at 37 °C. Phage 
containing supernatant (220 μL) from the second biopanning round was pre-
panned in the pre-blocked wells for 4 h at RT, shaking (Heidolph VIBRAMAX 100; 
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speed setting 3). The pre-panned phage was moved to a new well every hour. At 
the same time, biotinylated target (10 μL) was incubated in a pre-blocked well for 
immobilisation.  
The immobilised target and a blank negative control well (also pre-blocked) were 
washed 3x with PBST (300 μL per well) on a plate washer. Pre-panned phage 
(100 μL) and 10x Blocking Buffer (40 μL) were added to the target well and the 
negative control well, and incubated for 1 h on a shaker. Wells were washed 27x 
with PBST (300 μL per well) on a plate washer. 
For protocol 1: PBST with 20% glycerol (250 μL) was added and incubated 
shaking overnight with 1x buffer change. Wells were washed 27x with PBST (300 
μL per well) on a plate washer. The bound phage was eluted as previously 
described and added to ER2738 cell cultures. 
For protocol 2: No overnight washing was carried out. Bound phage were eluted 
at pH 9, pH 7, pH 5 and using the standard protocol with pH 2.2 and pH 10.75 
(Section 5.2.3.1). Each elution was neutralised with tris-HCl (1 M, pH 7, 50 μL) 
and added to separate ER2738 cell cultures.  
For both protocols, after 1 h amplification in E. coli cells (5 mL cultures), a range 
of volumes (0.1 μL, 1 μL, 10 μL) were plated on LB carb plates and incubated 
overnight at 37 °C. Ten microlitres of cell suspension containing phage eluted 
from the negative well was also plated for comparison.  
 
5.2.4 Phage ELISA to assess the binding behaviour of individual 
clones  
A sandwich ELISA (section 5.1.2.2) was carried out to investigate the binding 
behaviour of individual clones from the final round of phage display biopanning. 
Colonies from the final round of biopanning were picked and grown in a 96-well 
V-bottom deep well plate in 2TY carb (200 μL per well) overnight at 27 °C, shaking 
(750 rpm, Heidolph incubator 1000 and Titramax 1000). The overnight culture (10 
μL) was transferred to fresh 2TY carb (200 μL) and incubated for 1 hour at 37 °C, 
1200 rpm. M13K07 helper phage (titre ca. 1014/mL) was diluted 1:1000 in 2TY 
carb and added (10 μL per well) to the fresh cultures. The cultures were incubated 
for 30 min at 400 rpm. Kanamycin stock (25 mg/mL) was diluted 1:20 in 2TY carb 
and added at 10 μL per well to the phage-infected cultures. The cultures were 
incubated overnight at RT and 750 rpm. 
Streptavidin in PBS (2.5 μg/mL) was aliquoted (50 μL per well) into F96 Maxisorp 
Nunc-immuno plates (Thermo Scientific, 442404) and incubated overnight at        
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4 °C. The plates were blocked with 3x Blocking Buffer (100 μL per well) and 
incubated overnight at 37 °C. The plates were washed 1x with PBST (300 μL per 
well) on a plate washer. Biotinylated target protein was diluted 1:100 in 2x 
Blocking Buffer and aliquoted (50 μL per well) in one half of the plate and 2x 
Blocking Buffer (50 μL per well) was incubated in the second half of the plate 
(negative control wells). The plates were incubated for 2 h at room temperature, 
300 rpm, then washed 1x with PBST (300 μL per well). 
The phage-infected cultures were centrifuged at 3500 g for 5 min. The phage-
containing supernatant was added (40 μL per well) with 10x Blocking Buffer (10 
μL per well) to one well with biotinylated target and one negative control well. The 
plate was incubated for 1 hour at RT and 300 rpm. After 1x wash with PBST (300 
μL per well), anti-Fd-Bacteriophage-HRP (Seramun Diagnostica GmbH,  A-020-
1-HRP) was diluted 1:1000 in 2x Blocking Buffer and added at 50 μL per well. 
The plate was incubated for 1 h at 300 rpm and washed 6x with PBST (300 μL 
per well). TMB substrate (Seramun, S-001-TMB) was aliquoted at 50 μL per well 
and the colour developed for 5 min. The absorbance was measured at 620 nm 
on a microplate reader. 
 
5.2.5 DNA sequencing of individual clones from the phage ELISA 
Clones that demonstrated target-specific binding in the phage ELISA were sent 
to an external facility for DNA sequencing (Section 5.1.3).  
Phage-infected cultures (1 μL) prepared for the phage ELISA were transferred to 
2TY carb (4 mL) and grown overnight at 37 °C at 230 rpm. The cells were 
centrifuged at 4700 g for 15 min and the plasmid DNA extracted and purified 
using a QIAprep Spin Miniprep Kit (QIAGEN, 27106) according to the 
manufacturer’s instructions. The DNA was eluted in 50 μL purified water and sent 
to Genewiz for sequencing (15 μL at 100 ng/μL). 
 
5.2.6 Sub-cloning of unique DNA sequences 
Unique DNA sequences were subcloned (Section 5.1.4.2) from the pDHis 
phagemid vector to a pET11a expression vector for Affimer protein production 
and purification. 
The pET11a plasmid was digested with NheI and NotI restriction enzymes; 
pET11a plasmid (50 μg), sterile deionised water (150 μL), CutSmart™ Buffer (50 
μL, supplied with NEB restriction enzymes), NheI-HF™ (25 μL, NEB,  R3131S) 
and NotI-HF™ (25 μL, NEB,  R3189S) were mixed and incubated for 6 h at           
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37 °C. The total volume was divided between four tubes and Antartic 
Phosphatase Reaction Buffer (14 μL, 10x, NEB, B0289S) and Antartic 
Phosphatase (1 μL, 5000 units/mL, NEB, M0289S) were added and incubated 
for 15 min at 37 °C. The tubes were incubated at 65 °C for 5 min to heat inactivate 
the Antartic Phosphatase. A 10x Orange G Loading Dye (14 μL, 30% Glycerol; 
0.2% Orange G; H2O) was added and the digested vector separated on a 0.7% 
agarose gel. The digested vector was extracted from the gel using a FastGene 
Gel Extraction/PCR kit (FastGene, FG-91302) according to the manufacturer’s 
instructions. The vector DNA was stored at -20 °C. 
DNA sequences from the phagemid vector were amplified using PCR (Section 
5.1.4.1); sterile water (14.3 μL), 5x Phusion HF Buffer (5 μL, supplied with 
Phusion DNA polymerase), dNTP Mix (25 mM, MP Biomedicals, NTPMX255), 
DMSO (0.75 μL, supplied with Phusion DNA polymerase), Forward Primer (5’ – 
ATGGCTAGCAACTCCCTGGAAATCGAAG, 10 μM, 2 μL), Reverse Primer (5’ – 
TTACTAATGCGGCCGCACAAGCGTCACCAACCGGTTTG, 10 μM, 2 μL), 
Phusion High-Fidelity DNA Polymerase (0.25 μL, Thermo Scientific, F-530) and 
template DNA (phagemid vector, 0.5 μL, 100 ng/μL) were mixed. The PCR 
thermocycling conditions are shown in Table 5.1. DpnI (0.5 μL, NEB, R0176) was 
added to each PCR tube and incubated for 1 h at 37 °C. The amplified DNA was 
purified using a FastGene Gel Extraction/PCR kit according to the manufacturer’s 
instructions and eluted in 50 μL sterile water. 
 
Table 5.1 PCR thermocycling conditions 
Cycle step Temperature (°C) Time Cycles 
Initial denaturation 98 30 s 1 
Denaturation 
Annealing 
Extension 
98 
54 
72 
20 s 
20 s 
20 s 
 
30 
Final extension 
Hold 
72 
4 
10 min 
Hold 
1 
 
The PCR-amplified DNA sequences were digested with the same restriction 
enzymes as the pET11a vector. Sterile water (3.5 μL), CutSmart™ Buffer (6 μL), 
NheI-HF™ (0.25 μL) and NotI-HF™ (0.25 μL) were added and incubated at         
37 °C overnight. The digest products were purified using a FastGene Gel 
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Extraction/PCR kit according to the manufacturer’s instructions. The insert DNA 
was separated on a 2% agarose gel and stored at -20 °C. 
Digested insert DNA was ligated with digested pET11a vector DNA; 10x T4 DNA 
ligase buffer (supplied with T4 DNA ligase), vector DNA (75 ng), insert DNA (25 
ng), sterile water (14 μL) and T4 DNA ligase (1 μL, NEB, M0202) were incubated 
at RT overnight. A ligation reaction was also set up with no insert DNA as a 
negative control. The ligation reactions were transformed into XL1-Blue 
supercompetent cells (Agilent Technologies, 200236), plated on LB carb plates 
and incubated overnight at 37 °C.  
Single colonies were picked and grown in 4 mL 2TY carb overnight at 37 °C, 230 
rpm. The cultures were centrifuged at 4816 g for 15 min and the plasmid DNA 
extracted using QIAprep Spin Miniprep Kit (QIAGEN, 27106) according to the 
manufacturer’s instructions. Aliquots (15 μL, 100 ng/μL) of each DNA sample 
were sent for DNA sequencing (Genewiz) to ensure the correct sequence had 
been sub-cloned into the pET11a vector. 
 
5.2.7 Affimer protein production and purification 
Once it had been confirmed that the intended sequence had been sub-cloned 
into the pET11a vector, Affimer protein was produced and purified as described 
below.  
The DNA sequences were transformed into BL21 Star™ (DE3) chemically 
competent E. coli cells (Life Technologies, C6010-03), plated on LB carb plates 
and incubated overnight at 37 °C. A single colony was picked from each plate 
and grown up in 2TY carb (7 mL) at 37 °C, 230 rpm for 5 h. The starter culture (5 
mL) was transferred to pre-warmed 2TY carb (400 mL) and grown to OD600 ~0.8. 
The cultures were induced with IPTG (200 µL, 1 M) and incubated overnight at 
25 °C and 150 rpm. Cells were harvested by centrifugation at 4816 g for 15 min. 
The cell pellets were resuspended in a 1:50 ratio (of original culture volume) in 
lysis buffer3 (to a total volume of 8 mL) supplemented with Lysozyme® (80 µL, 
Sigma-aldrich, L6876-1G), Triton™ X-100 (80 µL, Sigma-aldrich, X100), 
Benzonase® Nuclease, Purity >99% (3.2 µL, Novagen®, 70664) and Halt 
protease inhibitor cocktail, EDTA-free (100X, 80 µL, Thermo Scientific,  78439). 
The cells were incubated for 20 min on a fixed speed rotator. Non-specific 
proteins were denatured in a water bath at 50 °C for 20 min. Cell debris was 
 
3 Lysis buffer: 50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, 10% glycerol, pH 7.4 
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removed by centrifugation at 4816 g for 20 min. Further centrifugation at 12 000 
g for 20 min removed any remaining cell debris and insoluble proteins.   
Amintra Ni-NTA resin (800 µL, Expedeon, ANN0100/ANN0025) was washed in 
wash buffer4 (5 mL) by centrifugation at 1000 g for 1 min. The soluble protein 
fractions were incubated with the resin for 1 h on a fixed speed rotator. The resin 
was washed several times (>5) by centrifugation at 1000 g for 1 min, then 
transferred to an equilibrated Pierce Centrifuge Column (Thermo Scientific, 
89897). The resin was washed on the column in wash buffer until the A280 reading 
(measured with a NanoDrop Lite Spectrophotometer) was consistently <0.09. 
The Affimer was eluted from the column in elution buffer5 (1 mL elutions) until no 
more protein was present.   
The insoluble protein fraction, soluble protein fraction, unbound protein, first 
wash, final wash and elutions were separated on a SDS-PAGE (15%) gel. The 
Affimers were dialysed into PBS, 5% glycerol, 1 mM dithiothreitol (DTT) and 
stored at -80 °C.   
 
5.2.8 Sandwich ELISA to investigate Affimer protein binding to 
CD271-Fc recombinant protein 
A sandwich ELISA (Section 5.1.2.2) was carried out to investigate the binding 
behaviour of the purified Affimer proteins. Since both the Affimer proteins and the 
CD271 recombinant protein had a His tag, detection via an anti-His tag antibody 
was not possible. To resolve this, a second CD271 recombinant protein was 
purchased from Sino Biological (13184-H02H-50), which was fused with the Fc 
region of human IgG1. The CD271-Fc protein was biotinylated in the same way 
as the CD271-His protein (Section 5.2.1) to allow immobilisation to a streptavidin-
coated ELISA plate.  
Streptavidin-coated plates were prepared and blocked as previously described 
(Section 5.2.4). Biotinylated CD271-Fc protein was diluted 1:100 in 2x Blocking 
Buffer and aliquoted at 50 µL per well for positive wells, whilst negative wells 
contained 2x Blocking Buffer only. The plate was incubated for 1 h on a vibrating 
platform shaker and washed 1x in PBST (300 µL per well). Affimers were added 
(10 µg/mL, 50 µL per well) and incubated for 1 h on a vibrating platform shaker. 
The plate was washed 1x with PBST (300 µL per well) and Anti-6X His tag® 
antibody-HRP (50 µL per well, Abcam, ab1187) was added 1:1000 in 2x Blocking 
 
4 Wash buffer: 50 mM NaH2PO4, 500 mM NaCl, 20 mM imidazole, pH 7.4 
5 Elution buffer: 50 mM NaH2PO4, 500 mM NaCl, 300 mM imidazole, 20% glycerol, pH 
7.4 
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Buffer. The plate was incubated for 1 h on a vibrating platform shaker. After 10x 
washes with PBST (300 µL per well), TMB (50 µL per well) was added and 
developed for 5 min. Absorbance was measured at 620 nm. 
 
5.2.9 Biotinylation of Affimer proteins 
Affimer insert sequences were expressed in an Affimer scaffold with a C-terminal 
cysteine to allow for site-specific labelling. A fraction of the purified Affimers were 
labelled with biotin to allow immobilisation to a streptavidin-coated substrate.  
Immobilised tris(2-carboxyethyl)phosphine (TCEP) disulphide-reducing gel (150 
µL, Thermo Scientific, 77712) was washed 3x with PBS containing 1 mM EDTA 
(300 µL). PBS containing 50 mM EDTA (4 µL) and Affimer (150 µL, 0.5 mg/mL) 
were added to the gel and incubated on a fixed speed rotator for 1 h. The gel was 
discarded and the Affimer molecules (with reduced cysteine’s,130 µL) were 
reacted with biotin malemide (Sigma-Aldrich, B1267, 6 µL, 2 mM) for 2 h at RT. 
Zeba Spin Desalting Columns, 7K MWCO (Thermo Scientific, 89882) were used 
to remove any excess biotin according to the manufacturer’s instructions. An 
equal volume of 80 % glycerol (130 µL) was added and the Affimers were stored 
at -20 °C. A direct ELISA was carried out to check biotinylation (Section 5.2.2) as 
well as mass spectrometry analysis (Section 5.1.5).  
 
5.2.10 Surface plasmon resonance analysis of Affimers binding 
to CD271 recombinant protein 
Surface plasmon resonance (SPR, Section 4.2) was used to characterise Affimer 
protein binding to CD271 recombinant protein, including the specificity and affinity 
of binding interactions.  
A 4-channel BIACORE 3000 instrument and BIACORE 3000 control software 
were used to collect data. The first set of experiments was carried out using a 
carboxymethylated dextran substrate where both CD271 recombinant proteins 
(CD271-His and CD271-Fc), and a negative control protein were immobilised to 
the substrate via crosslinking chemistry (Section 4.4). pH scouting was carried 
out prior to binding assays to find the pH at which proteins were immobilised to 
the sensor surface most efficiently. 
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5.2.10.1 Assessing the appropriate pH for protein immobilisation to a 
CM5 sensor substrate (pH scouting) 
The sensor substrate CM5 (GE Healthcare Life Sciences, BR100399) was 
docked and running buffer (0.1 M sodium acetate, pH 5.6) injected over all four 
flow cells. Target protein (15 μL at a concentration of 5 μg/mL) was injected in 
different pH buffers at 5 μL/min and the response units recorded before and after 
the injection. The pH range investigated included pH 7.4 (PBS), pH 5.6 (running 
buffer - 0.1M sodium acetate), pH 5.5, pH 5.0 and pH 4.5 (all 10 mM sodium 
acetate buffers). This range was chosen because efficient pre-concentration of 
the protein at the sensor surface requires the pH to lie between the pka of the 
surface and the isoelectric point of the protein. Between each buffer, a high salt 
wash (1 M NaCl, 15 μL) was injected to regenerate the substrate surface. The 
immobilisation buffer was chosen based on the increase in response units whilst 
minimising the compromise on biological pH. An example of pH scouting for 
CD271-Fc protein is shown in Figure 5.6 where pH 5.0 was chosen for 
immobilisation. 
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Figure 5.6 SPR Sensogram showing pH scouting for CD271-Fc 
recombinant protein 
pH scouting was carried out to assess the efficiency of protein 
immobilisation at different pHs. CD271-Fc recombinant protein (5 µg/mL) 
was injected at 5 µL/min in PBS (pH 7.4), running buffer (0.1 M sodium 
acetate, pH 5.6), 10 mM sodium acetate, pH 5.5, 10 mM sodium acetate, 
pH 5.0 and 10 mM sodium acetate, pH 4.5. A high salt solution wash (1 M 
NaCl) was carried out between each immobilisation to regenerate the 
substrate surface. pH 5.0 was considered the best compromise between 
efficiency and biological pH, however the protein concentration was 
increased to 10 µg/mL for binding assays.  
 
5.2.10.2 Protein immobilisation to a CM5 sensor substrate 
Proteins were immobilised to a CM5 sensor substrate using EDC and NHS 
crosslinking chemistry (Section 4.4).  
A mock immobilisation was carried out on flow cell 1 where no protein was 
immobilised. TNAP recombinant protein (His tag)(TNAP-His, Sino Biological, 
10440-H08H-50) was immobilised on flow cell 2 as a negative control, CD271-
His protein was immobilised on flow cell 3 and CD271-Fc protein was immobilised 
on flow cell 4. The flow rate was set to 5 μL/min. An NHS aliquot and an EDC 
aliquot (supplied with Amine Coupling Kit, GE Healthcare Life Sciences, 
BR100050) were mixed together in equal amounts (70 μL total) and injected to 
activate the sensor surface. The target protein was injected in the pre-determined 
buffer until the desired amount of units were immobilised (~10x the molecular 
weight of the protein). Unreacted protein was washed off the surface by a high 
salt solution (5 μL, 1 M NaCl) and unreacted sites were capped using 
ethanolamine hydrochloride (35 μL, 1.0 M, supplied with the Amine Coupling Kit, 
- 79 - 
GE Healthcare Life Sciences, BR100050). An example immobilisation of CD271-
His protein is shown in Figure 5.7. 
 
 
Figure 5.7 SPR sensogram showing the immobilisation of CD271-His 
recombinant protein to a CM5 sensor substrate 
Proteins were immobilised onto a CM5 sensor substrate via NHS/EDC 
crosslinking chemistry. In the above example, CD271-His protein (10 
µg/mL) was injected over the activated surface at 5 µL/min until the desired 
amount of protein was immobilised (~10x the molecular weight of the 
protein). A high salt solution wash (1 M NaCl) was carried out to wash away 
unreacted material and 1 M ethanolamine hydrochloride was injected to cap 
unreacted sites. 257.4 units of CD271-His were immobilised in the example 
above.  
 
5.2.10.3 SPR binding assays 
For the binding assays, Affimer protein was dialysed into PBS and injected in two-
fold concentration steps from 25 nM to 400 nM over all four flow cells. An 
automated method was used with 3 minute injections at 50 µL/min with running 
buffer of PBS with 0.1% Tween 20.  
A second sensor substrate CM5 was assembled for a further experiment. The 
same procedure of pH scouting and immobilisation was carried out with the 
following proteins immobilised; flow cell 1 had no protein immobilised, flow cell 2 
had CD45-Fc protein (Sino Biological, 10086-H02H) immobilised as a negative 
control, flow cell 3 had CD271-Fc protein immobilised in reducing conditions (5 
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mM DTT in the immobilisation buffer) and flow cell 4 had CD271-Fc immobilised 
in non-reducing conditions (no DTT in the immobilisation buffer). The Affimers 
were injected over all four flow cells in two-fold concentration steps beginning at 
3.125 nM and increasing to 50 nM for 6 min at 50 μL/min. The running buffer was 
PBS with 0.1% Tween 20. 
BIAevaluation software was used to analyse data and overlay curves from all four 
flow cells. For all experiments, the baseline was normalised before any injections 
and the sensogram from flow cell 1 (or a non-binding flow cell) subtracted from 
all other curves to minimise refractive index effects. BIAevaluation software was 
also used to carry out kinetic analysis of binding curves to find the equilibrium 
binding constant of Affimer and target protein interactions. 
 
5.2.11 Sandwich ELISA to investigate CD271 binding to 
Affimers when tethered to a solid substrate 
In a cell enrichment device, Affimers would be tethered to a solid substrate for 
cell capture. To investigate binding in this format, a sandwich ELISA (Section 
5.1.2.2) with biotinylated Affimers tethered to a streptavidin-coated ELISA plate, 
was carried out.  
Streptavidin-coated plates were prepared and blocked as previously described 
(Section 5.2.4). Biotinylated Affimer (10 µg/mL in 2x Blocking Buffer) was added 
to positive wells, whilst negative wells contained 2x Blocking Buffer only. The 
plate was incubated for 1 h at RT on a shaker (300 rpm). After 1x PBST wash 
(300 µL per well), CD271-Fc protein was added at 50 µL per well (1:100 in 2x 
Blocking Buffer). The concentration of CD271-Fc protein was not determined due 
to the small amount of reagent available. The plate was incubated for 1 h at RT 
with shaking (300 rpm) and washed 1x with PBST (300 µL per well). Mouse 
monoclonal anti-human IgG Fc antibody (Abcam, ab31925) was added at 50 µL 
per well (1:10000 in 2x Blocking Buffer) and incubated for 1 h at RT with shaking 
(300 rpm). The plate was washed 1x with PBST (300 µL per well) and rabbit anti-
mouse immunoglobulins/HRP (Dako, P0260) were added at 50 µL per well 
(1:1000 in 2x Blocking Buffer) for 1 h, RT, shaking (300 rpm). The plate was 
washed 10x with PBST (300 µL per well) and TMB substrate added (50 µL per 
well). The absorbance was measured at 620 nm.  
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5.2.12 Flow cytometry analysis of Affimer proteins binding to 
CD271+ cells 
Flow cytometry (see Chapter 2: Section 2.5.1.3) was used to compare CD271 
antibody and CD271 Affimer protein binding to CD271+ cells. CD271 Affimer 
protein and CD271 antibody were titrated to find the optimum concentration for 
cell labelling. IgG1-PE isotype-matched control antibody (BD BioSciences, 
555749) was used at the same concentration as CD271-PE antibody, and a 
control of unlabelled cells was analysed alongside all samples.  
Cells were detached from culture flasks using trypsin-EDTA solution (3-5 mL). 
The cell suspension was counted using a haemocytometer and diluted to a 
concentration of 5 x 106 cells/mL in FACS buffer6. Aliquots (100 µL) were 
dispensed into Falcon™ round-bottom polypropylene tubes (FACS tubes, 
Corning, 352063) and Affimer protein added to different tubes at 20 µg/mL, 10 
µg/mL, 5 µg/mL and 2.5 µg/mL. Human CD271 phycoerythrin-conjugated 
antibody (CD271-PE, Miltenyi Biotec,130-113-983) was added to different tubes 
at the manufacturer’s recommended working concentration (0.5 µg/mL), 0.25 
µg/mL and 0.125 µg/mL. Cells were incubated in the dark at 4 °C for 30 min.  
Cells were washed by adding 2 mL FACS buffer and centrifuging at 300 g for 5 
min. For indirect Affimer protein labelling, a secondary antibody was used for 
fluorescent detection. Streptavidin Alexa Fluor 488 conjugate (Thermo Scientific, 
S-11223) was added (1 µg/mL) and incubated in the dark at 4 °C for 30 min. 
Washing was repeated and samples were resuspended in 350 µL FACS buffer 
for analysis.  
A CytoFLEX S Flow Cytometer was used to record data. A minimum of 10,000 
events were collected for each experiment and analysed using CytExpert 
software (see Chapter 4: Section 4.5) 
 
5.2.13 Magnetic-activated cell sorting of CD271+ cells  
CD271+ cells were pre-enriched prior to flow cytometry analysis using MACS 
(see Chapter 2: Section 2.5.1.4). A CD271 MicroBead kit was purchased from 
Miltenyi Biotec (130-099-023) and used according to the manufacturer’s 
instructions (227), summarised below.  
Cells were detached from culture flasks using trypsin-EDTA solution (3-5 mL). 
The cell suspension was counted using a haemocytometer and re-suspended in 
 
6 FACS buffer: PBS (Lonza, 17-516F) 0.5% bovine serum albumin (BSA, Sigma 
Aldrich, A9647) and 0.05% sodium azide, filter sterilised (0.22 µm) 
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60 µL MACS buffer7 per 107 cells. CD271 MicroBeads and FcR Blocking Reagent 
(40 µL each per 107 cells) were added, mixed and incubated for 15 min at 4 °C. 
Cells were washed by adding 2 mL MACS buffer per 107 cells and centrifuged at 
300 g for 10 min. Cells were resuspended in 500 µL MACS buffer per 108 cells.  
A LS column (Miltenyi Biotec, 130-042-401) was placed in the magnetic field of a 
MACS separator. The column was prepared by rinsing with 3 mL MACS buffer 
before the cell suspension was applied. The column was washed with 3x 3 mL 
MACS buffer. The flow-through containing unbound cells were collected and 
counted using a haemocytometer. The column was removed from the magnetic 
field, 5 mL of MACS buffer added, and a plunger (supplied with the LS column) 
was used to flush out bound cells. Bound cells were counted using a 
haemocytometer. 
Bound and unbound cells were labelled with CD271-PE antibody, IgG1-PE 
isotype-matched control antibody and Affimer protein at the pre-determined 
concentrations from Section 5.2.12. The different populations were analysed 
using a flow cytometer as described in Section 5.2.12. 
 
5.2.14 Fluorescent labelling of Affimer proteins for flow 
cytometry experiments 
Affimer proteins were labelled with Alexa Fluor 647 C2 maleimide (Thermofisher 
Scientific, A20347) for direct detection in flow cytometry experiments. This was 
carried out using the same labelling method as for the biotinylation of Affimer 
proteins (Section 5.2.9), using the C-terminal cysteine for site-specific labelling. 
Labelling was carried out directly after purification (Section 5.2.7).  
Fluorescently-labelled Affimer proteins were separated on an SDS-PAGE gel 
(Section 5.1.4.5) alongside unlabelled Affimer proteins with known concentration. 
The intensity of the bands of Affimer proteins with known concentration was 
plotted and used to estimate the concentration of the fluorescently-labelled 
Affimers.  
The fluorescently-labelled Affimers were titrated for flow cytometry analysis using 
the same protocol as Section 5.2.12. Once an appropriate working concentration 
had been defined, fluorescently-labelled Affimer protein labelling was compared 
to antibody labelling also described in Section 5.2.12. 
 
 
7 MACS buffer: PBS (Lonza, 17-516F), 2 mM EDTA (Sigma Aldrich, E7889), 0.5% BSA 
(Sigma Aldrich, A9647), filter sterilised 
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5.3 Results and Discussion 
5.3.1 Phage display selection of CD271-specific Affimer proteins 
A commercial source of CD271-His recombinant protein was purchased for 
phage display screening. Screening was carried out in collaboration with the 
BSTG established at the University of Leeds in 2010. Two Affimer libraries were 
screened in total; one with a single variable loop region and the other with two 
variable loop regions (see Section 5.1.1), the two libraries were mixed and 
screened at the same time.  
The aim of phage display screening was to identify Affimer proteins which were 
highly specific towards CD271 protein, and thus able to act as capture molecules 
for MSCs in a microfluidic device. Various Affimer proteins were used as controls 
during the experiments described in this chapter. All control Affimer proteins were 
selected according to published data demonstrating target-specific binding.  
 
5.3.1.1 Biotinylation of phage display target: CD271-His recombinant 
protein 
The commercially sourced CD271-His recombinant protein was biotinylated 
using EZ-Link™ Sulfo-NHS-SS-Biotin (Section 5.2.1). This was to facilitate the 
immobilisation of the target protein to streptavidin/NeutrAvidin-coated wells and 
beads for phage display screening. An ELISA indicated that the biotinylation had 
been successful (Figure 5.8); wells that had been coated with the biotinylated 
protein reacted with streptavidin-HRP and TMB substrate to produce a soluble 
blue reaction product whereas wells where no protein was present remained 
clear. This provided reassurance that the target protein would be bound to 
streptavidin/NeutrAvidin-coated substrates during the phage display protocol.  
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Figure 5.8 ELISA results showing that CD271-His recombinant protein was 
successfully biotinylated  
An ELISA was carried out to see if the protein had been successfully 
biotinylated. Wells A and B were coated with biotinylated CD271 protein, 
wells C and D were coated with Blocking Buffer only. The blue reaction 
product is produced when TMB substrate reacts with streptavidin-HRP 
which has bound to biotin. The results shown here indicate that the protein 
was successfully biotinylated. In wells A and B, 1 µL and 0.01 µL of 
biotinylated CD271 protein were added to 50 µL PBS respectively. The 
concentration of biotinylated CD271 protein was not calculated due to the 
limited sample available. 
 
5.3.1.2 Phage display screening of biotinylated CD271 recombinant protein 
using a protocol with additional washing steps 
Two protocols of phage display screening were explored – a protocol with 
additional washing steps and a protocol with less stringent washing. Initially, a 
protocol with additional washes was used to isolate only the highest affinity 
binders. A ySUMO protein was screened alongside CD271 protein as it is known 
to produce positive hits from the Affimer libraries (156). 
After three rounds of biopanning, bound phage particles were eluted from wells 
coated with the target protein and wells with no target protein. The eluted phage 
were amplified in ER2738 E. coli cells and a range of volumes (0.1 µL, 1 µL, 10 
µL) were plated on LB carb plates overnight (Section 5.2.3.3). Colony-forming 
units were counted the following day to estimate the success of the screening 
process. If a large amplification in clone numbers is observed between negative 
and positive plates, it is more likely that phage particles have bound specifically 
to the target protein. The number of colonies on the CD271 positive plate was 19 
times greater than from the CD271 negative plate. The number of colonies on the 
ySUMO positive plate was >4000 times greater than from the ySUMO negative 
plate (Table 5.2). This was an early indication that fewer specific binders had 
been isolated for the CD271 target compared to the ySUMO target.   
 
A B C D 
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Table 5.2 The number of colony-forming units per 5 mL culture after three 
rounds of phage display biopanning 
After three rounds of phage display biopanning, bound phage particles were 
eluted from target protein wells (positive wells) and no-protein wells 
(negative wells) and amplified in ER2738 E. coli cells. After one hour, the 
cell suspensions were plated on LB carb plates in a range of volumes (0.1 
µL, 1 µL, 10 µL) and colonies were counted on the following day. The 
number of colony-forming units per 5 mL of cells was calculated for both 
positive and negative wells, where colony-forming units on the negative 
plate represent non-specific binding. The greater the amplification between 
negative and positive plates, the more likely it is that target-specific Affimer 
clones have been selected. ySUMO protein was screened alongside CD271 
as it is known to produce positive hits from the Affimer library (156). 
 
Target protein 
Colony-forming units/5 mL cells (102) 
Positive plate Negative plate 
CD271 4500 240 
ySUMO 240000 55 
 
5.3.1.3 Phage display screening of biotinylated CD271 recombinant protein 
using a protocol with less stringent washing 
The second protocol offered the opportunity to isolate weaker binders, this was 
important since for a cell enrichment application using positive selection, the cells 
need to be released from the binding protein after capture. Additionally, using this 
protocol, the bound phage were eluted to investigate pH change as a possible 
cell release mechanism.  
Table 5.3 details the number of colony-forming units on positive plates compared 
to negative plates for the elutions at different pH values. During this biopanning 
method, a tubulin protein was screened alongside CD271-His recombinant 
protein as a positive control (158). For CD271-His recombinant protein, the 
amplification between negative and positive plates was >20 times. For the tubulin 
protein, amplification was >100 times. The difference between positive and 
negative plates for CD271 protein was similar to the first phage display screen 
(around 20 times greater), suggesting that the number of specific clones identified 
from both screens would be similar. The difference between positive and negative 
plates for tubulin protein was around 5 times greater than for CD271 protein 
suggesting that the number of specific clones identified for CD271 protein would 
be less than the number of specific clones identified for tubulin protein.  
The majority of clones from the CD271 biopanning were eluted using the standard 
elution protocol – addition of 0.2 M glycine-HCl pH 2.2 then 1 mM triethylamine 
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pH 10.75. However, there were also clones eluted at pH 9.0, 7.0 and 5.0 
signifying pH change could be a possible cell release mechanism.  
 
Table 5.3 The number of colony-forming units per 5 mL culture after three 
rounds of phage display standard biopanning with elutions at different pH 
values 
After three rounds of phage display biopanning, bound phage particles were 
eluted from the target protein wells (positive wells) and no protein wells 
(negative wells), using different pH buffers, and amplified in ER2738 E. coli 
cells. After one hour, the cell suspensions were plated on LB carb plates in 
a range of volumes (0.1 µL, 1 µL, 10 µL) and colonies were counted on the 
following day. The number of colony-forming units per 5 mL of cells was 
calculated for both positive and negative wells where colony-forming units 
on the negative plate represent non-specific binding. The greater the 
amplification between negative and positive plates, the more likely it is that 
target-specific Affimer clones have been selected. Tubulin protein was 
screened alongside CD271 as it is known to produce positive hits from the 
Affimer libraries (158). 
 
Target protein 
 
pH elution 
Colony-forming units/5 mL cells 
(102) 
Positive plate Negative plate 
CD271 9.00 730 370 
7.00 770 
5.00 3100 
2.20 and 10.75 > 8000 
Tubulin 2.20 and 10.75 19000 170 
 
5.3.1.4 Determining the specificity of individual clones via phage ELISA 
Individual clones from the positive colony plates (thought to be positive hits as 
these cells were infected with bound phage) were randomly selected for 
subsequent analysis by phage ELISA (Section 5.2.4). Clones were picked, 
cultured and infected with helper phage to produce phage particles. The phage 
ELISA format mimics the phage display selection process by immobilising the 
biotinylated target protein onto a streptavidin-coated well. Phage from each 
individual clone were then added both to a well coated with target protein (positive 
well) and a well with no protein (negative well). Bound phage were detected using 
a HRP-conjugated anti-phage antibody. 
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For the first screening protocol, 92 clones from the CD271 positive plate were 
analysed, alongside four clones from the ySUMO positive control plate. Figure 
5.9 shows that only eight of these 92 clones demonstrated target-specific binding 
in the phage ELISA. This can be seen by a larger absorbance value detected in 
the positive well versus the negative well i.e. phage binding to wells coated with 
target-protein but not to wells with no protein. The four clones from the ySUMO 
screen also demonstrated target-specific binding.  
For the second screening protocol, 24 clones from each pH elution were 
analysed, alongside four clones from the tubulin positive control plate. Figure 5.10 
shows that nine CD271 clones demonstrated target-specific binding. 
Interestingly, the majority of these (seven out of the nine clones) were eluted at 
pH 9, with one additional clone eluted at pH 7 and one at pH 5, confirming that 
pH change could potentially be used as a cell release mechanism. The four 
positive control clones all demonstrated tubulin-specific binding.   
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Figure 5.9 Phage ELISA results of clones from the first phage display 
screen 
Phage ELISA results of 92 CD271 clones selected after three rounds of 
phage display biopanning. A larger absorbance value of the target protein-
coated well (green) compared to the no-protein well (blue) indicates that the 
clone bound specifically to the target protein. Upper panel: CD271 clones 1-
48, lower panel: CD271 clones 49-92 and ySUMO clones 1-4 (positive 
controls). CD271 clones 13, 27, 41, 45, 48, 77, 91 and 92 were investigated 
further.   
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Figure 5.10 Phage ELISA results of clones from the second phage display 
screen eluted at different pH values 
Phage ELISA results of 92 clones selected after three rounds of phage 
display biopanning and eluted using different pH buffers. A larger 
absorbance value of the target protein-coated well (green) compared to the 
no protein well (blue) indicates the clone binds specifically to the target 
protein. Upper panel: CD271 clones 1-48, lower panel: CD271 clones 49-92 
and tubulin clones 1-4 (positive controls, also eluted at pH 2.2 and 10.75). 
CD271 clones 2, 3, 11, 14, 18, 19, 21, 34 and 56 were investigated further.  
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5.3.1.5 DNA sequencing of clones indicating CD271-specific binding 
The clones that demonstrated target-specific binding were sent for DNA 
sequencing. Table 5.4 shows the unique Affimer insert sequences for the variable 
loop regions. Three unique sequences were identified; one from the first phage 
display screen and two from the second phage display screen. One sequence 
(CD271-1) was from the Affimer library with one variable loop region and two 
sequences (CD271-2 and CD271-3) were from the Affimer library with two 
variable loop regions.  
 
Table 5.4 Affimer variable loop sequences for clones identified in phage 
ELISAs 
Individual clones which showed specific binding in the phage ELISAs were 
sent for DNA sequencing. All clones from the first phage display screen were 
from the two-loop Affimer library and were identical (CD271-3). Two unique 
sequences were found from second phage display screen, one from the two-
loop Affimer library (CD271-2) and one from the single-loop Affimer library 
(CD271-1).  
Affimer 
sequence 
ID 
Frequency of 
sequence 
Loop 1 sequence Loop 2 sequence 
CD271-1 1 (from second 
screen) 
HGHWPFLDQ - 
CD271-2 8 (from second 
screen) 
SGHWPFDHH GLHAELRMM 
CD271-3 8 (from first 
screen) 
SQPLEFNWW TWQYYRKLN 
 
5.3.2 Producing and purifying Affimer proteins 
The three unique Affimer sequences CD271-1, CD271-2 and CD271-3 were sub-
cloned from the phagemid vector into a bacterial expression vector (Sections 
5.1.4.2 and 5.2.6), and Affimer proteins were recombinantly produced and 
purified (Sections 5.1.4 and 5.2.7). This was to enable more extensive 
characterisation of their binding to the target protein, and subsequently, cells 
expressing the target protein (Section 5.3.3).   
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5.3.2.1 DNA sub-cloning of Affimer insert sequences 
The insert DNA from the pDHis phagemid vector was sub-cloned into a pET11a 
expression vector. The insert DNA was amplified from the phagemid vector using 
PCR (Section 5.1.4.1 and 5.2.6), and both the insert DNA and the pET11a vector 
DNA were digested with NotI and NheI restriction enzymes to allow ligation of the 
compatible ends. Figure 5.11 shows the digested insert DNA separated on a 2% 
agarose gel. The Affimer insert DNA is expected to be around 300 base pairs 
which was confirmed by comparison to a DNA ladder.  
 
 
Figure 5.11  Agarose gel (2%) showing Affimer double-digested insert DNA  
Insert DNA was double-digested with restriction enzymes in preparation for 
ligation into an expression vector. The double-digested insert DNA was run 
on a 2% agarose gel and compared to a DNA ladder. Wells marked with an 
X were DNA sequences sub-cloned at the same time as CD271-1, CD271-
2 and CD271-3 but not discussed in this thesis. All insert DNA was 
approximately 0.3 kilobases (kb) which is the expected number of base pairs 
for Affimer insert DNA.  
 
Following ligation reactions (Section 5.2.6), the ligated samples were introduced 
into XL1-Blue supercompetent cells by bacterial transformation and samples 
were incubated overnight on LB carb plates at 37 °C. A negative ligation reaction 
with no insert DNA was set up as a control and no colonies grew. In comparison, 
colonies grew for all three insert DNA ligations. Single colonies were picked and 
the plasmid DNA extracted using a miniprep kit (Section 5.2.6). DNA sequencing 
of the isolated plasmids confirmed the correct Affimer sequences had been sub-
cloned into the pET11a vector.  
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5.3.2.2 Protein production and purification of Affimer proteins 
Affimer proteins were recombinantly produced and purified as described in 
Section 5.2.7. Following cell lysis and centrifugation, soluble His-tagged Affimer 
proteins were eluted from a Ni-NTA column using a buffer containing a high 
concentration (300 mM) of imidazole. Aliquots of the insoluble, soluble, unbound, 
first wash and final wash were taken to analyse on a 15% SDS-PAGE gel 
(Section 5.1.4.5), along with aliquots of each of the 1 mL elution samples (Figure 
5.12). From the gel images it can be seen that the Affimer proteins were of the 
expected size (~13 kDa) with some dimers present in Affimers CD271-1 and 
CD271-2. Dimers can form due to the C-terminal cysteine residue on the Affimer 
scaffold contributing to the formation of disulphide bridges.  
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Figure 5.12 SDS-PAGE gels (15%) of purified Affimer proteins 
Affimer proteins were purified using a Ni-NTA column and eluted in 1 mL 
fractions. The Affimer proteins were of the expected mass (~13 kDa) with 
some dimers present in CD271-1 and CD271-2. PL is a protein ladder 
(Thermofisher Scientific, 26616), I is the insoluble fraction, S is the soluble 
fraction, U is the unbound fraction, W1 is the first wash, FW is the final wash 
and E1 - E4 are respective elutions. All gels were stained with Coomassie 
blue.  
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5.3.3 Characterisation of Affimer-CD271 protein binding 
Once the Affimer proteins had been purified, more extensive characterisation of 
Affimer binding to CD271 could be carried out. The two main methods used for 
characterisation were ELISA (Section 5.2.8 and 5.2.11) and SPR (Section 
5.2.10). In order to carry out a sandwich ELISA (Section 5.1.2.2), a new CD271 
recombinant protein was bought with an Fc tag rather than a His tag (Sino 
Biological, 13184-H02H). The DNA sequence encoding the CD271 extracellular 
domain was fused with the Fc region of human IgG1 at the C-terminus. The 
secreted recombinant protein is a disulphide–linked homodimeric protein. Using 
a CD271-Fc protein allowed detection via the His tag on the Affimer scaffold 
without interference from a His tag on the CD271 recombinant protein.   
 
5.3.3.1 Biotinylation of CD271-Fc recombinant protein for characterisation 
assays 
The CD271-Fc recombinant protein was biotinylated for immobilisation to a 
streptavidin coated surface as described in the phage ELISA (Section 5.2.4). The 
protein was biotinylated in the same way as the CD271-His recombinant protein 
(Section 5.2.1) and a direct ELISA (Section 5.1.2.1) showed successful 
biotinylation (Figure 5.13). 
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Figure 5.13 ELISA showing the successful biotinylation of CD271-Fc 
recombinant protein 
An ELISA was carried out to see if the CD271-Fc recombinant protein had 
been successfully biotinylated. Different volumes of biotinylated CD271-Fc 
recombinant protein were added to 50 µL PBS and reacted with a 
streptavidin-HRP conjugate and TMB substrate. The protein showed strong 
absorbance at 620 nm indicating biotin was present, and the absorbance 
value decreased as the quantity of protein decreased. The concentration of 
the biotinylated CD271 protein was not measured due to the limited sample 
volume. Bars represent the mean result ± standard error of the mean (SEM), 
n=2 technical replicates. 
 
5.3.3.2 Sandwich ELISA to investigate Affimer protein binding to CD271-Fc 
recombinant protein 
It was important to check that the purified Affimer proteins demonstrated the 
same specific binding behaviour to CD271 protein as was observed by phage 
ELISA. This was achieved by carrying out a sandwich ELISA (Section 5.1.2.2) in 
the same format as the phage ELISA (Section 5.2.4) – wells were first coated 
with streptavidin, then coated with biotinylated CD271 protein and bound Affimer 
proteins were detected via an anti-His tag antibody. A GFP-18 Affimer was used 
as a negative control against biotinylated CD271 protein whilst a NDM1-21 
Affimer was used as a positive control against its own biotinylated target protein 
New Delhi metallo-beta-lactamase 1 (NDM1). 
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Figure 5.14 indicates that Affimers CD271-1 and CD271-2 demonstrated specific 
binding comparable to the positive control, however Affimer CD271-3 did not 
demonstrate any specific binding. Although a small amount of binding was 
observed for the negative control, it was of significantly smaller magnitude than 
the observed specific binding (for normally distributed data). 
 
 
Figure 5.14 Sandwich ELISA showing Affimers CD271-1 and CD271-2 
bound to CD271-Fc recombinant protein 
A sandwich ELISA was carried out to investigate if purified Affimer proteins 
bound to their target protein. Affimer proteins CD271-1 and CD271-2 
showed a large difference in absorbance between the wells coated with 
biotinylated target protein (CD271) and the wells coated with Blocking Buffer 
only and were taken forward for further investigation (***p<0.00001). 
CD271-3 Affimer was not taken forward for further investigation (n.s.=not 
significant). GFP-18 Affimer was used as a negative control and NDM1-21 
Affimer used as a positive control (*p<0.05). Statistical analysis was carried 
out by an independent t-test for normally distributed data (CD271-1, CD271-
2, CD271-3 and GFP-18 replicates). Statistical analysis was carried out by 
Mann-Whitney U test for NDM1-21 replicates since data was not normally 
distributed according to the Shapiro Wilk test of normality. Bars represent 
the mean result ± SEM, n=3 technical replicates.  
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5.3.3.3 Biotinylation of CD271-1 and CD271-2 Affimer proteins for 
characterisation assays 
Affimers CD271-1 and CD271-2  were biotinylated so that the Affimer proteins 
could be immobilised to a streptavidin surface. Binding in this format was crucial 
since in a cell capture device the Affimers would be immobilised to a solid 
substrate. Affimers were biotinylated via their C-terminal cysteine residue using 
biotin-malemide (Section 5.2.9). As before, a direct ELISA (Section 5.1.2.1) 
showed that both Affimers were successfully biotinylated (Figure 5.15).  
 
 
Figure 5.15 ELISA results showing the successful biotinylation of CD271-1 
and CD271-2 Affimer proteins 
Different volumes of biotinylated CD271-1 and CD271-2 Affimer proteins 
were added to 50 µL PBS and reacted with a streptavidin-HRP conjugate 
and TMB substrate. The proteins both showed strong absorbance at 620 
nm indicating biotin was present. The absorbance value decreased as the 
volume added decreased. The concentration of the biotinylated Affimer 
proteins was measured via bicinchoninic acid (BCA) assay at a later date 
(CD271-1: 9 µM, CD271-2: 6 µM). Bars represent the mean value ± SEM, 
n=2 technical replicates.  
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Additionally, the Affimers were analysed before and after biotinylation by mass 
spectrometry, and the masses compared with the calculated mass from their 
amino acid sequences. Good agreement was seen between the calculated 
masses and the mass spectrometry results and the mass spectrometry results 
again confirmed the addition of biotin-malemide (see Table 5.5). 
 
Table 5.5 Mass spectrometry results of biotinylated Affimer proteins 
The Affimer proteins were analysed via mass spectrometry before and after 
biotinylation to verify the addition of biotin-malemide (451.54 Da). The 
expected masses of the proteins were also calculated from the amino acid 
sequence of the Affimer proteins. There was good agreement between the 
calculated masses and the mass spectrometry results and the results 
confirmed the successful biotinylation of Affimers CD271-1 and CD271-2. 
Affimer protein Calculated mass 
from sequence (Da) 
Mass spectrometry 
result (Da) 
CD271-1 11608.08 11606.43 
CD271-2 12359.02 12357.82 
Biotinylated CD271-1 12058.62 12059.30 
Biotinylated CD271-2 12809.56 12810.25 
 
5.3.3.4 Sandwich ELISA to investigate whether CD271-Fc recombinant 
protein bound to biotinylated Affimers when tethered to a solid 
substrate 
With reassurance that the Affimers were biotinylated, a sandwich ELISA was 
carried out in the format analogous to cell capture in a microfluidic device. Wells 
were coated with streptavidin, then with biotinylated Affimer protein. Human 
CD271-Fc protein was added and after washing, bound target was detected via 
anti-human IgG antibody and anti-mouse IgG HRP antibodies. A biotinylated 
ToxinB-18 Affimer was used as a negative control as well as a human CD45-Fc 
recombinant protein in place of human CD271-Fc recombinant protein. 
Figure 5.16 shows that only Affimer CD271-1 showed a strong absorbance in the 
sandwich ELISA meaning that CD271-Fc protein was bound. None of the 
negative controls showed any specific binding, nor did Affimer CD271-2.  
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Figure 5.16 Sandwich ELISA results showing that CD271-Fc recombinant 
protein bound to CD271-1 Affimer when it was tethered to a solid 
substrate 
A sandwich ELISA was carried out to investigate if CD271-Fc recombinant 
protein bound to biotinylated Affimer proteins when they were tethered to a 
solid substrate (representative of cell capture within a cell separation 
device). There was a significantly larger absorbance value when CD271-Fc 
recombinant protein was added to a well coated with biotinylated CD271-1 
Affimer protein compared to a well coated with Blocking Buffer only 
(*p<0.05). There was no significant difference between the positive and 
negative wells for CD271-2 Affimer protein or ToxinB-18 Affimer protein 
(negative control). CD45 (Fc tag) recombinant protein was also used as a 
negative control and no significant differences between positive and 
negative wells were observed. Statistical analysis was carried out by Mann 
Whitney U test since data was not normally distributed according to the 
Shapiro Wilk test of normality. Bars represent the mean value ± SEM, n=3 
technical replicates.  
 
5.3.3.5 SPR analysis of Affimer CD271-1 binding to CD271 recombinant 
protein 
Next, the binding of Affimer CD271-1 was investigated using SPR (Sections 4.2 
and 5.2.10). A dextran CM5 substrate was used to covalently immobilise CD271 
protein via amine coupling (Section 4.4), and the CD271-1 Affimer was injected 
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into the flow cell at a range of concentrations. The SPR was carried out in this 
format since there was a limited amount of CD271 protein available, and only a 
small amount of protein is required for immobilisation compared to the amount 
required for multiple analyte injections. pH scouting was carried out prior to 
immobilisation to find the optimal pH for protein attachment to the surface 
(Section 5.2.10.1). Binding was detected by a change in the surface plasmon 
resonance and recorded as a sensogram in response units (RUs).  
There were four flow cells in total, the first flow cell was used as a reference cell 
with no protein immobilised. The second flow cell contained the originally 
screened CD271 protein (CD271-His recombinant protein) and the third flow cell 
contained the CD271-Fc recombinant protein used in the ELISA characterisation 
assays (Section 5.2.8). The final flow cell was immobilised with TNAP-His 
recombinant protein as a negative control.  
Figure 5.17 shows that Affimer CD271-1 displayed specific binding to the flow 
cells containing immobilised CD271 protein. It was however observed that 
Affimer CD271-1 showed a larger response to the CD271-Fc recombinant protein 
compared to the CD271-His recombinant protein, requiring further investigation 
(see below). Additionally, it was found that as the concentration of CD271-1 
Affimer injected was increased, the binding curves reached a maximum response 
and then began to dissociate during the injection period. It was hypothesised that 
the dissociation during the analyte injection could be caused by aggregation of 
the Affimers at higher concentrations. 
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Figure 5.17 SPR sensograms showing CD271-1 Affimer protein binding 
specifically to CD271 recombinant protein 
CD271-Fc recombinant protein (pink), CD271-His recombinant protein 
(blue) and TNAP-His recombinant protein (red) were immobilised to a CM5 
substrate. A reference cell had no protein immobilised (black) and was 
subtracted from all other flow cells to minimise refractive index effects. 
CD271-1 Affimer proteins were injected for 180 s at 50 µL/min at the 
concentrations indicated.  
 
To further investigate the specific binding of Affimer CD271-1, a second CM5 
substrate was functionalised. In this experiment, the aim was to further explore 
the larger binding response observed for the CD271-Fc protein compared to the 
CD271-His protein. To do this, a CD45-Fc protein was immobilised in one flow 
cell to ensure that the Affimer was not binding to the Fc portion of the protein. In 
addition, the CD271-Fc protein was immobilised under reducing conditions (with 
5 mM DTT added to the immobilisation buffer) as well as non-reducing conditions 
(no DTT added to immobilisation buffer) to assess whether binding was 
preferable due to the homodimeric form of the CD271-Fc protein compared to the 
monomeric form of the CD271-His protein. As previously, one flow cell was used 
as a reference cell with no protein immobilised. The Affimer was injected at a 
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lower concentration range to avoid aggregation of Affimers at high 
concentrations.  
The data gathered from this additional experiment (shown in Figure 5.18) 
confirms that CD271-1 Affimer binds specifically to the CD271 antigen rather than 
the Fc portion of the protein. Further to this, there was no difference in the binding 
behaviour of Affimer CD271-1 to CD271-Fc protein in reducing conditions 
compared to non-reducing conditions. This suggests that there was another 
reason for the greater response to the CD271-Fc protein, such as a difference in 
the quality of the target proteins.  
 
Figure 5.18 SPR sensogram showing CD271-1 Affimer protein binding 
specifically to CD271 recombinant protein in reducing and non-reducing 
conditions  
A second CM5 substrate was immobilised with CD271-Fc recombinant 
protein in non-reducing conditions (NRC, pink), CD271-Fc recombinant 
protein in reducing conditions (RC, purple) and CD45-Fc recombinant 
protein in non-reducing conditions (black). A reference cell had no protein 
immobilised (green). The reference cell had a drifting baseline so the cell 
with CD45-Fc recombinant protein immobilised was subtracted from all 
other flow cells to minimise refractive index effects (no binding was observed 
to CD45-Fc recombinant protein). The black arrows represent where 
CD271-1 Affimer was injected at increasing concentrations: A – 3.125 nM, 
B – 6.25 nM, C – 12.5 nM, D – 25 nM, E – 50 nM. CD271-1 Affimer was 
injected for 360 s at 50 µL/min. 
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To determine the approximate affinity of the binding interaction between CD271-
1 Affimer and CD271-Fc protein, BIAevaluation software was used to perform a 
kinetic fitting to the binding curve. The fitting was performed on an individual 
binding curve rather than a global fit, so must be considered an estimation only.  
The kinetic fitting was performed on a curve when 25 nM CD271-1 Affimer had 
been injected into a flow cell with CD271-Fc protein immobilised (Figure 5.19). 
The fitting estimated the equilibrium dissociation constant (KD) to be 10 nM with 
a small chi squared value indicating a good statistical fit (Table 5.6). The KD of 
antibodies is typically in the nanomolar range with high affinity antibodies in the 
low nanomolar range, and very high affinity antibodies in the picomolar range 
(228), therefore a KD of 10 nM is considered to be of high affinity. The optimum 
affinity of binders in a cell enrichment device must be investigated to ensure cells 
can be released for subsequent use. However, the affinity of Affimer proteins 
could be increased or decreased as required using affinity maturation or 
mutagenesis respectively.  
 
 
Figure 5.19 Kinetic fitting of Affimer CD271-1 binding to CD271-Fc protein 
using BIAevaluation software 
BIAevaluation software was used to estimate the association and 
dissociation rate constants for CD271-1 Affimer binding to CD271-Fc 
recombinant protein. The kinetic fitting was performed on the binding curve 
where 25 nM CD271-1 Affimer was injected into a flow cell immobilised with 
CD271-Fc recombinant protein in non-reducing conditions. The chi squared 
value for the fit was small (see Table 5.6) indicating it was a good statistical 
fit.  
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Table 5.6 Calculated constants from BIAevaluation kinetic fitting 
The association rate constant, dissociation rate constant and therefore the 
equilibrium dissociation constant were calculated from the kinetic fitting 
shown in Figure 5.19. It was found that the equilibrium dissociation constant 
was 10 nM. 
Affimer Association 
rate 
constant 
(ka)(M-1 s-1) 
Dissociation 
rate 
constant 
(kd)(s-1) 
Equilibrium 
dissociation 
constant 
(KD)(M) 
Chi2 
CD271-1 2 x 105 2 x 10-3 10 x 10-9 0.08 
 
 
5.3.4 Characterisation of Affimer binding to CD271+ cells 
The binding of Affimer CD271-1 to CD271+ cells was examined using two 
different flow cytometry approaches; indirect labelling of biotinylated Affimer 
protein using a streptavidin Alexa Fluor 488 conjugate (Section 5.2.12), and direct 
labelling of Affimer protein by Alexa Fluor 647 C2 maleimide (Section 5.2.14). 
Affimer binding was compared to antibody binding and was investigated using 
dental pulp stromal cells (DPSCs) as well as a CD271+ cell line (SH-SY5Y 
neuroblastoma cells).  
 
5.3.4.1 Antibody and Affimer titrations for flow cytometry analysis using 
indirectly labelled Affimer 
The first stage of characterisation was to carry out antibody and Affimer titrations 
to investigate the working concentration of both binding molecules. A CD271 
antibody conjugated to a phycoerythrin fluorescent dye (CD271-PE) was 
purchased from Miltenyi Biotec which has a manufacturer’s recommended 
working concentration of 0.5 µg/mL. It was considered that the antibody could be 
used reliably at lower concentrations and therefore a concentration range of 0.5-
0.125 µg/mL was examined. This was the first flow cytometry analysis of Affimers 
binding to cell surface markers and so the working concentration of Affimers in 
this application was unknown. The concentration of Affimer used in ELISA 
characterisation assays provided a starting point.  
Figure 5.20 shows that antibody CD271-PE binds to a small percentage of 
DPSCs compared to an isotype-matched control antibody and unlabelled cells. It 
also demonstrated that no difference in labelling was observed when the 
concentration of the antibody was lowered to 0.125 µg/mL. Figure 5.21 shows 
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that biotinylated Affimer CD271-1 can be used for flow cytometric analysis at 
lower concentrations than in ELISA assays (2.5 µg/mL compared to 20 µg/mL) 
without any differences observed in labelling.  
Figure 5.21 also shows a comparison of Affimer and antibody binding to DPSCs. 
The percentage positive for fluorescein isothiocyanate (FITC) labelling (indirect 
Affimer labelling) was 2.51% and the percentage positive for PE labelling 
(antibody labelling) was 2.11%. Despite the fact that these two values are close, 
the percentage of CD271+ cells in a DPSC population is very low, and possibly 
unreliable to compare antibody and Affimer binding. It was therefore decided to 
pre-enrich CD271+ cells to gain a larger target population.  
 
 
Figure 5.20 Flow cytometry histograms showing that CD271-PE antibody 
can be used reliably at lower concentrations 
CD271-PE antibody (Miltenyi Biotec) and IgG1-PE isotype-matched control 
antibody (BD Biosciences) were incubated with DPSCs at three different 
concentrations – 0.5 µg/mL, 0.25 µg/mL and 0.125 µg/mL. Histogram A 
shows DPSCs incubated with the isotype-matched control antibody 
compared to unlabelled DPSCs, and histogram B shows DPSCs labelled 
with CD271-PE antibody compared to unlabelled DPSCs. It was found that 
the antibodies could be used at the lowest concentration without any effect 
on the result. 
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Figure 5.21 Flow cytometry histograms comparing CD271-1 Affimer and 
CD271 antibody binding to DPSCs 
Histogram A shows different concentrations of Affimer CD271-1 binding to 
DPSCs compared to unlabelled DPSCs (red). In these experiments, 
biotinylated Affimer was used with a Streptavidin Alexa Fluor 488 conjugate 
detected in the FITC channel. Histogram B shows the same population of 
DPSCs incubated with CD271-PE antibody (at the previously determined 
concentration, red) compared to unlabelled DPSCs (pink), and DPSCs 
incubated with IgG1-PE (isotype-matched control antibody, green). It was 
found that the Affimer concentration did not affect cell binding and therefore 
Affimers could be used at the lowest concentration. It was also determined 
that the population of CD271+ cells in DPSCs was too low to make an 
accurate conclusion regarding the comparison of Affimer and antibody 
binding. 
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5.3.4.2 MACS enrichment of DPSCs prior to Affimer and antibody 
comparison using indirectly labelled Affimer 
In order to accurately compare Affimer and antibody binding, a larger population 
of CD271+ cells would be beneficial. To achieve this, DPSCs were pre-enriched 
for CD271+ cells using CD271 magnetic microbeads (Miltenyi Biotec). After 
incubation with the microbeads, cells were passed through a column surrounded 
by a strong magnetic field. CD271+ cells attached to microbeads should be 
retained in the column while the remaining cells should be washed from the 
column. The different cell fractions were then analysed by flow cytometry using 
both CD271 antibody (different clone to CD271 microbeads) and Affimer.  
Figure 5.22 compares antibody and Affimer binding to the different cell 
populations. It can be seen that where antibody was used for labelling (histogram 
A) a clear enrichment was established in the bound population (contour plot F). 
However, where Affimer was used for labelling (histogram B), all populations 
exhibited a small amount of fluorescence and no clear enrichment was seen 
(contour plot J).  
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Figure 5.22 Flow cytometry comparison of Affimer and antibody binding 
to MACS-enriched CD271+ cells from DPSC populations 
CD271+ cells were enriched from DPSCs using MACS technology. The 
eluate from the MACS column (unbound population), the cells retained in 
the column (bound population) and an unsorted population of cells were 
each incubated with CD271-PE antibody (histogram A, contour plots C-F: C 
– unlabelled unsorted population, D – labelled unsorted population, E – 
labelled unbound population, F – labelled bound population) or biotinylated 
CD271-1 Affimer (histogram B, contour plots G-J: G – unlabelled unsorted 
population, H – labelled unsorted population, I – labelled unbound 
population, J – labelled bound population). The bound population contained 
an enriched fraction of CD271+ cells identified by the CD271-PE antibody 
however not by the CD271-1 Affimer. 
 
A further experiment was carried out to troubleshoot the positive fluorescence 
observed for all populations when labelled with Affimer. In this experiment, a 
second Affimer was used as a negative control (ToxinB-18 Affimer, shown not to 
bind to CD271 recombinant protein in ELISA experiments (Section 5.3.3.4)) and 
the streptavidin Alexa Fluor 488 conjugate alone. The results of this experiment 
are shown in Figure 5.23. 
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The antibody bound specifically to a small percentage of the DPSC population 
(2.88%), consistent with previous antibody labelling. In contrast, both Affimers 
(CD271-1 and negative control ToxinB-18) and the streptavidin Alexa Fluor 488 
conjugate, all displayed positive labelling (6.18% and 5.95% for the ToxinB-18 
Affimer and streptavidin Alexa Fluor 488 conjugate respectively, 12.10% for the 
CD271-1 Affimer).  
 
 
Figure 5.23 Flow cytometry histograms showing extra control experiments 
carried out to investigate Affimer CD271-1 binding to DPSCs 
In histogram A, unseparated DPSCs were incubated with CD271-PE 
antibody (pink), IgG1-PE isotype-matched control antibody (green) or 
unlabelled (red). In histogram B, DPSCs were incubated with biotinylated 
CD271-1 Affimer (orange), biotinylated ToxinB-18 Affimer (negative control, 
green), streptavidin Alexa fluor 488 conjugate (negative control, pink) or 
unlabelled (red). A small percentage (2.88%) was CD271 antibody-positive 
compared to the unlabelled and isotype control. A shift in fluorescence was 
observed for both negative controls (ToxinB-18 Affimer - 6.18% positive, 
streptavidin Alexa fluor 488 conjugate - 5.95% positive, compared to 
unlabelled cells) and a larger percentage of 12.10% positive for CD271-1 
Affimer.  
5.3.4.3 Direct labelling of CD271-1 Affimer for flow cytometry analysis 
In the previous experiments using indirect Affimer labelling, there was a 
consistently low level of binding observed for all cell populations even when using 
the secondary antibody (streptavidin Alexa Fluor 488) alone. This suggests that 
the positive fluorescence observed for cell populations labelled with Affimer could 
have been artefactual due to non-specific labelling by streptavidin Alexa Fluor 
488. Moreover, the CD271-1 Affimer displayed a higher percentage of positive 
staining when directly compared to a control Affimer and the streptavidin Alexa 
Fluor 488 alone, suggesting that the CD271-1 Affimer could be displaying specific 
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binding to the small fraction of DPSCs that were CD271+. To investigate this 
further and to eliminate the artefactual labelling from the streptavidin Alexa Fluor 
488 conjugate, direct fluorescent labelling of Affimer CD271-1 was carried out 
(Section 5.2.14). 
An Alexa Fluor 647 C2 maleimide was used to fluorescently label Affimer CD271-
1 via its C-terminal cysteine residue (same principle as biotinylation, Section 
5.2.9). At the same time, a GFP-32 Affimer was fluorescently labelled to use as 
a negative control. To verify that the Affimers were correctly labelled, and 
estimate the concentration of the labelled Affimers, samples were separated on 
a 12% SDS-PAGE gel (Figure 5.24). A dilution series of unlabelled Affimer with 
known concentration was used alongside samples with unknown concentration.  
Imaging of the gels before Coomassie staining indicated that both Affimers were 
fluorescently labelled. There was dimer present in all samples, however in 
samples fluorescently labelled, more than 75% of sample had successfully 
reacted with Alexa Fluor 647 C2 maleimide, and since dimers were not labelled 
(disulphide bridges between Affimers prevent reaction with maleimide) it was not 
judged as a major concern for flow cytometry analysis. 
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Figure 5.24 SDS-PAGE (12%) gels showing Affimers CD271-1 and GFP-32 
labelled with Alexa Fluor 647 C2 maleimide 
Affimers CD271-1 and GFP-32 (to be used as a negative control) were 
conjugated to Alexa Fluor 647 C2 maleimide via the cysteine residue on the 
Affimer scaffold. Unlabelled Affimer of known concentration was run as a 
dilution series to calculate the concentration of the labelled Affimers. For 
Affimer CD271-1, wells 1 and 12 show protein ladders, wells 2-9 show a 
dilution of Affimer CD271-1 from 1 mg/mL to 0.05 mg/mL and well 11 shows 
Affimer CD271-1 conjugated to Alexa Fluor 647 C2 maleimide. For GFP-32, 
wells 1 and 15 show protein ladders, wells 2-9 show a dilution series of 
Affimer GFP-32 from 1 mg/mL to 0.05 mg/mL, well 11 shows GFP-32 
Affimer dialysed into PBS (unknown concentration), well 12 shows Affimer 
GFP-32 conjugated to Alexa Fluor 647 C2 maleimide and well 13 shows 
Affimer GFP-32 conjugated to biotin maleimide. On the right-hand side of 
each gel, an image is shown of the fluorescently labelled Affimers before 
Coomassie staining. All samples had dimers present however when 
labelled, >75% of protein was fluorescently labelled monomer.  
 
5.3.4.4 Affimer titrations for flow cytometry analysis using directly labelled 
Affimer 
The fluorescently labelled Affimers were titrated to see the effect of concentration 
on cell labelling with fluorescently-tagged Affimers. The proportion of cell labelling 
decreased as the concentration of Affimer decreased suggesting that the cells 
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interacted non-specifically with the fluorescently-tagged Affimer at high 
concentrations (Figure 5.25). 
 
 
Figure 5.25 Flow cytometry histograms showing fluorescently-tagged 
CD271-1 Affimer titrations  
DPSCs were incubated with different concentrations of fluorescently-tagged 
CD271-1 Affimer. Histogram A shows unlabelled DPSCs (red) and DPSCs 
labelled with 20 µg/mL Affimer (green), 10 µg/mL Affimer (pink) and 5 µg/mL 
Affimer (orange). Histogram B shows unlabelled DPSCs (red) and DPSCs 
labelled with 2.5 µg/mL Affimer (green), 1.25 µg/mL Affimer (pink) and 0.625 
µg/mL Affimer (orange). At higher concentrations of fluorescently-tagged 
Affimer there was a large shift in fluorescence which reduces as the Affimer 
concentration was reduced.  
 
Figure 5.26 displays a comparison of directly labelled CD271-1 Affimer (at the 
lowest concentration tested) with CD271 antibody, and also with a non-specific 
GFP-32 Affimer at the same concentration. Here it can be seen that although the 
binding of CD271 antibody and CD271-1 Affimer is similar (3.86% and 5.24% 
respectively), the positive labelling of GFP-32 Affimer is almost identical to the 
positive staining of the CD271-1 Affimer (5.29% and 5.24% respectively - Figure 
5.26, panel B). 
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Figure 5.26 Flow cytometry histograms showing fluorescently labelled 
Affimer and antibody comparison 
The same population of DPSCs was incubated with both CD271 antibody 
and fluorescently labelled CD271-1 Affimer. Histogram A shows DPSCs 
unlabelled (red), labelled with IgG1-PE (isotype-matched control, green) 
and labelled with CD271-PE antibody (pink). Histogram B shows DPSCs 
unlabelled (red), labelled with GFP-32 Affimer (negative control, green) and 
CD271-1 Affimer (pink). A small positive percentage was observed for cells 
incubated with CD271 antibody (3.86%). A larger positive percentage was 
observed for cells incubated with CD271-1 Affimer (5.24%), which was 
almost identical to the positive percentage observed for a non-specific 
Affimer (GFP-32, 5.29%).   
  
5.3.4.5 MACS enrichment of DPSCs prior to Affimer and antibody 
comparison using directly labelled Affimer 
It was previously seen that a CD271+ population of cells could be enriched from 
DPSCs using CD271 microbeads (Figure 5.22) and that this enriched population 
was more useful in providing conclusive results with respect to antibody and 
Affimer binding. The same MACS enrichment procedure was carried out and 
analysed with directly-labelled CD271-1 Affimer and CD271 antibody.   
No clear enrichment of CD271+ cells was seen using either the CD271 antibody 
or the CD271-1 directly-labelled Affimer (Figure 5.27). The bound population after 
MACS enrichment was less than 300,000 cells and did not appear to be enriched 
for CD271+ cells when analysed by flow cytometry. The previous MACS 
enrichment results observed with CD271 antibody labelling were not reproduced. 
As before, a shift in fluorescence was observed in all populations when labelled 
with Affimer. 
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Figure 5.27 Flow cytometry comparison of Affimer and antibody binding to 
MACS-enriched CD271+ cells using directly labelled Affimer 
DPSCs were enriched using MACS technology. The eluate from the MACS 
column (unbound population), the cells retained in the column (bound 
population) and an unsorted population of cells were each incubated with 
CD271-PE antibody (histogram A, contour plots C-F: C – unlabelled 
unsorted population, D – labelled unsorted population, E – labelled unbound 
population, F – labelled bound population) or biotinylated CD271-1 Affimer 
(histogram B, contour plots G-J: G – unlabelled unsorted population, H – 
labelled unsorted population, I – labelled unbound population, J – labelled 
bound population). There was no clear enrichment of CD271+ cells seen 
from either antibody or Affimer labelling.  
 
5.3.4.6 Flow cytometry analysis of CD271-1 Affimer and CD271 antibody 
binding to SH-SY5Y cells using directly labelled Affimer 
When it was found that the CD271+ population of DPSCs could not be 
consistently enriched, a new strategy was sought to compare antibody and 
Affimer labelling of CD271+ cells. A search of the literature revealed a 
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neuroblastoma cell line that constitutively expressed CD271 (229). The cell line 
– named SH-SY5Y – was obtained and analysed by flow cytometry using both 
CD271 antibody and CD271-1 Affimer.  
The antibody results confirmed the fact that SH-SY5Y cells express CD271 with 
approximately 80% of the population labelling positive for CD271-PE antibody 
(Figure 5.28, panel A). The Affimer labelling results for both CD271-1 and GFP-
32 were again very similar and not comparable with antibody labelling 
(approximately 5% and 6% positively labelled respectively, Figure 5.28, panel B). 
The Affimer labelling suggested a small amount of non-specific binding and was 
in good agreement with the DPSC flow cytometry data. 
 
 
Figure 5.28 Flow cytometry comparison of Affimer and antibody binding to 
SH-SY5Y cells  
SH-SY5Y cells were used to compare Affimer and antibody binding since 
there is literature evidence that this cell line expresses CD271 (229). 
Histogram A shows CD271 antibody (pink) binding to SH-SY5Y cells 
compared to an isotype-matched control antibody (IgG1-PE, green) and 
unlabelled cells (red). Histogram B shows CD271-1 Affimer (pink) binding to 
SH-SY5Y cells compared to a non-specific Affimer (GFP-32, green) and 
unlabelled cells (red). The antibody labelling confirmed that SH-SY5Y cells 
express CD271 (~80% CD271 antibody positive). The CD271-1 Affimer 
labelling was similar to the GFP-32 Affimer labelling and only labelled a 
small percentage of the SH-SY5Y cells (~5-6%).  
 
5.4 Conclusions 
In this chapter, human CD271 recombinant protein was screened against Affimer 
libraries containing approximately 1.3 x 1010 independent clones. Two screens 
were carried out using two different protocols for biopanning. Three unique clones 
were identified as potential binders to human CD271 protein and were 
characterised by ELISA and SPR. Following initial characterisation with CD271 
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recombinant protein, one Affimer (CD271-1) displayed specific binding, with an 
equilibrium dissociation constant estimated to be 10 nM – comparable to that of 
a typical antibody. This Affimer was further investigated with cells expressing 
CD271 protein, and the binding behaviour compared with that of a CD271 
antibody. It was found that the Affimer did not display the same binding behaviour 
as a CD271 antibody. This was compared using two different labelling methods 
and two different cell types. 
There is evidence that suggests the success of phage display screening relies 
heavily upon the quality of the target protein (158, 230). The phage display 
screens carried out here only resulted in the identification of three unique clones 
and this could be due to the quality of the CD271-His recombinant protein that 
was used. It can be difficult to achieve high quality soluble proteins for membrane 
proteins with large hydrophobic transmembrane domains, and with extended 
extracellular regions made up of multiple domains (231), as is the case for 
CD271. This is because they are often flexible and unstable leading to challenges 
at all stages of protein production including expression, solubilisation and 
purification (232). From the initial colony counting it could be seen that the 
amplification from negative to positive colony plates was not as large as was 
observed in the case of both positive control proteins. Colony counting is an early 
indicator of the likeliness that specific binders have been selected.  
Additionally, during the characterisation assays the Affimer clones exhibited 
preferable binding to the CD271-Fc recombinant protein compared with the 
CD271-His variant. It was hypothesised that this CD271-Fc recombinant protein 
could be of better quality than the originally screened protein. In previous Affimer 
library screens it has been found that when several commercial sources of the 
same protein were screened, only one source selected suitable Affimers (158). 
To investigate this further a third screen using both proteins – CD271-His and 
CD271-Fc – was carried out by the BSTG group. The results were consistent with 
the initial screens where only a handful of unique clones were identified from 
screening both CD271 proteins – three in total (data not shown). There was some 
cross reactivity between clones screened against the CD271-His protein with the 
CD271-Fc protein (and vice versa) however only for two out of three of the unique 
sequences.  
For this research project it was decided not to investigate the newly identified 
sequences any further. When phage display screening is carried out, it is hoped 
that a large pool of unique clones will be selected, which are then narrowed down 
during characterisation, resulting in a handful of appropriate binders for the 
desired application. Unfortunately, when only a handful of unique clones are 
selected in the initial stages, it becomes increasingly unlikely that a suitable 
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binder will be found. It was therefore considered not likely that the third screen 
would result in a specific binder for CD271+ cells.  
There were no further commercial sources of CD271 protein available to buy (at 
this time), however in future, a different screening strategy could be considered 
such as whole cell biopanning. By using whole cell biopanning the antigen source 
is presented to the phage display library in its native conformation along with post-
translational modifications (230, 231). This increases the chances of isolating 
binders appropriate for in vivo applications. However, whole cell biopanning can 
be challenging due to high backgrounds of non-relevant proteins with 
comparatively low abundance of target protein.  
Jones et al. (2016)(231) developed a method for whole cell biopanning using 
transient transfection of the target protein to increase the target antigen density 
on the cell surface. As well as this, GFP was transiently transfected alongside the 
target protein to enable cell sorting to select cells with high expression of the 
target protein. The host cell line was alternated between biopanning rounds to 
minimise binding to host cell proteins and a low pH wash reduced the enrichment 
of phage clones bound non-specifically. They found that the method was able to 
isolate high affinity binders which showed better binding to cells than those 
isolated from the same library but panned on soluble protein.  
Likewise, Crepin et al. (2017)(233) used whole-cell biopanning with a synthetic 
phage display library of nanobodies (single domain antibodies) and successfully 
isolated nanobodies against follicle-stimulating hormone receptor overexpressed 
in L-cells. Similarly to Jones et al., a number of modifications were made to 
decrease non-specific nanobodies present in the final elution fraction. These 
included two initial depletion steps with wild type L-cells reducing the initial 
number of phages, and reducing the number of cells used for enrichment. The 
resulting nanobodies exhibited inhibitory behaviour on follicle-stimulating 
hormone-dependent cyclic adenosine monophosphate accumulation.  
Alfaleh et al. (2017)(230) provide a detailed review of studies where different 
strategies for whole cell biopanning have been optimised. Methods have been 
developed to screen low numbers of cells - such as a microfluidic phage display 
system (234), and the use of microselection to target single rare cells amongst a 
heterogeneous population of cells (235). In addition, strategies have been utilised 
to further reduce non-specific binding such as the removal of dead cells and 
cellular debris prior to biopanning (236), as well as the optimisation of 
temperature and incubation times during biopanning (237, 238). Giordano et al. 
(2001)(239) developed a washing method using differential centrifugation which 
eliminated the need for repeated washing steps.  
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Although these studies highlight several novel cell-based biopanning strategies, 
the success still relies heavily upon the nature of the antigen. For example, 
Hoogenboom et al. (1999)(240) expressed two antigens of interest in Chinese 
hamster ovary cells but was only able to select receptor specific binders to one 
of the antigens. Where binders were successfully isolated, the antigen in question 
is characterised by a large, highly glycosylated immunogenic extracellular 
domain. In contrast, where binders were not selected, the antigen is 
characterised by short, heavily glycosylated extracellular loops of approximately 
40 amino acids and has low immunogenicity.  
The CD271 receptor contains an extracellular domain containing four 40-amino 
acid repeats followed by a serine/threonine-rich region containing the CD271 
antigen (241). Whole cell biopanning for CD271+ cells would require its own 
optimisation but has the potential to provide binders which would recognise 
CD271 in its native confirmation on the cell surface membrane rather than to the 
recombinant protein only. 
However, for this research project the priority was to develop a microfluidic cell 
enrichment device, and during the characterisation of Affimers their binding was 
compared to a commercially-available CD271 antibody. Reliable and 
reproducible binding was established with the CD271 antibody providing a 
suitable candidate binding molecule for cell capture within a cell enrichment 
device. Although there are potential advantages of using Affimers as cell capture 
molecules (Chapter 2: Section 2.5.3.2), the antibody provided a good starting 
point for development of this technology.  
The work in this chapter has also established a cell line model which could be 
used during proof-of-concept stages. Whilst carrying out the initial 
characterisation of Affimer-target-cell binding, it was found that the percentage of 
CD271+ cells in a DPSC population was very low and could not be reliably 
enriched by CD271 microbeads. There are varying reports of CD271 expression 
of DPSCs found in the literature, Ducret et al. (2016)(242) found that 2.4% of the 
CD31 negative population (to exclude endothelial and leukocytic cells) of dental 
pulp cells expressed CD271, however this decreased to less than 1% upon in 
vitro expansion. The same pattern was observed by Tomlinson et al. (2016)(243), 
where uncultured dental pulp cells were found to express 1.24 ± 0.46% CD271 
but an average expression of 0.2% was found across passages 2 to 4. Pan et al. 
(2016)(244) investigated expression across eight different donors and discovered 
that CD271 expression ranged from 1.57% to 6.35% (no in vitro expansion). 
Alvarez et al. (2015)(245) reported unusually high CD271 expression in passage 
4-8 dental pulp cells at 10.6%, however the flow cytometry gating strategies are 
not detailed in their paper.  
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Due to the low and varying levels of expression of CD271 on cultured DPSCs, it 
was decided to carry out experiments during the device development stages 
using a neuroblastoma cell line where approximately 80% of cells were found to 
express CD271. Not only is high expression of CD271 an advantage (not 
requiring any pre-enrichment techniques) but established cell lines grow 
indefinitely, providing a good supply of cells for experiments. Once proof-of-
concept had been shown using an established cell line, clinical utility was 
investigated using primary cells.  
In conclusion, novel binding proteins – Affimers – were investigated for use as 
cell capture molecules in a cell enrichment device. At this time, no binders were 
found to be suitable for the application. Instead, an appropriate antibody was 
found to reliably bind to CD271+ cells and a neuroblastoma cell line was found 
to express a high percentage of CD271. In Chapter 6, the development of a cell 
enrichment device will be described using a CD271 antibody as a capture 
molecule, and the efficacy of the device validated using the neuroblastoma cell 
line.   
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Chapter 6:  
Developing a prototype microfluidic device for CD271-specific 
cell capture and release 
6.1 Introduction 
The aim of the work carried out in this chapter was to design, fabricate and 
evaluate a prototype microfluidic device capable of specific cell capture and 
release. In Chapter 5, a CD271 antibody was identified which reliably bound to 
CD271+ cells and was thus able to act as a capture molecule in a prototype 
device. A device was designed using Autodesk Fusion360 (Section 6.2.4.1), 
fabricated and assembled into a prototype device (Sections 6.1.1 and 6.2.4.3) 
and a series of experiments carried out to evaluate the specificity of cell capture 
(Section 6.3.2). Once cell capture and release had been optimised (Section 
6.3.3), post-enrichment analysis was carried out on cells that had been captured 
and released in the device to ensure they remained viable (Section 6.3.6 and 
6.3.7) and were minimally manipulated during the enrichment procedure (Section 
6.3.8).  
 
6.1.1 Soft lithography techniques 
Soft lithography refers to a branch of photolithography adapted to process 
photoresists for the fabrication of microfluidic devices (246), such as the device 
described in this chapter. Standard photolithography was primarily developed for 
microelectronics whereas soft lithography is termed as such as it deals with 
mechanically soft materials. The most widely used material is 
polydimethylsiloxane (PDMS) since it has low cost, it is biocompatible, and has 
high durability (247).  
In this work, soft lithography techniques were used to fabricate microfluidic 
channels using a negative mould, where PDMS is poured into the mould, cured 
and then released from the mould (Figure 6.1). A typical procedure for making a 
negative mould is outlined in Figure 6.2. The procedure requires a mask and a 
light source to pattern a photosensitive resist (248). However in this work, a 
maskless aligner was used which eliminates the need for a mask and directly 
exposes the pattern onto the resist-covered substrate. The photoresist is spin-
coated onto a substrate with the spin speed determining the coat thickness. The 
photoresist is then pre-baked so that its solvent is evaporated before exposure to 
UV radiation (an optimum wavelength of 365 nm for SU-8 photoresists). Post-
baking is necessary to aid crosslinking of the exposed photoresist before a 
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developer is applied to dissolve the remainder of the photoresist. A negative 
mould is the result of the procedure which is then ready for PDMS casting.  
 
 
 
Figure 6.1 The process of making PDMS channels using a negative mould 
A negative PDMS mould is typically fabricated using photolithography 
techniques (see Figure 6.2). PDMS is poured into the mould and cured for 
24 h at 65 °C. The PDMS can then be released from the mould creating 
ridges which act as microfluidic channels.  
 
 
Figure 6.2 A typical photolithography procedure to make a PDMS mould 
Flow diagram adapted from (248). 
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6.2 Materials and Methods 
6.2.1 Flow cytometry analysis of the CD271 expression of human 
dermal fibroblast cells and the CD34 expression of SH-SY5Y 
cells 
Flow cytometry (Chapter 2: Section 2.5.1.3) was used to verify that human dermal 
fibroblast cells (Section 4.1.3) did not express the CD271 antigen on their cell 
surface and that SH-SY5Y cells (Section 4.1.2) did not express the CD34 antigen. 
This information was required to verify the controls used during the experiments 
described in this chapter. 
For the fibroblast cells, the same antibodies and protocol was used as described 
in Chapter 5: Section 5.2.12. Briefly, CD271-PE antibody (Miltenyi Biotec, 130-
091-885) and IgG1-PE isotype-matched control antibody (BD Biosciences, 
555749) were incubated with cells in the dark at 4 °C for 30 min. Cells were 
washed by adding 2 mL FACS buffer and centrifuging at 300 g for 5 min. Cells 
were re-suspended in 350 µL FACS buffer and analysed using a CytoFLEX S 
Flow Cytometer.  
The same procedure was used for the analysis of SH-SY5Y cells using a CD34-
PE antibody (Miltenyi Biotec, 130-113-741).  
 
6.2.2 SPR analysis of CD271+ cells binding to CD271 antibody on a 
gold surface 
Surface plasmon resonance (SPR, Section 4.2) is an established method to 
characterise protein-protein, DNA-DNA and DNA-protein interactions, however, 
more recently it has also been used to study whole cell interactions. Ogura et al. 
(2016)(249) published a method to detect the interactions of anti-TNF agents with 
transmembrane TNF-α on living whole cells, and Mizuguchi et al. (250) described 
a similar technique using epidermal carcinoma A431 cells as an analyte, and 
immobilised epidermal growth factor as a ligand, with the aim of future 
applications in drug discovery against membrane receptors on pathological cells. 
In this work, it was decided to use SPR as an initial method of assessment for 
the specific cell capture of CD271+ cells on a CD271-antibody functionalised 
surface - analogous to cell capture in the microfluidic device. Two CD271 
antibodies were investigated for specific cell capture, a CD271 antibody 
conjugated to phycoerythrin dye (CD271-PE, Miltenyi Biotec, 130-091-885, 
previously shown to bind to CD271+ cells in Chapter 5: Section 5.3.4) and a 
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CD271 antibody conjugated to biotin (CD271-biotin, Miltenyi Biotec, 130-113-
419).  
An Autolab ESPIRIT Data Acquisition 4.3 was used for SPR analysis, where 
antibodies were immobilised on a gold-coated glass disk (Xantec Bioanalytics). 
The disk was cleaned using the following protocol: 
• 10 min sonication in acetone 
• Wash in beaker of 100% ethanol 
• 10 min sonication in fresh beaker of 100% ethanol 
• Wash in fresh beaker of 100% ethanol  
and then coated with a monothiol-alkane-PEG self-assembled monolayer (SAM, 
Section 4.3)(ProChima Surfaces TH 003-m11.n6) terminated with a carboxylic 
acid group (HS-C11-(EG)6-OCH2-COOH). The disk was incubated in the SAM 
solution (1 mM in 95% ethanol, 5% acetic acid) for 24 h minimum at RT prior to 
use. Excess SAM molecules were washed from the disk using 100% ethanol and 
the disk dried using a nitrogen gun. The glass disk was loaded on to the Autolab 
ESPIRIT hemi-cylinder using a drop of immersion oil. 
The Autolab ESPIRIT has two flow cells which can be run simultaneously with 
continuous mixing during injections. All injections were carried out such that 
buffer was injected until the baseline was stable, then the analyte was added 
whilst measuring and with continuous mixing.  
 
6.2.2.1 Assessing the appropriate pH for protein immobilisation (pH 
scouting) 
pH scouting was carried out to assess a favourable pH for CD271-PE 
immobilisation. pH 8.0 sodium phosphate buffer was injected into one flow cell 
and pH 7.0 sodium phosphate buffer was injected into the second flow cell. When 
the baseline was stable, 5 µg/mL CD271-PE antibody (diluted in the respective 
buffer) was injected for 6-10 min (until saturation). After the injection, the injection 
needles were washed, the flow cell drained and fresh buffer injected. The surface 
was regenerated with 10 mM sodium hydroxide for 2 min before the next two 
buffers were tested. A pH range of pH 8.0-pH 4.0 was investigated and a 
compromise of pH 5.0 sodium acetate buffer was selected for CD271-PE 
immobilisation. Using pH 5.0 sodium acetate buffer resulted in ~50% of the 
maximum coverage and was closer to biological pH than pH 4.0 - which resulted 
in a higher coverage (Figure 6.3).  
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Figure 6.3 pH scouting for the immobilisation of CD271-PE antibody 
CD271-PE antibody was immobilised on the SPR disk in buffers of different 
pH (range pH 8.0 – pH 4.0). Antibody was injected for 6-10 minutes and the 
antibody loading evaluated. pH 5.0 sodium acetate buffer was selected as 
the immobilisation buffer for binding assays as a compromise between 
antibody loading and biological pH.  
 
For the CD271-biotin antibody, streptavidin was first immobilised onto the glass 
disk at a pH of 5.0 (10 mM sodium acetate buffer) following an online protocol 
(251), summarised below. 
 
6.2.2.2 Protein immobilisation onto the gold-coated glass disk 
For binding assays for both antibodies, the monolayer was first activated using 
NHS and EDC crosslinking chemistry (see Section 4.4); equal volumes of NHS 
(GE Healthcare, BR-1000-50, 200 mM) and EDC (GE Healthcare, BR-1000-50, 
800 mM) were mixed with an equal volume of 2-(N-morpholino)ethanesulfonic 
acid (MES) buffer8. MES buffer was injected into both channels until the baseline 
was stable, and then 125 µL of the NHS/EDC solution was injected for 10 min. 
Between each injection, buffer was injected until the baseline was stable. Sodium 
acetate buffer (pH 5.0, 10 mM, 50 µL) was injected and when stable, 20 µg/mL 
CD271-PE antibody (50 µL, final concentration 10 µg/mL) injected until 
saturation.  
 
8 MES buffer: MES hydrate (Sigma, M2933), pH 5.5  
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For the immobilisation of CD271-biotin, 250 µg/mL streptavidin in sodium acetate 
buffer (50 µL, final concentration 125 µg/mL) was injected for 10 min. After the 
immobilisation of streptavidin, unreacted sites were capped by injection of 1 M 
ethanolamine, pH 8.5 (supplied with amine coupling kit, GE Healthcare, BR-
1000-50) for 10 min. Finally, CD271-biotin antibody was injected in PBST (20 
µg/mL, final concentration 10 µg/mL) until saturation.  
 
6.2.2.3 SPR binding assays to study whole cell interactions 
When the antibodies were immobilised, alpha MEM culture medium with 0.005% 
Tween 20 was injected and used as a running buffer throughout the cell binding 
assays. For each injection, 75 µL of medium was injected followed by 75 µL of 
cell suspension. The concentration of cell suspensions started at 3.125 x 105 
cells/mL and increased two-fold to a concentration of 2.0 x 107 cells/mL. The SPR 
signal was measured for 15 min, the needles washed, the flow cell drained and 
running buffer injected until a stable baseline was achieved.  
After the highest cell concentration was injected and a stable baseline 
established, the pH was increased by injection of glycine-NaOH (80 mM, pH 8.5). 
The pH was gradually increased to pH 10.0 (in 0.5 steps) until there was no 
further change in the SPR angle. Between each pH, running buffer (Alpha MEM 
culture medium with 0.005% Tween 20) was injected until the baseline was 
stable.         
 
6.2.3 Colorimetry experiment to investigate the immobilisation of 
CD271 antibody to the channel surface 
To ensure that antibody was uniformly present on the channel surface, a 
colorimetry experiment was carried out on the channel surface substrate. The 
substrate was a gold-coated glass slide or silicon wafer (see Section 6.2.4.2 for 
fabrication details), with an adhesion layer of 5 nm titanium and a gold layer of 50 
nm – similar to the gold-coated SPR glass disk (Section 6.2.2). From SPR 
experiments, it was decided to use a CD271-biotin antibody for specific cell 
capture (see Section 6.3.1.1) which could be detected by an alkaline 
phosphatase (ALP) conjugated anti-biotin secondary antibody (Miltenyi Biotec, 
130-092-612) and reacted with 5-bromo-4-chloro-3-indolyl phosphate 
(BCIP)/nitro blue tetrazolium (NBT) substrate (Sigma Aldrich, B5655) to produce 
a blue-purple reaction product which precipitates onto the gold surface (252). 
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A series of controls was carried out alongside the test condition to ensure the 
antibody was immobilised via NHS/EDC crosslinking only. Six conditions were 
tested in total, including a titration of the secondary antibody: 
1. Full immobilisation with secondary antibody concentration of 1 µg/mL 
2. Full immobilisation with secondary antibody concentration of 0.5 µg/mL 
3. Full immobilisation with secondary antibody concentration of 0.1 µg/mL 
4. Immobilisation without streptavidin 
5. Immobilisation without CD271-biotin antibody  
6. Immobilisation without secondary antibody 
Two replicates of each condition were carried out.  
The same procedure of antibody immobilisation was carried out as for the SPR 
disk; the gold-coated glass slide was incubated with SAM solution (ProChima 
Surfaces TH 003-m11.n6, 1 mM in 95% ethanol, 5% acetic acid) at RT for 24 h 
minimum. The slide was washed with 100% ethanol and dried using a nitrogen 
gun. The slide was washed with MES buffer for 5 min in a shaker (Stuart orbital 
incubator S150) then incubated with NHS and EDC solution (200 mM NHS (150 
µL), 800 mM EDC (150 µL)) in an equal volume of MES buffer for 15 min at RT. 
Washing with MES buffer was repeated for 5 min and then in sodium acetate 
buffer (10 mM, pH 5.0) for 5 min. All washing steps were carried out on a shaker. 
A solution of streptavidin (250 µg/mL in sodium acetate buffer (10 mM, pH 5.0)) 
was spotted in test conditions and buffer spotted in control conditions. Spots were 
2 µL in volume and pipetted directly onto the gold surface.  
After 15 min, the spots were pipetted off and the slide washed with sodium 
acetate buffer (10 mM, pH 5.0) for 5 min. A solution of 1 M ethanolamine (pH 8.5) 
was pipetted over the entire surface of the slide and incubated for 10 min to cap 
unreacted sites on the monolayer. Washing with sodium acetate buffer was 
repeated then the buffer changed to PBST for 5 min. CD271-biotin (10 µg/mL in 
PBST) was spotted in the test conditions and buffer only spotted for control 
conditions. The substrate was incubated for 30 min before washing in PBST for 
5 min. The slide was incubated in 1% bovine serum albumin (BSA, in PBST) for 
30 min and then washed. Anti-biotin ALP (1 µg/mL, 0.5 µg/mL and 0.1 µg/mL in 
PBST) was spotted in test conditions and incubated for 45 min. The slide was 
washed in PBST twice, then three times in PBS for 5 min each. 
After the last wash, the slide was placed in BCIP/NBT substrate (1 tablet 
dissolved in 10 mL distilled water) and incubated for 10 min. The slide was 
washed three times in water (2 min each) and dried. Photographs were taken 
using a Zeiss AX10 microscope and AxioCam MRc 5 camera with 10x 
magnification.  
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6.2.4  Design, fabrication and assembly of a prototype microfluidic 
device 
6.2.4.1 Overall device design using Autodesk Fusion360 software 
The initial design for a prototype microfluidic device was drawn in Autodesk 
Fusion360 software. The design consisted of a gold-coated substrate which could 
be functionalised with antibodies for specific cell capture. On top of the gold 
surface, four PDMS channels were designed to allow microfluidic flow, with inlets 
from the top side of the device and outlets from the bottom side of the device. 
This was designed so that the fluid flow would be in the direction of gravity to 
increase cell recovery. The gold substrate had four holes where the outlets were, 
and a bottom layer of PDMS was designed to secure the outlet tubing in place. 
The bottom layer of PDMS had four 1 mm cylinder protrusions so it would fit flush 
with the 1 mm gold substrate.  
On top of the channels a Perspex clamp was designed to hold the channels in 
place, and a Perspex rig was designed to hold the PDMS, gold substrate, and 
clamp structure. The Perspex rig had indents where valves could sit to control the 
fluid flow before fluid entered the channels. The Autodesk Fusion360 design is 
shown in Figure 6.4.  
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Figure 6.4 Autodesk Fusion360 design for a prototype microfluidic device 
An overall device design was drawn using Autodesk Fusion360 software. 
The top left photo shows the full device, the top right photo shows a closer 
view of the microfluidic channels, the bottom left photo shows a side view of 
the channels and the bottom right photo shows the top view of the channels.  
 
6.2.4.2 Fabrication of a gold-coated surface for antibody functionalisation 
Once an overall design had been established, the individual parts were drawn in 
2D in L-Edit v12.6 (Figure 6.5), and fabricated. Two different substrates were 
used as a basis for the gold-coated substrate – standard glass slides (Fisher 
Scientific, 12373118) and silicon wafers (650 – 700 micron thickness, 150 mm 
diameter). The glass slides were scribed in half and the silicon wafers were cut 
using a wafer saw to the same size as half a glass slide (25 mm x 37.5 mm). Four 
3 mm-diameter holes were laser cut from the substrate to allow for the outlet 
tubing (see Figure 6.4 and Figure 6.5).  
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Figure 6.5 L-Edit drawing of the gold-coated substrate, microfluidic 
channels and clamp for fabrication 
The Perspex clamp (grey), the gold substrate (blue), and the microfluidic 
channels (green) were drawn in 2D in L-edit. The red circles and rectangles 
show laser-cut holes in the Perspex clamp for screws (larger red circles), 
inlet tubing (smaller red circles) and to view the channels (red rectangles), 
and the blue circles show holes in the gold substrate for the outlet tubing. 
The channel dimensions were 25.5 mm in length and 900 µM in width.  
 
Once the holes in the substrate had been laser cut, the substrates were coated 
with a 50 nm layer of gold using an e-beam evaporator (Leybold). The substrates 
were cleaned using piranha solution (70% sulphuric acid, 30% hydrogen 
peroxide) and placed in an oxygen plasma for 5 min, 50 W. The substrates were 
dehydrated on a hot plate for 5 min at 200 °C before placed in the evaporation 
chamber. A 5 nm layer of titanium was used as an adhesion layer. Figure 6.6 
shows gold-coated substrates ready for antibody functionalisation.  
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Figure 6.6 Gold-coated substrate for antibody functionalisation 
Glass slides or silicon wafer were coated with a 5 nm titanium adhesion layer 
and a 50 nm gold layer using an e-beam evaporator.  
 
6.2.4.3 Microfluidic channel design and fabrication of a PDMS mould using 
SU-8 photoresist 
The microfluidic channel design was drawn in L-Edit v12.6 and consisted of four 
individual channels, 25.5 mm in length and 900 µM in width (shown in green in 
Figure 6.5). Four channels were designed so that each channel could be used 
for separate control experiments. The dimensions were designed so that the 
channels would fit on half a microscope slide, had a low aspect ratio, and were 
similar to a microfluidic device used by Qasaimeh et al. (2017)(253) to capture 
CD138-expressing cells. 
A PDMS mould was made using standard soft lithography techniques (see 
Section 6.1.1). A silicon wafer (Nova Electronic Materials) was cleaned using 
piranha solution (70% sulphuric acid, 30% hydrogen peroxide) and placed in an 
oxygen plasma for 5 min, 50 W. The wafer was dehydrated on a hot plate for 5 
min at 200 °C, then spin-coated with SU-8 photoresist (MicroChem formulations 
50-100) according to the manufacturer’s recommendations for 100 µM thickness. 
The spin-coated wafer was pre-baked for 5 min at 65 °C and soft-baked for a 
further 25 min at 95 °C. A Maskless Aligner (MLA-150) was used to pattern the 
microfluidic channels directly onto the resist-covered wafer (375 nm, dose 1600). 
The patterned wafer was post-baked for 1 min at 65 °C then the temperature 
ramped to 95 °C for 10 min. After post-exposure baking, SU-8 photoresist was 
developed in EC solvent (MicroChem) for 11 min with a solvent change after 6 
min. The wafer was hard-baked at 200 °C for 5 min to reduce cracks in the mould.  
The height of the ridges in the mould were measured using a surface profiler 
(Alpha-Step IQ) to estimate the height of the PDMS channels subsequently made 
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from the mould. A 5 mm PDMS gasket was laser cut from Perspex and attached 
to the wafer using double-sided sticky tape (3M™ VHB™). The finished PDMS 
mould is shown in Figure 6.7. 
 
 
Figure 6.7 PDMS mould fabricated using photolithography techniques 
A PDMS mould was fabricated using SU-8 negative photoresist and a 
maskless aligner. Four microfluidic channels were patterned onto the 
photoresist to create channels with height of 90-100 microns. A 5 mm PDMS 
gasket was made from Perspex and attached to the wafer using double-
sided sticky tape.  
 
PDMS (Sylgard 184, Dowsil) was mixed in a ratio of 10:1, siloxane: curing agent, 
and degassed in a vacuum chamber. The PDMS was poured into the mould and 
levelled using a glass slide to scrape away excess. The mould was placed in an 
oven at 65 °C for 24 h. The PDMS was released out of the mould using a scalpel 
and 1.5 mm holes punched at each inlet for inlet tubing.  
 
6.2.4.4 Fabrication of a bottom-layer PDMS mould using a milling machine 
The mould for the bottom layer of PDMS was required to have four 1 mm cylinder 
indentations so that the PDMS would have four 1 mm cylinder protrusions that 
would fit flush with the laser-cut holes in the gold substrate. The PDMS mould 
was drawn in 3D in Autodesk Fusion360 (Figure 6.8) and milled from 10 mm 
Perspex using a computer numerical control (CNC) milling machine (Roland). 
The PDMS was mixed and cured as described in Section 6.2.4.3.  
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Figure 6.8 Bottom layer PDMS mould fabricated using a milling machine 
The bottom layer PDMS mould was drawn in Autodesk Fusion360 (left-hand 
side) and fabricated using a CNC milling machine (right-hand side). The four 
1 mm indentations were designed so that the PDMS had four 1 mm 
protrusions and would fit flush with the holes in the gold-coated substrate.  
 
6.2.4.5 Assembly of a prototype device 
The Perspex clamp and rig were laser cut and assembled using M3 and M6 
screws. Acetone was used to solvent-weld the smaller pieces of Perspex. 
Polytetrafluoroethylene (PTFE) tubing (0.3 mm inner diameter, 1.6 mm outer 
diameter) was cut and assembled as inlet tubing, and 1 mm inner diameter, 1.6 
mm outer diameter PTFE tubing was cut and assembled as outlet tubing. A larger 
diameter outlet tubing was used to reduce fluidic resistance at the outlet and 
prevent leaks in the channel. Four-way valves (IDEX Health & Science, V101L) 
were positioned so that buffer or cell suspension could be injected to waste before 
injection into the channels, thus reducing the possibility of air bubbles entering 
the channels. The assembled device is shown in Figure 6.9. 
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Figure 6.9 Fabricated and assembled prototype device 
The prototype device was assembled using screws and solvent welding. 
PTFE tubing was used for inlet and outlet tubing. Four-way valves were 
positioned to control the fluid flow before fluid entered the channels.  
 
6.2.5 Prototype device experiment protocols 
For all experiments using the prototype device, the gold substrate was 
functionalised in the same way as for the colorimetry experiment (Section 6.2.3) 
using a PEG SAM and NHS/EDC crosslinking chemistry (Sections 4.3 and 4.4), 
streptavidin and a CD271-biotin antibody. Each solution was pipetted onto the 
substrate and incubated for 10 min. Between each solution the substrate was 
washed by pipetting buffer over the surface and for each buffer change the new 
buffer was incubated for 2 min before the subsequent solution. The substrate was 
incubated with 1% BSA for 30 min to help prevent non-specific adsorption of 
proteins to the substrate surface, then dried using a nitrogen gun, and assembled 
with the PDMS channels onto the Perspex rig. The channels were manually 
flushed with 1% BSA, then a syringe pump (PHD 2000 Programmable, Harvard 
Apparatus) was programmed at a low flow rate (1 µL/min) for 30-60 min. The 
buffer was changed to the running buffer for the experiment, and injected for 30-
60 min before cell suspension injection.  
The cells for each experiment were harvested using 3-5 mL trypsin-EDTA 
solution (Sigma, T4049), filtered through a 40 micron cell strainer (Corning, 
352340) and counted using a haemocytometer. For each injection, buffer or cell 
suspension was injected to waste to purge the tubing of any air bubbles, then the 
four-way valve rotated to inject the medium into the channel. Cell suspensions 
were kept on ice before and after injection into the device.  
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6.2.5.1 Experiments using single cell populations 
The initial experiments carried out using the prototype device used single cell 
populations to determine the specificity of cell capture. Channels were 
functionalised with either CD271-biotin antibody (Miltenyi Biotec, 130-113-419) 
or CD34-biotin antibody (Miltenyi Biotec, 130-113-177), both at 10 µg/mL. Three 
conditions were tested in total: 
1. CD271+ SH-SY5Y cells in a CD271-biotin functionalised channel 
2. CD271- fibroblast cells in a CD271-biotin functionalised channel 
3. CD271+ SH-SY5Y cells in a CD34-biotin functionalised channel 
Two running buffers were investigated during the initial experiments; serum-free 
alpha MEM culture medium with 0.005% Tween 20 and MACS buffer9 with 
0.005% Tween 20. Cells were suspended in running buffer at a concentration of 
2.5 million cells/mL. Cell suspensions (50 µL) were injected into a channel using 
a syringe pump programmed at 100 µL/min. The cells were incubated in the 
channel for 5 min to allow sedimentation of the cells to the channel surface then 
unbound cells were washed away at 5 µL/min, until no more cells were moving.  
Photos were taken at the same location of the channel before the cell injection, 
during the 5 min incubation and after the 5 µL/min buffer wash. Using ImageJ, 
the number of cells in each photo could be estimated as follows: for each photo 
the smooth continuous background was subtracted by setting a rolling ball radius 
(e.g. 6 pixels), the threshold was adjusted, and the number of particles above 25 
pixels analysed. The same values were set for all associated images. The 
number of ‘cells’ before the cell injection (i.e. background fouling on the channel 
surface) was subtracted from both the ‘5 min incubation’ and ‘after 5 µL/min wash’ 
photos. The percentage of cells bound could then be calculated.  
 
6.2.5.2 Experiments using mixed cell populations 
To assess specific cell capture from mixed cell populations, SH-SY5Y cells and 
fibroblast cells were mixed in different ratios and the mixed populations injected 
into the device. The following ratios were evaluated (SH-SY5Y cells: fibroblast 
cells); 100: 0, 75: 25, 50: 50, 25: 75, 12: 88, 6: 94, 3: 97, 1.5: 98.5. The mixed cell 
populations were injected into the device using the same procedure as above 
(Section 6.2.5.1), using MACS buffer with 0.005% Tween 20 as the running buffer 
 
9 MACS buffer: PBS (Lonza, 17-516F), 2 mM EDTA (Sigma Aldrich, E7889), 0.5% BSA 
(Sigma Aldrich, A9647), filter sterilised 
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(see Section 6.3.2) and at a total cell concentration of 20 million cells/mL (see 
Section 6.3.3.2). 
The results from the device were compared to the specificity of flow cytometry. 
For flow cytometry analysis, SH-SY5Y and fibroblast cells were mixed in the 
same ratios as described above and analysed using a Cytoflex S cytometer. The 
mixed populations were suspended in FACS buffer10 and labelled with a CD271-
PE antibody (Miltenyi Biotec, 130-113-421, 0.5 µg/mL) or an isotype-matched 
control antibody (IgG1-PE, BD Biosciences, 555749, 0.5 µg/mL). Unlabelled cells 
were also analysed for gating purposes. The cells were incubated with the 
antibody for 15 min at 4 °C in the dark. FACS buffer (2 mL) was added to each 
FACS tube and the cells washed by centrifugation for 5 min at 300 g and 4 °C. 
Cells were re-suspended in 350 µL FACS buffer and 20,000 events were 
collected for each sample. Flow cytometry events were gated for single cells 
using the gating strategy shown in Chapter 4: Section 4.5.  
 
6.2.5.3 Fluorescent labelling of cells  
To confirm the specificity of cell capture within the device, the two cell types were 
fluorescently labelled with different coloured cell trackers and analysed using a 
multiband filter set (Semrock, LF488/561-B-000) and a multichannel imaging 
system (Photometrics DV2™). 
Cells were fluorescently labelled 24 hours prior to testing as it was found that 
fluorescent labelling affected the cell binding behaviour when carried out 
immediately prior to testing. SH-SY5Y cells were labelled with green cell tracker 
(Invitrogen, C7025) and fibroblast cells were labelled with red cell tracker 
(Invitrogen, C34552). The cell trackers were warmed to RT and re-suspended in 
filtered DMSO to make 10 mM solutions. The solutions were diluted to 10 µM in 
serum-free culture medium and warmed to 37 °C. Culture medium was removed 
from the cell culture flask, replaced with cell tracker solution and incubated for 
30-45 min in the cell culture incubator. Cell tracker solution was removed and the 
cells incubated in their normal culture conditions until the following day.  
The mixed cell population experiments with fluorescently-labelled cells were 
carried out in the same way as Section 6.2.5.2 but only 100% SH-SY5Y, 50% 
SH-SY5Y,  25% SH-SY5Y and 6% SH-SY5Y populations were evaluated.  
 
 
10 FACS buffer: PBS (Lonza, 17-516F), 0.5% BSA (Sigma Aldrich, A9647) and 0.05% 
sodium azide, filter sterilised (0.22 µm) 
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6.2.6 Post-enrichment analysis 
6.2.6.1 Investigating the viability of cells post-enrichment 
The viability of cells post-enrichment was investigated using flow cytometry. SH-
SY5Y cells that had been captured and released in the device were collected and 
their viability compared to cells suspended in medium, on ice, for the same 
duration (medium control) and cells that had been injected into the device at 
different flow rates but with no incubation period (microfluidic controls). A new 
channel design with higher throughput (see Section 6.3.5) was used for viability, 
proliferation (Section 6.2.6.2), manipulation (Section 6.2.6.3) and cell recovery 
(Section 6.2.6.4) experiments. 
The cell enrichment procedure in the new channels was carried out as follows; 
cells were injected into the device at a concentration of 20 million cells/mL at 100 
µL/min and incubated with no flow for 5 min. Unbound cells were washed away 
at 20 µL/min for 100 µL to ensure cells reached the end of the outlet tubing (70 
µL tubing volume). Bound cells were collected directly into a FACS tube at 320 
µL/min for 200 µL. The flow rates used for the buffer wash and cell release were 
four times higher than previously used because the new channel design branched 
into four separate channels. Microfluidic controls were injected into the device at 
three different flow rates; 100 µL/min, 500 µL/min and 3000 µL/min for 200 µL, 
and collected directly into a FACS tube. Medium controls were kept on ice at the 
same cell concentration (20 million cells/mL, 50 µL) for the duration of the 
experiment. 
All cells were centrifuged at 300 g, 4 °C for 5 min and re-suspended in ice-cold 
FACS buffer. A 7-amino-actinomycin D (7-AAD) Staining Solution (Miltenyi 
Biotec, 130-111-568, 0.525 µg/mL) was added to each tube and incubated in the 
dark for at least 5 min before analysis. A Cytoflex S flow cytometer was used for 
analysis and 20,000 events recorded for each sample. 
Cells that had been through a MACS column were also analysed in the same way 
for comparison to a “gold standard” method of cell enrichment.   
 
6.2.6.2 Investigating the proliferation of cells post-enrichment 
To look at the longer-term viability and function of the cells, bound and released 
cells were seeded in  24-well plates and their proliferation assessed at two 
different time points using a Pico green assay for dsDNA quantification. The same 
controls were used as for viability testing (Section 6.2.6.1) – medium controls and 
microfluidic controls.  
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After the enrichment procedure in the device (carried out in the same way as 
Section 6.2.6.1), the cells were counted and seeded at 40,000 cells per well in 
normal SH-SY5Y cell culture medium (0.5 mL per well) in two 24-well plates 
(Corning, 3526). Each experimental condition was carried out in triplicate (with 
the exception of the captured and released population where 1-3 replicates were 
carried out depending on the number of cells collected) and the entire experiment 
carried out three times on different days with different cells and a new device. 
After 2 days in culture, the cells in one plate were washed twice with PBS and 
lysed with 0.1% Triton-X100 (200 µL per well) with repeated freeze/thaw cycles; 
the cell culture plate was frozen at -80 °C for 10 min then thawed at 37 °C for 10 
min. After thawing, the cell suspension was mixed and the freeze/thaw cycle 
repeated twice more. 
A Quant-iT™ PicoGreen™ dsDNA Assay Kit (Invitrogen, P11496) was used to 
quantify the dsDNA in each sample. A standard curve was prepared using 
lambda DNA supplied with the kit (100 µg/mL in TE buffer11) and lysed cells were 
diluted 20-fold in TE buffer. Quant-iT™ PicoGreen® dsDNA reagent  (supplied 
with the kit) was diluted 200-fold and protected from light until ready to use. All 
standards and samples were pipetted in triplicate in a 96-well plate (Corning, 
3599), 100 µL per well. Quant-iT™ PicoGreen® dsDNA reagent was added at 
100 µL per well and incubated in the dark for 5 min. The samples were excited at 
480 nm and the fluorescence emission intensity measured at 520 nm using a 
spectrofluorometer (Thermo Scientific Varioskan® flash).  
The fluorescence mean value of the blank wells was subtracted from all 
standards and samples. A standard curve was plotted in Origin and the dsDNA 
content of the samples calculated using linear regression analysis.  
The second 24-well plate was processed in the same way 5 days after seeding 
to assess cell proliferation between the two time points and the relative difference 
between samples.  
 
6.2.6.3 Investigating the manipulation of cells during the enrichment 
process 
In order to have significant advantages over current affinity-based enrichment 
technologies, the cells must be minimally manipulated during the procedure. For 
an initial analysis of the cell manipulation, flow cytometry was used to assess if 
any of the antibody immobilised on the channel surface was present on the cells 
 
11 TE buffer: 200 mM tris-HCl, 20 mM EDTA, pH 7.5 (supplied with Quant-iT™ 
PicoGreen™ dsDNA Assay Kit, Invitrogen, P11496) 
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after they had been captured and released. This was carried out by incubating 
the cells with an anti-biotin-PE conjugated secondary antibody (Miltenyi Biotec, 
130-111-068) to detect if any of the CD271-biotin antibody was present. A further 
experimental condition using CD271-biotin and anti-biotin-PE as a secondary 
antibody was conducted alongside to ensure the CD271 antigen was not affected 
by the capture and release process.   
Samples were processed through the device as described in Section 6.2.6.1. Two 
samples of captured and released cells were collected, one for incubation with 
anti-biotin-PE and one for incubation with CD271-biotin antibody (and 
subsequent labelling with anti-biotin-PE). Samples were centrifuged at 300 g at 
4 °C for 5 min and re-suspended in 100 µL FACS buffer for antibody labelling. 
Labelling was carried out according to the manufacturer’s recommendations; 
each antibody was used at a dilution of 1:50 (2 µL in 100 µL) and incubated for 
10 min in the dark at 4 °C. Cells were washed by addition of 2 mL FACS buffer 
and centrifuged at 300 g and 4 °C for 5 min. Cells were re-suspended in 100 µL 
FACS buffer for secondary antibody labelling or 350 µL FACS buffer for analysis.  
Control samples at a concentration of 20 million cells/mL were suspended in 
medium on ice for the duration of the cell enrichment experiment and labelled at 
the same time as test samples. Control samples were labelled with anti-biotin-PE 
and CD271-biotin for comparison, as well as a sample unlabelled for gating 
purposes.  
A Cytoflex S Flow Cytometer was used to record data and at least 10,000 events 
were collected in the single cells gate (see Chapter 4: Section 4.5 for flow 
cytometry gating strategy).  
 
6.2.6.4 Investigating cell recovery from the prototype device 
The cell recovery from the device was calculated and compared to the recovery 
of cells from a MACS column.  
A SH-SY5Y cell suspension (20 million cells/mL, 200 µL) was injected into the 
device at 100 µL/min and then immediately washed out with 400 µL buffer (at 100 
µL/min). Cells were counted using a haemocytometer and a percentage 
calculated from the original volume of cells injected (4 million cells in a 200 µL 
injection, plus 210,000 cells in the tubing volume from the syringe to the valve 
after flushing out air bubbles). The percentage recovery was compared to cells 
which had been through a MACS column following the standard MACS protocol 
but with no microbead labelling; unlabelled cells were pipetted into the column in 
a 500 µL volume and the column was washed with 3x 3 mL MACS buffer. The 
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cells were centrifuged at 300 g for 5 min to re-suspend in a smaller volume for 
counting.  
   
6.3 Results and Discussion 
6.3.1 Immobilisation of a CD271 antibody to a gold substrate for 
specific cell capture 
A prototype device was designed and the individual parts fabricated and 
assembled as described in Section 6.2.4. The design of the device relies upon 
the specific capture of cells on the surface of a functionalised microfluidic 
channel. The first step was to ensure that a CD271 antibody (for specific cell 
capture) could be immobilised to the channel surface in a uniform manner and 
via a controlled mechanism.  
The proposed mechanism of immobilisation was the same method used in 
Chapter 5: Section 5.2.10 for SPR analysis, using a PEG monolayer (Section 4.3) 
and crosslinking chemistry (Section 4.4). The gold-coated wafer substrate 
prepared in Section 6.2.4.2 was first incubated with a SAM to help prevent non-
specific binding to the channel surface, and carboxylic acid groups in the 
monolayer were activated by NHS and EDC chemistry. 
Two CD271 antibodies were initially investigated; one conjugated to 
phycoerythrin dye (CD271-PE) and the other conjugated to biotin (CD271-biotin). 
The CD271-PE antibody was found to reliably bind to CD271+ cells during the 
work carried out in Chapter 5: Section 5.3.4. The CD271-biotin antibody was 
purchased from the same supplier (Miltenyi Biotec) and was produced by an 
identical clone. The CD271-PE antibody was immobilised directly to the SAM via 
NHS and EDC crosslinking, whereas in the case of the CD271-biotin antibody, 
streptavidin was immobilised to the SAM then CD271-biotin bound to the 
streptavidin (Section 6.2.2.2).  
During the development of a prototype device, an established cell line was used 
to optimise cell capture and release rather than primary cells. This was because 
primary cells were of limited supply and were only used when the efficacy of the 
device had been recognised. Established cell lines are continuous which means 
they can divide indefinitely ensuring a good supply of cells for preliminary 
experiments. In Chapter 5: Section 5.3.4.6, it was shown that the SH-SY5Y cell 
line expresses the CD271 antigen and can therefore act as a positive cell line for 
specific cell capture. For a negative control, primary human dermal fibroblast cells 
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were purchased which do not express the CD271 antigen. This was confirmed 
by flow cytometry analysis as shown in Figure 6.10.  
 
 
Figure 6.10 Flow cytometry histograms showing CD271- fibroblast cells and 
CD271+ SH-SY5Y cells used for optimisation of specific cell capture 
The left panel shows fibroblasts analysed by flow cytometry either 
unlabelled (pink), labelled with an isotype-matched control antibody (IgG1-
PE, green) or labelled with a CD271-PE antibody (red). All histograms are 
identical showing that fibroblasts do not express the CD271 antigen on their 
cell surface. The panel on the right shows the same analysis of SH-SY5Y 
cells for comparison. SH-SY5Y cells were either unlabelled (red), labelled 
with an isotype-matched control antibody (IgG1-PE, green) or labelled with 
a CD271-PE antibody (pink). The pink histogram shows a large percentage 
of SH-SY5Y cells are positive for anti-CD271-PE labelling compared to the 
negative controls, and therefore express the CD271 antigen on their cell 
surface.  
 
6.3.1.1 Surface plasmon resonance analysis of specific cell capture 
Initial analysis of specific cell capture on a surface functionalised with either 
CD271-PE or CD271-biotin was measured via SPR. The SPR experiments were 
carried out on an Autolab ESPIRIT SPR instrument which has sensor substrates 
almost identical to the channel surface in the prototype device. The SPR sensor 
discs were purchased from Xantec Bioanalytics and are glass discs with a gold 
layer of approximately 50 nm. In this work, gold-coated glass slides and gold-
coated silicon wafers were used as a surface for antibody functionalisation - both 
with a gold layer of approximately 50 nm.  
During SPR measurements it was found that using a layer of streptavidin and a 
CD271-biotin antibody reduced non-specific cell fouling to the gold surface 
compared to using a CD271-PE antibody alone (Figure 6.11). After the last cell 
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injection on the CD271-biotin functionalised surface, 411 response units were 
recorded in the flow cell where SH-SY5Y cells had been injected compared to 
2.5 response units in the flow cell where fibroblast cells had been injected. After 
the last cell injection on the CD271-PE functionalised surface, 129 response units 
were recorded in the flow cell where SH-SY5Y cells had been injected compared 
to 29 response units in the flow cell where fibroblast cells had been injected. This 
means there was proportionally 37 times more non-specific binding on the 
CD271-PE functionalised surface.  
This could be for a number of reasons; firstly, the protocols differed slightly in that 
the unreacted sites on the monolayer were blocked using ethanolamine after the 
immobilisation of streptavidin (and before the immobilisation of CD271-biotin 
antibody) whereas for the CD271-PE antibody, ethanolamine was not used as it 
was thought that any unreacted sites on the monolayer would no longer be active 
by the time cells were injected (at least 2 hours later due to the harvesting and 
transport of cells).  
Further to this, the SPR results observed for both CD271-PE and CD271-biotin 
functionalised surfaces could not be repeated and therefore reliable conclusions 
could not be drawn. During repeats, SH-SY5Y cells bound to the functionalised 
surface during the injection (i.e. the SPR angle increased) however, when buffer 
was injected after the cells were bound, cells were immediately washed from the 
surface (the SPR angle decreased to the baseline level). In comparison, the SPR 
sensogram shown in Figure 6.11, shows that the SH-SY5Y cells remained bound 
to the surface until the pH of the running buffer was increased.  
It was decided to investigate the CD271 antibody conjugated to biotin for cell 
capture in the prototype device. This was because the initial result indicated less 
non-specific binding using this antibody and it was also available at a higher 
concentration meaning it was more economical and there would be less batch-
to-batch variation between experiments.  
The initial results indicated that by using a pH 9.0 buffer, more than 70% of bound 
cells could be released from the functionalised surface. This is important because 
the cells need to be released from the surface post-enrichment in order to use 
them in cellular therapies. This preliminary result suggests a change in pH could 
be used as a mechanism for cell release. 
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Figure 6.11 SPR sensograms showing CD271+ cells binding to CD271 
antibodies immobilised to a gold surface 
The upper panel shows SPR measurements recorded when SH-SY5Y cells 
and fibroblast cells were injected onto a CD271-biotin functionalised surface 
(310 - 330 units immobilised). The lower panel shows SPR measurements 
recorded when both cell types were injected onto a CD271-PE 
functionalised surface (170 - 200 units immobilised). More non-specific 
binding was observed on the CD271-PE functionalised surface compared 
to the CD271-biotin functionalised surface.  
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6.3.1.2 Colorimetry assessment of antibody immobilisation on the channel 
surface 
During SPR measurements, the immobilisation of antibody on the surface can be 
measured by a change in the SPR angle (Section 4.2). However, for the 
immobilisation of an antibody on the microfluidic channel surface this information 
was not available. Instead, a colorimetry experiment was carried out to ensure 
that antibody was present and coating the surface in a uniform manner. A series 
of controls were also tested to ensure antibodies were immobilised via 
crosslinking chemistry and were not present through any other interaction with 
the surface.  
An anti-biotin-ALP secondary antibody was used with BCIP/NBT substrate for 
detection of the CD271-biotin antibody on the gold surface (Section 6.2.3). It was 
found that where the correct biochemistry had been applied, antibody was 
present on the gold surface (Figure 6.12). There was a small amount of 
secondary antibody present when no CD271-biotin antibody was present (Figure 
6.12 - panels 5a and 5b), however a clear difference was observed where 
antibody was present (Figure 6.12 - panels 1a and 1b). The pixel intensity of a 
22x22 pixel square (drawn in the top right corner for each image) was quantified 
using ImageJ (Figure 6.13). The average pixel intensity for replicates 6a and 6b 
(where no secondary antibody was used) was subtracted from all other values 
and the result reported as the absolute value. There was an average difference 
of 22 pixel intensity units when CD271 antibody was present in test condition 1 
to when no CD271 antibody was present in test condition 5. Altogether, this result 
provided confidence that the channel surface would be functionalised and 
antibodies would be available for specific cell capture within the prototype device.  
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Figure 6.12 Colorimetry experiment showing CD271-biotin was present on 
the gold channel surface 
The upper left panel shows a macroscopic image of the gold substrate 
spotted with CD271-biotin antibody or relevant control condition. The upper 
right panel shows the same substrate microscopically imaged. The bottom 
table details each of the conditions tested, corresponding to the numbers 
displayed on the upper panels (two repeats of each condition – a and b). 
sAb=secondary antibody.  
1. Full immobilisation (sAb – 1 
µg/mL ) 
2. Full immobilisation (sAb – 0.5 
µg/mL) 
3. Full immobilisation (sAb – 
0.1 µg/mL) 
4. Immobilisation without 
streptavidin (sAb – 1 µg/mL) 
5. Immobilisation without 
CD271-biotin antibody (sAb 
– 1 µg/mL) 
6. Immobilisation without 
secondary antibody 
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Figure 6.13 The pixel intensity of images from each test condition of the 
colorimetry experiment 
ImageJ was used to quantify the pixel intensity of a square (22x22 pixels) 
in the top right corner of each of the microscope images shown in Figure 
6.12. The test conditions correspond to the table shown in Figure 6.12. 
The background staining observed for test condition 5 (where no CD271 
antibody was present) is comparable to test condition 3 (where secondary 
antibody was used at 10x lower concentration). There is a clear difference 
between test conditions 1 and 5 where the secondary antibody was used 
at the same concentration. No statistical analysis was carried out due to 
the low number of replicates. Bars represent the mean value and error 
bars represent the standard error of the mean (n=2 technical replicates).  
 
6.3.2 Investigating specific cell capture and release in the prototype 
device using single cell populations 
The aims of the first experiments using the prototype device were to assess the 
specificity of cell capture using single cell populations. Furthermore, the protocol 
of cell enrichment was refined including the buffer used for cell suspension and 
washes, and the procedure for injecting, capturing, releasing and collecting 
enriched cells.  
Using the two cell populations described in Section 6.3.1, different combinations 
of specific and non-specific antibody were tested with different cells. The 
substrate was functionalised with either CD271-biotin antibody or CD34-biotin 
antibody. It was confirmed that SH-SY5Y cells did not express the CD34 antigen 
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on their cell surface and therefore should not bind to a channel functionalised with 
CD34-biotin antibody (Figure 6.14). 
 
 
Figure 6.14 Flow cytometry analysis showing SH-SY5Y cells do not express 
the CD34 antigen  
SH-SY5Y cells were labelled with CD34-PE antibody (red), an isotype-
matched control antibody (IgG1-PE, pink), or unlabelled (green). The 
histograms show that SH-SY5Y cells do not express the CD34 antigen since 
there is no PE fluorescence detected for cells labelled with CD34-PE 
compared to the isotype control antibody and unlabelled cells.  
 
Cell suspensions were injected into the device via a syringe pump at 100 µL/min 
flow rate and a 5 minute incubation period allowed cells to sediment and interact 
with the cell surface. Buffer washes at 5 µL/min were used to wash away unbound 
cells. Two buffers were trialled as running buffers in these experiments: Alpha 
MEM cell culture medium with 0.005% Tween 20 and MACS buffer12 with 0.005% 
Tween 20. Each experiment was carried out in a single channel of the four-
channel device (see Figure 6.5 for details of the channel design).   
Figure 6.15 shows an example of a specific interaction in the device, where SH-
SY5Y cells (CD271+) have been injected into a channel functionalised with a 
CD271-biotin antibody. Figure 6.16 shows an example of a non-specific 
interaction in the device, where fibroblast cells (CD271-) have been injected into 
a channel functionalised with CD271-biotin antibody. Figure 6.17 shows a non-
 
12 MACS buffer: PBS, 2 mM EDTA and 0.5% BSA 
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specific interaction in the device where SH-SY5Y cells (CD271+) have been 
injected into a channel functionalised with CD34-biotin antibody. 
Images were taken in the same location of the channel before a cell suspension 
injection, during the 5 minute incubation period and after a 5 µL/min buffer wash. 
Using ImageJ it was possible to analyse the number of ‘particles’ above a set 
number of pixels (25 pixels), and therefore using all three images it was possible 
to estimate the percentage of cells bound for each experiment (shown in Figure 
6.18). There was a significant difference between specific interactions and non-
specific interactions in the device. 
 
 
Figure 6.15 An example of a specific interaction in the prototype device 
using SH-SY5Y cells (CD271+) and a CD271 antibody-functionalised 
channel 
Images were taken of the same section of channel before the cell 
suspension injection, during the 5 minute incubation period and after a 5 
µL/min buffer wash. The top row shows images taken with a microscope 
camera, and the bottom row shows the same images analysed by ImageJ 
for particles above 25 pixels. These images show the injection of SH-SY5Y 
cells (CD271+) into a channel functionalised with a CD271-biotin antibody.  
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Figure 6.16 An example of a non-specific interaction in the prototype 
device using fibroblast cells (CD271-) and a CD271-biotin functionalised 
channel  
Images were taken of the same section of channel before the cell 
suspension injection, during the 5 minute incubation period and after a 5 
µL/min buffer wash. The top row shows images taken with a microscope 
camera, and the bottom row shows the same images analysed by ImageJ 
for particles above 25 pixels. These images show the injection of fibroblast 
cells (CD271-) into a channel functionalised with a CD271-biotin antibody.  
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Figure 6.17 An example of a non-specific interaction in the prototype device 
using SH-SY5Y cells (CD271+) and a CD34-biotin functionalised channel  
Images were taken of the same section of channel before the cell 
suspension injection, during the 5 minute incubation period and after a 5 
µL/min buffer wash. The top row shows images taken with a microscope 
camera, and the bottom row shows the same images analysed by ImageJ 
for particles above 25 pixels. These images show the injection of SH-SY5Y 
cells (CD271+) into a channel functionalised with a CD34-biotin antibody.  
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Figure 6.18 The percentage of cells bound in a prototype device for different 
antibody/cell interactions 
The percentage of cells bound after a 5 µL/min buffer wash was estimated 
using ImageJ. Data shown here is data collated from experiments using both 
Alpha MEM culture medium and MACS buffer as running buffers. There was 
a significant difference between the specific interaction (CD271-biotin/SH-
SY5Y cells) and non-specific interactions (CD271-biotin/fibroblast cells and 
CD34-biotin/SH-SY5Y cells), p<0.01, n=6. Statistical analysis was carried 
out using a Mann Whitney-U test since not all data was normally distributed 
according to the Shapiro Wilk test of normality. Bars represent the mean 
result and error bars represent the SEM. 
 
Next, the percentage of cells bound using different running buffers was compared 
(Figure 6.19). It was found that there was no significant difference between the 
percentage of cells bound using either Alpha MEM or MACS buffer in any of the 
antibody/cell combinations.  
However, it was assumed that there could be small advantages to using MACS 
buffer, for example; MACS buffer contains 0.5% BSA which could help prevent 
non-specific binding and it is not susceptible to pH change. On the other hand, 
Alpha MEM culture medium contains a carbonate buffering system and in 
atmospheric conditions the pH of the medium can rise due to carbon dioxide 
diffusing out. For these reasons, it was decided to use MACS buffer as the cell 
suspension buffer for future experiments. 
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Figure 6.19 The percentage of cells bound in the prototype device using 
different running buffers 
Alpha MEM culture medium with 0.005% tween 20 and MACS buffer with 
0.005% Tween 20 were investigated as running buffers for cell enrichment 
experiments. It was found that there was no significant difference between 
the percentage of cells bound for any of the different antibody/cell 
interactions using either buffer. (n.s.=not significant, n=3). Statistical 
analysis was carried out using a Mann Whitney-U test since not all data was 
normally distributed according to the Shapiro Wilk test of normality. Bars 
represent the mean result and error bars represent the SEM. 
 
It was also found that as the flow rate was increased, cells began to release from 
the cell surface with only 6 ± 3% of cells (mean value ± SEM, n=3) remaining 
bound after a buffer wash at 160 µL/min (Figure 6.20). Since releasing bound 
cells by increasing the flow rate was found to be effective, using buffer solutions 
with an increased pH was not investigated at this time. The impact of higher flow 
rates on cell viability was investigated and the results shown later in this chapter 
(Sections 6.3.6 and 6.3.7).  
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Figure 6.20 The percentage of bound cells when the flow rate was increased 
The flow rate of buffer washes was increased from 5 µL/min to 160 µL/min 
and the number of cells bound after each wash was estimated using ImageJ. 
Each coloured line represents one experiment and the dashed line 
represents the mean value (n=6). As the flow rate was increased, bound 
SH-SY5Y cells (CD271+ cells) were released from the channel surface 
functionalised with CD271-biotin antibody. 
 
6.3.3 Optimising cell capture and release in the prototype device 
6.3.3.1 Reducing cell clumping  
The initial experiments carried out with the prototype device showed that specific 
cell capture and release was achievable, however, there were still areas that 
required optimisation. For example in Figure 6.18 it can be seen that the 
percentage of bound cells was inconsistent between individual experiments. The 
reason for this was because cells in the small-diameter (0.3 mm) tubing during 
the 5 minute incubation period formed large cell clumps, and during the buffer 
wash the large cell clumps would “drag” bound cells from the channel surface. 
Therefore when the photo was taken after the buffer wash, the number of cells 
was diminished from the true value.   
To overcome this issue a second inlet tubing was installed for the buffer wash 
(Figure 6.21). This allowed the cell suspension to be injected via one syringe 
pump (PHD 2000 Programmable, Harvard Apparatus) and inlet tubing, and the 
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buffer wash to be injected via a second syringe pump (NE-1000 Programmable, 
KF Technology) and inlet tubing. Adapting the protocol in this way meant that no 
cells incubated in the small-diameter tubing would flow across the cell surface 
when cells were bound, and the tubing could be flushed out before subsequent 
experiments. Using this protocol increased the consistency between experiments 
and ensured accurate data was being recorded (see Section 6.3.3.2). 
 
 
 
 Figure 6.21 A second inlet tubing was installed for buffer washes 
A second inlet tubing was installed in the second channel of the four-channel 
prototype device. This allowed the cell suspension to be injected via the first 
inlet tubing (indicated by the blue arrow and labelled in the schematic), and 
the buffer wash to be injected via the second inlet tubing (indicated by the 
red arrow and labelled in the schematic). Using the second channel only, 
meant cell clumps formed in the inlet tubing did not lead to inaccurate data 
collection. See Figure 6.5 for further description of this schematic.  
 
- 154 - 
6.3.3.2 Investigating the initial cell concentration  
A further area of optimisation was to investigate the initial concentration of the 
cell suspension injected into the device. This was important in order to capture 
the maximum number of cells during one incubation period. Initial experiments 
were carried out at a concentration of 2.5 million cells/mL, to maximise the 
number of cells available for capture 5, 10 and 20 million cells/mL were trialled 
as initial cell concentrations.  
It was found that increasing the initial cell concentration increased the number of 
cells bound during one 5 minute incubation (Figure 6.22) and that there was no 
significant difference between the percentage of cells bound at different cell 
concentrations (Figure 6.23). This meant it was beneficial to use the highest cell 
concentration of 20 million cells/mL. Although saturation of the channel surface 
was not observed, cell concentrations higher than 20 million cells/mL were not 
investigated because at the higher cell concentrations the cells began to clump 
together and caused more variable results.  
 
Figure 6.22 The number of cells bound increased when the initial cell 
concentration was increased 
The initial cell suspension concentration was investigated with the aim to 
bind the maximum number of cells on the channel surface during one 
incubation. The number of cells bound to the channel surface increased as 
the initial concentration of the cell suspension was increased. The dashed 
line connects the median values, bars represent the mean values and the 
error bars represent the SEM.  
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Figure 6.23 There was no difference in the percentage of cells bound when 
the initial cell concentration was increased 
The initial cell suspension concentration was investigated with the aim to 
bind the maximum number of cells to the channel surface during one 
incubation. There was no significant difference between the percentage of 
cells bound to the channel surface as the initial concentration of the cell 
suspension was increased (n.s.=not significant, n=3). The dashed line 
connects the median values, bars represent the mean values and the error 
bars represent the SEM. Statistical analysis was carried using an 
independent samples t-test as the data was normally distributed according 
to the Shapiro-Wilk test of normality. 
 
When comparing this data to the data recorded using the one-inlet device, it can 
be seen that the percentage of cells bound after the buffer wash was significantly 
higher and more consistent when using the second inlet tubing for buffer washes 
(Figure 6.24). Using the two-inlet device, the average percentage of cells bound 
in a 100% CD271+ population was 83 ± 3% (mean ± SEM, n=12), compared with 
60 ± 7% (mean ± SEM, n=6) for the earlier data recorded using only one inlet 
tubing. 
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Figure 6.24 Comparison of data recorded using one-inlet device and two-
inlet devices 
For a 100 % SH-SY5Y population of cells, the percentage of cells bound 
after a 5 µL/min buffer wash was calculated using ImageJ. The percentage 
bound using a one-inlet device was compared to the percentage bound 
using a device with two inlets - designed to avoid large cell clumps distorting 
the percentage of cells bound to the channel surface. It was found that there 
was a significant difference in the percentage of cells bound using the two 
different device designs, with a higher and more consistent percentage of 
cells bound using a two-inlet device. Statistical analysis was carried out 
using an independent samples t-test as data was normally distributed 
according to the Shapiro Wilk test of normality (n=6 and n=12 respectively). 
Bars represent the mean values, the error bars represent the SEM and the 
dashed line connects the median values.  
 
Further to this, the release of cells at higher flow rates was investigated using the 
optimised protocol. It was found that the profile of cell release was more 
consistent and predictable using the two-inlet device (Figure 6.25). SH-SY5Y 
cells reliably bound to the channel surface using flow rates of up to 20 µL/min and 
when flow rates were increased above 20 µL/min, cells were released. After 
buffer washes at 40 µL/min and 80 µL/min, only 1.7 ± 0.7% (mean ± SEM, n=12) 
of cells remained bound to the channel surface.  
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Figure 6.25 The percentage of bound cells remaining when the flow rate 
was increased using the two-inlet device 
The flow rate of buffer washes was increased from 5 µL/min to 80 µL/min 
and the percentage of cells bound after each wash was calculated using 
ImageJ. Each coloured line represents one experiment and the dashed line 
represents the mean (n=12). SH-SY5Y cells reliably bound to the channel 
surface up to flow rates of 20 µL/min and released from the surface at flow 
rates above 20 µL/min. 
 
6.3.4 Investigating specific cell capture and release in the prototype 
device using mixed cell populations 
6.3.4.1 Analysis of mixed cell populations using the prototype device and 
flow cytometry 
Once specific cell capture and release in the prototype device was optimised, the 
next aim was to increase the complexity of cell populations and assess specific 
cell capture from mixed cell populations. The fibroblast and SH-SY5Y cells were 
mixed together in different ratios and the mixed populations injected into the 
device using the protocol optimised in Section 6.3.3 (using one channel in the 
device only, with two inlets).  
It was found that as the percentage of CD271+ SH-SY5Y cells in the initial cell 
population was decreased, the number of cells bound to the channel surface also 
decreased (Figure 6.26). This indicated that CD271+ cells were specifically 
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captured from mixed cell populations. The device performance was then 
compared to a gold standard method of cell enrichment – flow cytometry or 
FACS. Mixed cell populations of the same ratios were analysed by flow cytometry 
(Figure 6.27) and the number of CD271-expressing cells detected by flow 
cytometry compared to the number of cells bound to the channel surface (Figure 
6.28).  
 
 
Figure 6.26 The percentage of cells bound to the channel surface 
decreased as the percentage of CD271+ cells in the population decreased 
SH-SY5Y cells and fibroblast cells were mixed in different ratios and injected 
into the prototype device. Photos were taken during the 5 minute incubation 
period (shown on the left-hand side of each panel) and after a 5 µL/min 
buffer wash (shown on the right-hand side of each panel).The number of 
cells bound to the surface decreased as the percentage of SH-SY5Y cells 
in the initial population decreased.  
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Figure 6.27 Flow cytometry analysis of mixed cell populations  
SH-SY5Y cells and fibroblast cells were mixed in different ratios and 
analysed by flow cytometry. The top panel shows how the two different 
populations have been gated according to their forward and side scatter. 
The middle panel shows the CD271 expression of each population 
compared to an isotype control antibody (IgG1-PE) and unlabelled cells. The 
bottom panel shows how the number of cells in each population changes in 
the different mixed cell populations.  
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Figure 6.28 Microfluidic device and flow cytometry comparison using 
mixed cell populations 
SH-SY5Y cells and fibroblast cells were mixed in different ratios and the 
percentage of CD271+ SH-SY5Y cells detected by the prototype device (red 
circles) compared to the number of CD271+ SH-SY5Y cells detected by flow 
cytometry (black squares). The data was normalised such that in an initial 
100% SH-SY5Y population, 100% of CD271+ cells were detected by each 
method. The upper panel shows all percentages tested from 100% to 0% 
SH-SY5Y, the bottom panel shows the lower percentages only (25% to 0% 
SH-SY5Y – highlighted by the blue dashed box in the upper panel). 
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There was good overall agreement between the two methods of cell enrichment 
however by only analysing a small section of the channel at a time (approximately 
1/12th), the device (or the method used for analysis) was not as sensitive as flow 
cytometry at detecting the lower percentages of CD271+ cells. Further to this, in 
a 75% population of CD271+ cells, there was a large discrepancy between the 
device data and the flow cytometry data. It could be that the relationship is non-
linear and more complex than can be rationalised using this data only.  
The cell capture efficiency of the device can be estimated by comparing the 
percentage of cells bound in the device to the percentage of cells in the initial cell 
population. For a more accurate analysis of the capture efficiency, the percentage 
of cells captured in a 0% CD271+ cell population was subtracted from all other 
populations to negate the effects of non-specific binding. By doing this, the 
capture efficiency of the device - taking into account all the different populations 
analysed - was calculated to be 45 ± 11% (mean ± SEM, n=8). Evidently, this 
value is relatively low. 
As previously discussed, the sensitivity of the device (or analysis method) 
decreased as the percentage of CD271+ cells decreased, therefore subgroup 
analysis of the data may provide more useful information. The higher percentage 
populations (25-100% CD271+ cells) were analysed separately to the lower 
percentage populations (12.5-1.5% CD271+ cells) and from this analysis, the 
capture efficiency was calculated to be 70 ± 10% and 20 ± 3% respectively (mean 
± SEM, n=4). These values emphasise the challenges involved in capturing cells 
present at low percentages, however this result could also be an artefact of the 
analysis method at lower percentages. Currently, the cells bound in only 1/12th of 
the device were analysed, this means that at lower percentages of CD271+ cells, 
there could have been greater inaccuracy in the result due to the smaller number 
of CD271+ cells present. In Chapter 7, different device protocols and methods of 
analysis are optimised to assess the binding of a low percentage of CD271+ cells.  
For comparison, the detection efficiency according to the flow cytometry results 
was calculated. As before, the percentage of CD271+ cells detected in a 0% 
CD271+ population was subtracted from all other populations. The detection 
efficiency of the flow cytometry results was calculated to be 71 ± 5% (mean ± 
SEM, n=8). The capture efficiency of the device was therefore comparable to flow 
cytometry at higher percentages of CD271+ cells. The same subgroup analysis 
of the flow cytometry data revealed that the detection efficiency was 81 ± 8% for 
the higher percentage populations (25–100% CD271+ cells) and 62 ± 4% for the 
lower percentage populations (12.5–1.5% CD271+ cells), showing that the 
detection efficiency of the flow cytometry method also decreased at lower 
percentages, however it was still much greater than the device efficiency.  
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The capture efficiency of affinity-based microfluidic devices is often reported in 
the literature. Although there are no affinity-based microfluidic devices based on 
the capture of CD271+ cells (or any other MSC surface marker), there are many 
devices described for the capture of circulating tumour cells (CTCs) using anti-
epithelial cell adhesion molecule (EpCAM) antibodies. These are discussed in 
detail in Chapter 8: Section 8.1.2. The possibility of using a hybrid microfluidic 
technology, with a high throughput pre-enrichment step, is also discussed in 
Chapter 8: Section 8.1.4. This could result in an increased percentage of CD271+ 
cells in a second stage of enrichment using this technology. Further development 
of the device to increase the throughput for clinical application and to allow 
analysis of the cells post-enrichment, is described in Section 6.3.5.  
 
6.3.4.2 Analysis of mixed cell populations with fluorescent labelling 
To further confirm the results of Section 6.3.4.1, and to assess the purity of 
captured cells, the two cell populations were fluorescently labelled with different 
coloured cell trackers. SH-SY5Y cells were labelled with green cell tracker and 
fibroblasts were labelled with red cell tracker (Section 6.2.5.3, Figure 6.29). Using 
a multiband filter set (Semrock, LF488/561-B-000) and a multichannel imaging 
system (Photometrics DV2™), spatially identical but spectrally distinct images 
were acquired simultaneously to determine if the CD271+ cells were the cells 
bound to the channel surface.  
 
 
Figure 6.29 SH-SY5Y and fibroblast cells fluorescently labelled with green 
and red cell tracker respectively 
On the left-hand side, SH-SY5Y cells are shown labelled with green cell 
tracker. On the right-hand side, fibroblast cells are shown labelled with red 
cell tracker. Labelling was carried out 24 h prior to testing in the device.  
 
Four different populations were analysed; 100%, 50%, 25% and 6% SH-SY5Y 
populations, made up to a 100% with fibroblast cells. These experiments 
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confirmed the specificity of cell binding in the device as the majority of cells 
labelled with green cell tracker (CD271+ SH-SY5Y cells) bound to the 
functionalised surface, whereas the majority of cells labelled with red cell tracker 
(CD271- fibroblast cells) were washed away (Figure 6.30). A small percentage of 
fibroblasts bound to the channel in some cases, however, this was not of great 
concern since in all cases the CD271+ cells were significantly enriched from the 
initial cell population (approximately 13-fold enrichment observed from a 6% SH-
SY5Y original population).  
Using ImageJ, the purity of the enriched populations was estimated by counting 
the number of cells labelled with green cell tracker after the 5 µL/min buffer wash, 
and comparing with the number of cells labelled with red cell tracker. From the 
four different populations analysed – 6% SH-SY5Y, 25% SH-SY5Y and 50% SH-
SY5Y the calculated purity was 80 ± 3% (mean ± SEM) after enrichment. The 
purity of enriched populations was therefore consistent at even the lowest 
percentage analysed.  
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Figure 6.30 Specific cell capture confirmed using fluorescently-labelled 
mixed cell populations 
SH-SY5Y cells were stained with green cell tracker and fibroblasts were 
stained with red cell tracker. The two cell types were mixed to make 
populations of 100% SH-SY5Y, 50% SH-SY5Y, 25% SH-SY5Y and 6% SH-
SY5Y. Photos on the left-hand side were taken during the 5 minute 
incubation period. Photos on the right-hand side were taken after a 5 µL/min 
buffer wash. The majority of non-specific fibroblast cells were washed away 
whilst the majority of specific SH-SY5Y cells bound to the channel surface. 
ImageJ software was used to convert the images to RGB colour and the two 
spectrally distinct images were merged. 
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6.3.5 Increasing the surface area for cell capture and release 
The worked carried out thus far demonstrated the efficacy of the device using a 
cell line that expressed the CD271 antigen and cells that did not express the 
CD271 antigen. To progress this work further and to show clinical utility, the 
number of cells processed and collected from the device needed to be increased 
further. This was for two reasons; firstly, clinical samples of bone marrow 
mononuclear cells typically contain less than 0.04% of CD271+ cells (Chapter 7: 
Section 7.3.1) and therefore large numbers of cells need to be processed to 
enrich (and visualise in the device) such a small percentage of cells. Secondly, 
to investigate the viability and manipulation of cells post-enrichment, a substantial 
number of cells needed to be collected to carry out post-enrichment analysis. Two 
device iterations were investigated to increase the surface area available for cell 
capture, detailed in the sections below.   
6.3.5.1 Device iteration 1: using multiple-port manifolds 
The prototype device was originally designed with four channels, however, it was 
only possible to operate one channel at a time due to the syringe pump and valve 
arrangement. Simultaneous use of the channels would therefore increase the 
throughput of the device by four times, allowing enough cells to be captured for 
post-enrichment analysis.  
The first method trialled for simultaneous cell injection was using a 9-port 
manifold (IDEX Health & Science). Two manifolds were positioned so that all four 
channels were controlled by two valves (Figure 6.31), one valve and manifold for 
cell injection and one valve and manifold for buffer injection. The remaining 4 
ports of each manifold were blocked with microfluidic plugs. 
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Figure 6.31 Manifolds incorporated into device design for simultaneous 
operation of four parallel channels 
Two 9-port manifolds were positioned between the four-way valves and the 
channels so that each valve could operate four parallel channels 
simultaneously. One manifold was used for cell injection and the other 
manifold was used for buffer injection. 
 
Using this design resulted in uneven cell distribution between the four channels, 
ranging from over 500 cells in channel 2 to less than 50 cells in channel 4 (Figure 
6.32). This could have been due to the manifold itself, or the fact that having 
multiple inlets and outlets meant that microscopic differences in the channels led 
to less fluidic resistance in some channels than others. For example, the clamping 
of the PDMS could slightly favour channels on one side of the device compared 
to the other, or the position of outlet tubing could provide less resistance in one 
channel compared to another. Furthermore, the use of extra tubing exacerbated 
cell clumping issues (indicated in Figure 6.31) and it was considered that a 
simpler design would be more beneficial.  
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Figure 6.32 Distribution of cells in four parallel channels using 9-port 
manifolds for simultaneous operation 
When 9-port manifolds were used for simultaneous operation of four parallel 
channels, the cells were unevenly distributed between the channels 
demonstrated by the vast difference in the number of cells bound (indicated 
in the bottom right corner of each image). In addition, using longer tubing 
before the cells entered the channels meant that large cell clumps formed 
(indicated by red arrows).  
 
6.3.5.2 Device iteration 2: branched channel design 
The second device iteration involved changing the channel design; rather than 
having four separate channels that required eight separate inlets and four 
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separate outlets, it was hypothesised that two inlets (one for cells and one for 
buffer) and just one outlet would provide more even flow, eradicating some of the 
complications introduced by the first device iteration. It was also hypothesised 
that having the channels closer together would reduce the effects of uneven 
clamping. 
The design was first drawn in COMSOL in order to check the flow would be 
theoretically even in all channels (Figure 6.33). Once this was confirmed, the 
design was drawn in L-edit and a PDMS mould made using soft lithography 
techniques as previously described (Section 6.2.4.3). Using the new channel 
design, cells were more evenly distributed between all four channels, with the 
number of cells bound ranging from 900 to 1400 in all four channels (Figure 6.34). 
The more even cell distribution also led to an overall increased number of cells 
bound in the four channels during one incubation period, with an average of 320 
cells bound per image using device iteration 1 compared to an average of 1198 
cells bound per image using device iteration 2. It was therefore concluded that 
device iteration 2 would be suitable to collect enough cells for post-enrichment 
analysis, where the surface area available for cell capture was increased by 4.8 
times compared to when using one single straight channel (see Figure 6.5) in 
previous experiments.  
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Figure 6.33 COMSOL simulation showing the theoretical flow in a two-inlet, 
one-outlet four-channel design 
COMSOL simulations predicted the flow to be even in four parallel channels 
using a two-inlet, one outlet design. The top image shows the entire design 
and the bottom image is a closer view of the middle section of the four 
channels. 
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Figure 6.34 Cell distribution in four parallel channels using a two-inlet, one 
outlet channel design 
When a two-inlet, one outlet channel design was used for simultaneous 
operation of four parallel channels, the cells were evenly distributed 
between the channels. There were no large cell clumps due to the shortened 
tubing length and the surface area available for cell capture was increased 
by 4.8 times.  
 
6.3.6 Investigating the viability of cells post-enrichment 
Due to the low percentage of CD271+ cells in clinical samples, post-enrichment 
analysis was carried out using SH-SY5Y cells that had been captured and 
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released in the prototype device. The first parameter analysed was the viability 
of cells, carried out via flow cytometry analysis using a 7-AAD viability stain 
(Section 6.2.6.1).  
From the initial experiments, it was found that the number of intact cells was 
significantly decreased in control samples suspended in different medium. It was 
found that when cells were suspended in the buffer used for device experiments 
(MACS buffer with 0.005% Tween 20) the number of intact cells decreased 
dramatically compared to when cells were suspended in MACS buffer or Alpha 
MEM culture medium (Figure 6.35). It was therefore decided to carry out a 
controlled study into the effects of different buffers on the number of intact cells 
to ensure the buffer used for device experiments would not be detrimental to cells, 
since the loss of cell membrane integrity is a characteristic of cell death. 
 
 
Figure 6.35 Variability in the percentage of intact cells when cells were 
suspended in different buffers 
The upper panels show the forward/side scatter analysis of cells suspended 
in Alpha MEM culture medium and MACS buffer, and the lower panel shows 
the forward/side scatter analysis of cells suspended in MACS buffer with 
0.005% Tween 20. The percentage of intact cells dramatically decreased 
when 0.005% Tween 20 was added to the buffer.   
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6.3.6.1 Investigating the viability of cells in different buffer solutions  
To investigate the percentage of intact cells further, one million cells were either 
kept in serum-free cell culture medium, serum-free cell culture medium with 
0.005% Tween 20, MACS buffer, or MACS buffer with 0.005% Tween 20. The 
volume of the medium was 50 µL replicating the cell concentration used during 
device experiments (20 million cells/mL). 
It was found that after 2-3 hours in each medium, there was no significant 
difference in the percentage of intact cells when suspended in MACS buffer 
compared to serum-free cell culture medium (Figure 6.36). However, it was found 
that when 0.005% Tween 20 was added to either serum-free medium or MACS 
buffer the percentage of intact cells decreased significantly (p<0.05 and p<0.01 
respectively).  
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Figure 6.36 The percentage of intact cells when suspended in different 
medium  
The percentage of intact cells was compared when cells were suspended in 
serum-free medium, serum-free medium with 0.005% Tween 20, MACS 
buffer or MACS buffer with 0.005% Tween 20. Cells were at a concentration 
of 20 million cells/mL in 50 µL for 2-3 hours before analysis via flow 
cytometry. Statistical analysis was carried out by an independent samples 
T-test as data was normally distributed according to the Shapiro Wilk test of 
normality. (n.s.= not significant, *p<0.05, **p<0.01, n=3). Bars represent the 
mean values and error bars represent the SEM. 
 
Tween 20 was initially added to running buffer during device experiments to 
reduce non-specific binding (as was used for SPR experiments, Section 6.3.1.1) 
however even at low concentrations it was found to have a detrimental effect on 
the percentage of intact cells. Although there was no significant difference 
between culture medium and MACS buffer, it was noted that cells suspended in 
culture medium produced more consistent results than cells suspended in MACS 
buffer. It was therefore decided to carry out all future experiments in serum-free 
cell culture medium with no additional supplements to ensure the highest 
percentage of intact cells.  
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6.3.6.2 Investigating the viability of cells captured and released in the 
prototype device 
Once the running buffer for device experiments had been optimised, the viability 
of cells bound and released in the device could be compared without any 
interfering factors. The viability of cells bound and released was compared to 
microfluidic controls (where the cells had been through the device at different flow 
rates with no incubation), and medium controls (where the cells had been kept in 
cell culture medium, on ice, for the duration of the experiment). Further to this, 
cells were also processed through a MACS column (in MACS buffer but without 
microbead labelling) and their viability analysed in the same way. 
Repeats were carried out on different days using different cell cultures therefore 
natural biological variability was captured. The viability of cells according to the 
7-AAD viability stain was reported from all the events recorded by the flow 
cytometer i.e. no gates were drawn around intact cells or single cells since cells 
damaged in the device may no longer be intact.  
The results showed that there was no significant difference in the viability of cells 
between any of the conditions tested (Figure 6.37). It was observed that the 
results for the captured and released cells were more consistent than for any of 
the controls, this could be because only healthy viable cells are bound in the 
device (due to the specific antibody interaction for capture) and therefore intact 
and dead cells are washed away in the buffer wash. This result indicates that the 
cells were not harmed by the process of being captured and released in the 
device or by experiencing high flow rates (higher than those used for cell release) 
- as far as this limited analysis can show.   
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Figure 6.37 Cell viability after enrichment in the prototype device  
The viability of cells which had been captured and released in the prototype 
device was compared to cells which had been through the device at different 
flow rates with no incubation (100 µL/min, 500 µL/min and 3000 µL/min) and 
cells which had not been through the device (medium control). Cells were 
also processed through a MACS column for comparison, or incubated in 
MACS buffer for the duration of the experiment. The viability of cells was 
evaluated using a 7-AAD viability stain and analysed using a flow cytometer. 
No significant difference was found between any of the conditions tested. 
Statistical analysis was carried out using an independent samples t-test or 
Mann Whitney U test to compare means depending on whether the data 
was normally distributed according to the Shapiro Wilk test of normality. 
Bars represent the mean values and error bars represent the SEM (n=4).  
 
6.3.7 Investigating the proliferation of cells post-enrichment 
For viability testing, the cells were analysed immediately after enrichment in the 
device. To establish if there were any adverse effects which may not be observed 
immediately, enriched cells were seeded at 40,000 cells/well in a 24-well plate 
and cultured for five days. On day two and day five, cell cultures were lysed and 
a Pico green dsDNA quantification kit (Invitrogen, P11496) was used to compare 
the quantity of dsDNA in each sample. The fold-increase in dsDNA content from 
day two to day five was calculated to negate differences in cell counting/cell 
seeding density, and the same medium and microfluidic controls were used as in 
previous experiments. 
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It was found that cells that had been captured and released in the device were 
able to proliferate at a comparable rate to cells that had not been through the 
device, and cells that had been through the device but not captured. There was 
no significant difference between any of the conditions tested (Figure 6.38). There 
are a number of potential sources of error associated with the experimental 
procedure for dsDNA quantification, including the human error associated with 
manual cell counting and the numerous pipetting steps in the dsDNA assay itself. 
Small differences in cell seeding density could lead to greater differences in the 
proliferation rate since cell density is a critical factor determining the proliferation 
of cells in culture (254). Although there was noticeable variation between 
replicates carried out on different days (each replicate series connected by a 
dashed line in Figure 6.38), in all experiments there was a minimum two-fold 
increase in the dsDNA present on day five compared to day two. The lowest fold-
increase was observed from a medium control replicate suggesting that factors 
beside the microfluidic device had an effect on the rate of proliferation.  
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Figure 6.38 The fold-increase in dsDNA content between day two and day 
five of cells cultured post-enrichment 
After enrichment in the microfluidic device, cells were seeded at 40,000 
cells/well in a 24-well tissue culture plate. On day two and day five cells were 
lysed and the dsDNA content of each well quantified. The fold-increase 
between day two and day five was calculated to compare the proliferation 
rate of cells enriched in the device, to microfluidic and medium controls. 
There was no significant difference found between any of the conditions 
tested and there was a minimum 2-fold increase between day two and day 
five in all replicates. Statistical analysis was carried out using an 
independent samples t-test as the data was normally distributed according 
to the Shapiro-Wilk test of normality. Bars represent the mean result and 
error bars represent the SEM. The dashed lines connect the data points 
recorded in the same experiment.  
 
6.3.8  Investigating the manipulation of cells post-enrichment 
One of the key limitations of current affinity-based enrichment technologies is the 
need to pre-label cells with antibodies which remain attached to the cells post-
enrichment. The enrichment technology developed here aims to be minimally 
manipulative and does not require any pre-labelling steps. The antibody 
interaction in the device is designed to be transient so that once cells are released 
from the antibody-functionalised surface they have no antibody attached to their 
cell surface. To evaluate whether this was the case, cells that had been captured 
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and released in the device were collected and labelled with anti-biotin-PE 
antibody to see if any of the CD271-biotin antibody on the functionalised surface 
remained attached to the cells post-release. The same antibody labelling was 
carried out on cells that had not been processed in the device.  
As well as testing whether any antibody was attached to the cells, it was also 
necessary to check whether the CD271 antigen was still present on the cell 
surface and unaffected by the cell release process. For this, cells that had been 
captured and released were labelled with the CD271-biotin antibody and then 
anti-biotin-PE secondary antibody. 
When analysed by a flow cytometer, it was found that less than 4% of cells that 
had been captured and released in the device were positive for anti-biotin-PE 
antibody, and there was no significant difference between the captured and 
released cells compared to cells that had not been through the device (Figure 
6.39). Similarly, there was no significant difference in the percentage of positive 
cells labelled with CD271-biotin and anti-biotin-PE when captured and released 
compared to control cells. These results indicated that the antibody interaction in 
the device is only transient and no antibody remains attached to the cell surface 
post-release, nor is the antigen affected by the cell release process. 
Although these results are encouraging, it is noted that further experiments are 
required to ensure that cells are truly minimally manipulated. For example, a 
transient interaction with an antibody may still affect downstream cell signalling 
processes and to assess this it would be necessary to carry out more in-depth 
gene expression analysis.  
- 179 - 
 
Figure 6.39 The percentage of antibody attached to the cell surface post-
enrichment 
To investigate whether any antibodies from the device were attached to the 
cells post-enrichment, captured and released cells were labelled with anti-
biotin-PE (anti-biotin test, shown in red) and compared to cells that had not 
been processed in the device (anti-biotin control, shown in black). To 
investigate whether the CD271 antigen was still present on the cell surface 
after the cell release process, captured and released cells were labelled with 
CD271-biotin and anti-biotin-PE as a secondary antibody (CD271-biotin 
test, blue) and compared to cells that had not been processed in the device 
(CD271-biotin control, green). No significant difference was found between 
either of the test and control conditions (n.s.=not significant, n=3). Statistical 
analysis was carried out using an independent samples t-test since the data 
was normally distributed according to the Shapiro Wilk test of normality. 
Bars represent the mean values and the error bars represent the SEM. 
 
6.3.9 Cell recovery from the device  
Finally, the cell recovery from the device was calculated to ensure that cells were 
not lost in the microfluidic tubing during processing. A known volume and 
concentration of SH-SY5Y cells was injected into the device followed by a 400 
µL buffer wash (100 µL/min flow rate) to flush cells out of the tubing and channels 
(Section 6.2.6.4). The recovered cells were counted using a haemocytometer. 
For comparison, cells were also processed through a MACS column using the 
standard protocol but without microbead labelling. The cells in the eluate from the 
column were counted and compared to the cells recovered from the microfluidic 
device. 
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It was found that there was no significant difference in the percentage of cells 
recovered using either method and that the percentage of cells recovered from 
the device was more than 80% for each replicate (Figure 6.40). This result 
demonstrates that there is no significant loss of cells in the microfluidic tubing 
compared to a gold standard method of cell enrichment.  
 
 
Figure 6.40 The percentage of cells recovered from the device compared to 
a MACS column 
The cell recovery from the device was calculated and compared to the cell 
recovery from a MACS column. It was found that there was no significant 
difference in the cell recovery from both methods and the cell recovery from 
the device was above 80% in all replicates. Statistical analysis was carried 
out using an independent samples t-test since the data was normally 
distributed according to the Shapiro Wilk test of normality. Bars represent 
the mean values and the error bars represent the SEM (n=3).  
 
6.4  Conclusions 
This Chapter describes the design, fabrication and development of a microfluidic 
device capable of the specific cell capture of CD271+ cells. The specificity of the 
device was confirmed using different antibody-functionalised channels and 
different cell combinations, as well as using mixed cell populations to compare 
the device performance to a gold standard method of cell sorting. Moreover, it 
was shown that the enrichment process had no effect on the viability or 
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proliferation of cells and that according to the analysis carried out thus far, the 
cells could be classified as minimally manipulated.    
For Human Cells, Tissues and Cellular and Tissue-Based Products (HCT/Ps), 
regulatory guidance from the FDA (section 1271.10(a)(1), (21 CFR 
1271.10(a)(1))) states that a HCT/P must be minimally manipulated and defines 
this as ‘processing that does not alter the relevant biological characteristics of 
cells or tissues’ (255). The data described in this chapter showed no significant 
difference between cells processed in the device compared to non-processed 
cells, however, the experiments carried out here only demonstrate an initial 
assessment and more in-depth studies would be required to be certain. For 
example, analysis must be carried out using clinically-relevant cells rather than 
cell lines, and the therapeutic potential of the cells tested in relevant applications 
in vitro and in vivo.  
The device has been shown to be comparable to FACS in terms of cell capture 
efficiency (for cell populations containing >25% of the target population) and 
comparable to MACS in terms of cell viability and recovery. The device has also 
been shown to enrich target populations with purities of approximately 80%. What 
is more, the device has significant advantages over both MACS and FACS in that 
no pre-labelling steps are required - which could lead to shorter processing times 
- and that no antibody is attached to the cells post-enrichment.  
Currently, FACS is more suited to diagnostic applications due to the expense of 
instruments, and the expertise required for operation (256), whereas MACS 
provides a more cost-effective approach for clinical applications. However at this 
time the majority of MACS products are only certified for in vitro use (131), and 
there are varied reports on the safety of using iron-oxide containing nanoparticles 
for in vivo applications. There have been several reports indicating phenotypical 
alterations to cells labelled with iron-oxide containing particles for cell tracking 
purposes (257-259), however it has been shown that the iron levels used for 
magnetic resonance imaging and magnetic targeting of stem cells are typically 
several orders of magnitude higher than those used for microbead labelling (260). 
The same study by Müller et al. (2017)(260) used MACS technology to enrich 
CD133+ HSCs and CD271+ MSCs and assessed the impact of the stem cells as 
well as the co-injected microbeads on the cardiac remodelling processes after 
myocardial infarction. The study was carried out in immunodeficient mice and it 
was found that 48 hours after transplantation no microbeads could be detected 
in the cells or surrounding heart tissue and improvements of cardiac function were 
reported.    
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Conversely, there is evidence to suggest that the ligation of receptors utilised for 
positive selection of cells has detrimental effects on downstream cellular 
processes. A study by Bhattacharjee et al. (2017)(261) found that monocytes 
isolated by positive selection using CD14 microbeads were impaired due to the 
microbead-blocked CD14 receptors. Stimulation by lipopolysaccharide led to 
activation and increased proliferation of monocytes isolated by negative selection 
however the response by positively selected cells was reduced and the cells did 
not proliferate. Similarly, in a comparison of FACS, positive selection by MACS 
and negative selection by MACS, Beliakova-Bethell et al. (2014)(262) reported 
changes in the gene expression of positively-selected cells compared to negative 
selection and FACS.  
There are still insufficient studies exploring the effects of antibody-labelling on 
cellular processes for in vivo application and effects are likely to be dependent on 
the specific application of the cell therapy as well as the dose of cells required. 
Although the prototype device investigated in this chapter ligates CD271 cell 
surface receptors, the ligation is transient and no receptors remain blocked when 
the cells are collected from the device (i.e. before transplantation as a cellular 
therapy). Gene expression analysis of collected cells would elucidate whether the 
transient interaction affects any cell signalling processes and would further 
confirm if this novel enrichment method is advantageous over current affinity-
based methods.  
The work carried out in this chapter has provided proof-of-concept data for the 
use of a microfluidic device with affinity-based cell capture. In order to progress 
this technology further, the work in Chapter 7 investigates the feasibility of 
enriching CD271+ cells from clinical samples of bone marrow aspirate.   
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Chapter 7:  
Enriching CD271+ cells from clinical samples of bone marrow 
aspirate 
7.1 Introduction  
In Chapter 6, a prototype cell enrichment device was developed for the specific 
capture of CD271+ cells, and optimised using a cell line known to constitutively 
express CD271. The work in this chapter aimed to establish the potential clinical 
utility of the device using cells derived from clinical bone marrow aspirates, 
typically with very low percentages of CD271+ cells. Initially, cells were 
characterised using existing cell enrichment technologies – MACS and FACS 
(Section 7.3.1) and the therapeutic potential of the enriched population 
investigated using a CFU-F assay (Section 7.1.1 and 7.3.4). Once critical 
information such as the typical number of CD271+ cells in BM-MNC populations 
had been established, enrichment of CD271+ cells was investigated using the 
prototype device (Section 7.3.6).  
In Chapter 6, it was found that the capture efficiency of the device was low (~20%) 
when the target population was present at low concentrations of the total cell 
population. However, this could have been due to the analysis method where 
only a small section of the channel was analysed during one experiment. This 
would lead to greater inaccuracies where fewer CD271+ cells were present. In 
this chapter, different device protocols and methods of analysis were investigated 
(Section 7.3.7), as well as using a channel with greater surface area (developed 
in Chapter 6: Section 6.3.5) to gain a greater perspective of the binding of low 
percentage CD271+ populations typical of clinical samples.  
 
7.1.1 Colony forming units-fibroblast (CFU-F) assay 
A colony forming units-fibroblast (CFU-F) assay is an assay used to assess the 
number of MSCs present in a population of cells. When Friedenstein and 
colleagues first described MSCs in 1970 (263), their ability to generate colonies 
when plated at a low seeding density was a definitive property (264). To date, 
this remains one of the only accepted methods to identify MSCs. The method is 
relatively simple, cells are seeded at low densities, cultured in cell-culture medium 
and typically, adherent colonies are counted after 14 days. Unfortunately, several 
variables such as the initial seeding density, the medium used for culture and the 
colony counting method can make it difficult to compare results between different 
studies (265).  
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In this chapter of work, a CFU-F assay was performed after the enrichment and 
depletion of CD271+ cells from BM-MNC populations and the generation of CFU-
Fs compared.  
 
7.2 Materials and Methods 
7.2.1 Bone marrow sample processing 
Bone marrow aspirate samples from 15 different donors were used to carry out 
the experiments described in this chapter. All samples were taken 
intraoperatively following informed consent (REC reference number 
06/Q1206/127 from the NRES Committee Yorkshire & the Humber–Leeds East) 
from patients admitted to Leeds General Infirmary for orthopaedic surgery. 
Patients did not have any known systemic illness, cancer, or metabolic diseases. 
Donor age ranged from 27 to 64 years. All bone marrow aspirates were 
consistently harvested from the same location (zone 6) of the posterior region of 
the iliac crest as previously described (266). 
Samples were received as 4 mL volumes immediately following harvesting and 
were filtered through a 70 micron filter (Falcon, 352350). A 10x concentrate of 
red blood cell lysis buffer (BioLegend, 420301) was diluted to 1x with distilled 
water and warmed to RT. A 1 mL aliquot of bone marrow aspirate was added to 
19 mL of lysis buffer, vortexed and incubated for 10 min at RT. Samples were 
centrifuged at 350 g for 5 min and the BM-MNCs re-suspended in 2 mL Alpha 
MEM culture medium (Lonza, BE12-169F). The centrifugation was repeated once 
more and the cells re-suspended in freezing medium (10% DMSO, 30% FBS, 
60% Alpha MEM). BM-MNCs were frozen in 1 mL aliquots in specialised  freezing 
containers (Sigma, C1562) which provided a cooling rate of 1 °C/min in a -80 °C 
freezer. After 24 h, the vials were transferred to a -180 °C cryotank.  
 
7.2.2 Enrichment of CD271+ cells using MACS and FACS 
BM-MNC populations were enriched for CD271+ cells using existing cell sorting 
methods – MACS and FACS. This was carried out in order to gain information 
with regards to the typical percentage and number of CD271+ cells in clinically-
relevant populations.  
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Cryopreserved BM-MNCs, prepared as described in Section 7.2.1, were thawed 
at 37 °C and added dropwise to thawing medium13 (4 mL per 1 mL vial thawed). 
Cells were washed by centrifugation for 10 min at 300 g and re-suspended in 10 
mL thawing medium for 15 min for Deoxyribonuclease I (DNase I) treatment. 
Cells were then counted using a haemocytometer and a fraction of unseparated 
cells set aside on ice for FACS analysis.  
The remaining cell suspension was centrifuged for 10 min at 300 g and re-
suspended in 60 µL of MACS buffer14 (with 0.1 mg/mL DNase I (Sigma, 
11284932001)) per 107 cells. FcR blocking agent and CD271 microbeads 
(Miltenyi Biotec, 130-099-023) were added (40 µL per 107 cells) and incubated 
for 15 min at 4 °C (and mixed every 5 min). Cells were washed by adding 1-2 mL 
of MACS buffer (per 107 cells) and centrifuged for 5 min at 350 g. Cells were re-
suspended in MACS buffer (500 µL for up to 108 cells) and passed through a cell 
strainer (Corning, 352350, 70 micron).  
A LS column (Miltenyi Biotec, 130-042-401) was placed in the magnetic field of a 
MACS separator and prepared by rinsing with MACS buffer (3 mL). The cell 
suspension was applied to the column and the flow through collected (CD271-
depleted population). The column was washed with MACS buffer (3x 3 mL) and 
the flow-through added to the CD271-depleted population of cells. The column 
was removed from the magnetic field and 5 mL MACS buffer added. The plunger 
supplied with the column was used to flush out CD271-enriched cells.  
CD271-depleted and enriched populations were centrifuged (10 min, 350 g) and 
re-suspended in a smaller volume of MACS buffer for counting. Cells were 
aliquoted into Falcon™ round-bottom polypropylene tubes (FACS tubes, 
Corning, 352063; 1 million cells per tube for CD271-depleted and unseparated 
populations, all cells for CD271-enriched population) and labelled with antibodies 
according to Table 7.1. Human fibroblasts (known not to express the CD271 
antigen – see Chapter 6: Figure 6.10) were added to the CD271-enriched cells 
to provide a final population of 1 million cells. This was to minimise the loss of 
CD271-enriched cells during processing, for example in centrifugation steps. Due 
to the much higher forward and side scatter of fibroblast cells, they were easily 
eliminated from all analyses. UltraComp eBeads™ Compensation Beads 
 
13 Thawing medium: MEM - Alpha Eagle with Earle’s BSS (Lonza, BE12-169F) 
supplemented with 0.1 mg/mL Deoxyribonuclease I (DNase I, Sigma, 
11284932001), 10% FBS (Sigma Aldrich,  F7524), 1% L-Glutamine (200 mM, 
Sigma, G7513) and 1% P/S solution (Sigma, P4458) 
14 MACS buffer: PBS (Lonza, 17-516F), 2 mM EDTA (Sigma, E7889), 0.5% BSA 
(Sigma, A9647), filter sterilised 
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(Invitrogen, 01-2222-41) were used to compensate for fluorescence spectral 
overlap and the compensation matrix applied to all samples. 
Antibody-labelled samples were incubated in the dark at 4 °C for 15 min. Cells 
were washed by addition of ice cold FACS buffer15 (2 mL per tube) and 
centrifuged (5 min, 300 g). The supernatant was aspirated using Pasteur pipettes 
and the cells re-suspended in 350 µL for analysis. Propidium iodide (PI) or 7-AAD 
staining was carried out 5 min prior to analysis with no washing steps required. A 
Cytoflex S flow cytometer was used to record events or a BD Influx™ cell sorter 
for sterile FACS. Flow cytometry data was analysed using CytExpert software 
and gated for single cells (see Chapter 4: Section 4.5). 
For sterile FACS, sorted cells were collected into 1.5 mL Eppendorf tubes with 
0.5 mL Alpha MEM culture medium (Lonza, BE12-169F) supplemented with 20% 
FBS (Sigma Aldrich, F7524), 1% L-glutamine (200 mM, Sigma, G7513) and 1% 
P/S solution (Sigma, P4458). Sorted cells were seeded in 24-well plates for CFU-
F analysis (Section 7.2.4). 
 
15 FACS buffer: FACS buffer: PBS (Lonza, 17-516F, 0.5% BSA (Sigma, A9647), 0.05% 
sodium azide, filter sterilised (0.22 µm) 
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Table 7.1 Antibody labelling for FACS 
 Anti-CD271 
antibody 
Monoclonal 
CD271-PE, 
human 
(Miltenyi 
Biotec, 130-
113-983) 
Anti-CD45 
antibody 
Monoclonal 
CD45-FITC, 
human 
(Miltenyi 
Biotec, 130-
110-679) 
Dead cell 
staining 
PI/7AAD 
(BioLegend, 
421301)/(Miltenyi 
Biotec, 130-111-
568) 
Cells or 
beads 
Unseparated 
cells 
N/A N/A N/A Cells 
Unseparated 
cells 
N/A N/A 14 µg/mL/0.525 
µg/mL 
Cells 
Unseparated 
cells 
N/A 7.5 µg/mL N/A Beads  
Unseparated 
cells 
0.5 µg/mL N/A N/A Beads  
Unseparated 
cells 
Isotype 
control 
Monoclonal, 
mouse IgG1-
PE 
(BD 
Biosciences, 
555749) 
0.5 µg/mL 
Isotype 
control 
Monoclonal, 
mouse IgG2a-
FITC 
(Miltenyi 
Biotec, 130-
113-833) 
7.5 µg/mL 
14 µg/mL/0.525 
µg/mL 
Cells 
Unseparated 
cells 
0.5 µg/mL 7.5 µg/mL 14 µg/mL/0.525 
µg/mL 
Cells 
CD271-depleted 
cells 
0.5 µg/mL 7.5 µg/mL 14 µg/mL/0.525 
µg/mL 
Cells 
CD271-enriched 
cells  
0.5 µg/mL 7.5 µg/mL 14 µg/mL/0.525 
µg/mL 
Cells 
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7.2.3 Investigating the viability of cells in cryopreserved and fresh 
bone marrow aspirate samples 
To study the effects of the cryopreservation and thawing process, a population of 
BM-MNCs was analysed without cryopreservation. The bone marrow aspirate 
sample was processed as described in Section 7.2.1, but after the cells were 
washed in Alpha MEM culture medium, the cells were re-suspended in FACS 
buffer and aliquoted into FACS tubes. Cells were labelled according to Table 7.1 
(“unseparated cells”) using the same procedure as described in Section 7.2.2. 
Data was recorded using a Cytoflex S flow cytometer and analysed using 
CytExpert software (see Chapter 4: Section 4.5). 
 
7.2.4 Investigating the clonogenic potential of enriched CD271+ cells 
The cell populations sorted by MACS and FACS were seeded in well plates and 
cultured for 14 days. The original BM-MNC population (unseparated cells) and 
the CD271-depleted population were both seeded at 50,000 cells/cm2 in a 6-well 
culture plate (Corning, 3516). The CD271-enriched population from MACS was 
further sorted by FACS into a population characterised by high CD271 expression 
and low CD45 expression (CD271bright/CD45low population). This population 
was seeded in a 24-well cell culture plate (Corning, 3526) at 200 - 1600 cells/cm2 
depending on the number of cells collected from FACS and the number of 
replicates carried out. Results were normalised to the cell seeding density. All 
populations were cultured in Alpha MEM culture medium supplemented with 20% 
FBS, 1% P/S and 1% L-glutamine (0.5 mL per well for 24-well plate cultures, 2 
mL per well for 6-well plate cultures). Medium was changed on day seven and 
the colonies stained on day 14. 
For colony staining, the medium was removed and the cultures were washed 
twice with PBS. The PBS was then removed and cultures were fixed with 
methanol for 5 min at RT. The methanol was removed and the culture plates air-
dried in a sterile tissue culture hood. Giemsa staining solution (Sigma, GS500) 
was prepared by diluting 1: 20 in deionised water and added to each well for 30-
45 min at RT. The stain was removed and the culture plates washed twice with 
deionised water. The culture plates were air-dried and colonies with more than 
20 cells counted microscopically.  
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7.2.5 Estimating the number of CD271 molecules (antigens) on cell 
membranes of CD271+ cells 
The number of CD271 antigens expressed on the cell membranes of different 
CD271+ populations was investigated using BD Quantibrite™ Beads (BD 
Biosciences, 340495). This experiment was carried out so that avidity effects 
could be taken into account when comparing the capture and release behaviour 
of the SH-SY5Y cell line compared to clinically-relevant populations.  
SH-SY5Y cells were cultured and harvested as described in Chapter 4: Section 
4.1.2. Cells were counted using a haemocytometer and 2.5 x 105 cells aliquoted 
per FACS tube. Cells in one tube were unlabelled, cells in a second tube were 
incubated with CD271-PE (Miltenyi Biotec, 130-113-421, 0.5 µg/mL) and cells in 
a third tube were incubated with an isotype-matched control antibody (IgG1-PE, 
BD Biosciences, 555749, 0.5 µg/mL). Cells were incubated in the dark for 10 min 
at 4 C. Cells were washed by adding 2 mL FACS buffer and centrifuged (10 min, 
300 g). The supernatant was aspirated and the cells re-suspended in 350 µL 
FACS buffer for analysis.  
The BD Quantibrite™ Beads were re-suspended in 0.5 mL FACS buffer and 
vortexed. Beads and cell events were recorded using a Cytoflex S flow cytometer 
and analysed using CytExpert software. The beads were gated according to their 
forward and side scatter and 10,000 events collected. The singlet bead 
population was analysed using a histogram plot of PE fluorescence in linear 
values. The beads consisted of four levels of PE conjugation; low beads, med-
low beads, med-high beads and high beads, producing four peaks in the 
histogram. Four gates were established around the four peaks (Figure 7.1, left 
panel) and the mean PE fluorescence value from each gate recorded. A linear 
regression was plotted of the Log10 value of the mean PE fluorescence and the 
Log10 value of the known amount of PE molecules per bead in each of the four 
categories (Figure 7.1, right panel). The mean PE fluorescence was then 
recorded for the SH-SY5Y cells and the number of PE molecules per cell 
calculated from the linear regression analysis. This method assumes there is a 
1: 1 ratio of PE molecules to monoclonal antibody. 
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Figure 7.1 Flow cytometry analysis of BD Quantibrite™ Beads  
The Quantibrite beads contained beads with four different levels of PE 
conjugation. A flow cytometry gate was drawn around the peak of each set 
of beads and the mean PE fluorescence value recorded (left panel). The 
Log10 value of the mean PE fluorescence was plotted against the Log10 
value of PE molecules per bead (information supplied with the beads)(right 
panel). The linear regression was used to calculate the number of PE 
molecules per bead for different CD271+ populations (Section 7.3.5). 
 
The same settings were applied to analyse a population of CD271bright/CD45low 
cells. The number of PE molecules per cell was also calculated for SH-SY5Y cells 
labelled with an isotype-matched control antibody and this number subtracted 
from antibody-labelled populations.  
 
7.2.6 Investigating the enrichment of CD271+ cells from clinical 
bone marrow aspirate using the prototype microfluidic device 
Using the current design of the prototype microfluidic device, BM-MNC 
populations required pre-enrichment before analysis. This was because the 
current processing capabilities of the device are limited and further device 
development is required before whole BM-MNC populations can be enriched.  
The device was prepared as described in Chapter 6: Section 6.2.5. BM-MNC 
populations were pre-enriched using MACS as described in Section 7.2.2 but with 
a longer incubation with DNase I (60 min) prior to any centrifugation steps. The 
longer incubation before any centrifugation steps eliminated cell clumping 
observed previously. CD271-enriched and CD271-depleted cell populations were 
counted and stained with calcein AM (Biotium, 30002) to allow easier 
identification above the channel background. A staining solution of 2 µM calcein 
AM was prepared in MACS buffer. Cells were washed by centrifugation (10 min, 
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300 g) and re-suspended in the staining solution for 30 min at RT. The cells were 
washed by centrifugation (10 min, 300 g) and CD271-enriched cells re-
suspended in 200 µL (the minimum loading volume of a 1 mL syringe used for 
cell suspension injection into the device). A fraction of the CD271-depleted 
population was diluted and prepared in the same volume for an equivalent 
comparison.  
Cell suspensions were injected into the device using the same protocol as 
described in Chapter 6: Section 6.2.6.1. Briefly, the cell suspension was injected 
at 100 µL/min and incubated for 2 - 5 min. Unbound cells were washed away at 
20 µL/min and the number of cells captured from each population compared. 
Photos were taken using a Hamamatsu ORCA-ER-1394 camera and analysed 
using ImageJ. For fluorescent images, the brightness and contrast were set at 
constant values for every image.   
 
7.3 Results and Discussion 
7.3.1 MACS and FACS analysis of clinical samples of bone marrow 
aspirate 
Established cell enrichment technologies - MACS and FACS - were used to 
investigate the percentage of CD271+ cells typically present in clinical bone 
marrow aspirates in these initial experiments.  
A commercially-available CD271 microbead kit (Miltenyi Biotec) was used to 
enrich CD271+ cells and the enriched population analysed using a flow cytometer 
(Section 7.2.2). An unseparated population was also analysed for comparison 
alongside the population of cells eluted from the MACS column (CD271-depleted 
population). All populations were labelled with a CD271-PE antibody (Miltenyi 
Biotec) - compatible with the CD271 microbead kit - and a CD45-FITC antibody 
(Miltenyi Biotec). A CD45 antibody was used in combination with a CD271 
antibody in order to recognise a population of CD271bright/CD45low cells which 
have been well characterised in the literature (Chapter 2: Section 2.6.2.2). 
UltraComp eBeads™ Compensation Beads (Invitrogen) were used to 
compensate for fluorescence spectral overlap and the compensation matrix 
applied to all samples. Unlabelled samples and samples labelled with isotype-
matched control antibodies were analysed alongside test samples for gating 
purposes (see Chapter 4: Section 4.5 for an example of flow cytometry gating of 
single cells).  
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The CD271 microbead kit bound 0.38 ± 0.08% of BM-MNCs with a total cell 
recovery of 46 ± 8% from the MACS column (mean ± SEM, n=3). When analysed 
by flow cytometry, it was found that an average of 4.7 ± 1.6% of the CD271-
enriched population was the desired CD271bright/CD45low cell phenotype 
(mean ± SEM, n=3), enriched on average 125-fold from the unseparated 
population (range 84-fold to 193-fold, n=3). It was also found that the 
CD271bright/CD45low population was entirely depleted from the CD271-
depleted population in all experiments. Representative flow cytometry plots from 
one experiment are shown in Figure 7.2. 
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Figure 7.2 Flow cytometry dot plots showing MACS separated BM-MNC 
populations 
Dot plots A-C show unseparated BM-MNC populations either unlabelled (A), 
labelled with isotype-matched controls (B), or labelled  with CD271-PE and 
CD45-FITC antibodies (C). Dot plot D shows the MACS BM-MNC CD271-
enriched population and dot plot E shows the MACS BM-MNC CD271-
depleted population labelled with the same CD271-PE and CD45-FITC 
antibodies. A red box gate has been drawn around the 
CD271bright/CD45low population according to the unlabelled and isotype 
control samples. In the unseparated population, 0.03% of total single cells 
are in the box, in the CD271-enriched population, 2.53% of total single cells 
are in the box and in the CD271-depleted population, 0.00% of total single 
cells are in the box (as with the unlabelled and isotype-matched controls). 
500,000 events were collected for unseparated and CD271-depleted 
populations, 200,000 events were collected for CD271-enriched 
populations.  
 
When considering the actual number of CD271bright/CD45low cells rather than 
the percentage of the total single cell population, the average number of 
CD271bright/CD45low cells in an unseparated BM-MNC sample was 50 ± 15 
cells recorded from 200,000 total events, and 2500 ± 1500 cells in the MACS BM-
MNC CD271-enriched populations (mean ± SEM, n=3 (three separate 
experiments using BM-MNCs pooled from multiple donors). This is an average 
enrichment of 50-fold. Both the percentage and number of cells must be 
considered since the number of therapeutic cells is ultimately important for a cell 
therapy however the percentage demonstrates the purity of the population. The 
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large variation in the number of CD271bright/CD45low cells between 
experiments is expected since bone marrow aspirate samples were collected 
from different donors and factors such as the total aspiration volume were not 
controlled. It has been shown that the number of CD271bright/CD45low cells 
decreases 7-fold in a second draw of bone marrow aspirate compared to the first 
(aspirated from the same location)(180). The percentages and number of 
CD271bright/CD45low cells are summarised in Table 7.2.  
 
Table 7.2 Summary of results from the initial characterisation of BM-MNCs 
using MACS enrichment and subsequent flow cytometry analysis 
Data shown represents the mean ± SEM (n=3).  
 Unseparated 
population 
CD271-
enriched 
population 
CD271-
depleted 
population 
Average 
enrichment 
factor 
Percentage of 
CD271bright/CD45low 
cells (%) 
0.04 ± 0.02 4.7 ± 1.6 0.0 ± 0.0  118-fold 
Number of 
CD271bright/CD45low 
cells (per 200,000 
events) 
50 ± 15 2500 ± 
1500 
1 ± 1 50-fold 
 
The percentage of CD271bright/CD45low events reported by Cuthbert et al. 
(2012)(180) was in the range 0.001 – 0.100% with a median value of 0.026%. 
This is in good agreement with the percentage of CD271bright/CD45low events 
recorded in this work (0.04 ± 0.02%, range 0.02 – 0.08%). Furthermore, Jones et 
al. (2006)(184) used CD271-based positive selection and reported 0.3 ± 0.1% of 
cells were in the enriched fraction with 5.2 ± 1.5% MSC purity assessed by flow 
cytometry. Again, these results are comparable to the results found in this work 
where 0.38 ± 0.08% of cells were in the enriched fraction with 4.7 ± 1.6% MSC 
purity. Interestingly, Jones et al. experienced much improved recovery rates 
compared with those achieved in this work (77 ± 17% compared to 46 ± 8%) 
which could be caused by differences in the experimental procedure such as 
incubation times, centrifugation parameters and cell counting methods. 
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7.3.2 Investigating the impact of cryopreservation on the percentage 
and number of CD271bright/CD45low cells in clinical samples 
of bone marrow aspirate 
The flow cytometry results described above confirmed that the CD271 microbead 
kit successfully enriched CD271+ cells from BM-MNCs, however, it was also 
found that the percentage of viable cells was less than 21% when analysed by 
flow cytometry (Figure 7.3, upper right panel). It was hypothesised that the reason 
for this was because the cells were thawed immediately prior to analysis with no 
in vitro culture. To test this hypothesis, a fresh sample of bone marrow aspirate 
was analysed without cryopreservation.  
It was found that when the BM-MNCs were not cryopreserved, the viability 
increased to 74% according to PI viability staining (Figure 7.3, lower right panel). 
However the increase in viability was due to the shift of one population in 
particular (marked by a red box in Figure 7.3) which appeared to become 
apoptotic after cryopreservation and thawing. Fortunately the desired 
CD271bright/CD45low population are small cells that reside in the population 
marked by an orange box in Figure 7.3, therefore the viability of 
CD271bright/CD45low cells should be largely unaffected by the cryopreservation 
process. Previous research supports this data, demonstrating that the surface to 
volume ratio of a cell has an impact on its viability after cryopreservation (267). 
This is because larger cells have a smaller transfer surface for heat and mass 
transfer, and cryopreservation with high viability depends on the ability of water 
to flow out of the cell faster than the thermal flow. If the thermal flow is equal to 
the water flow, the freezing rate will induce intracellular water crystallisation 
during the osmotic exit of water leading to cell death.  
In further support of this, the percentage of CD271bright/CD45low cells in the 
fresh sample was analysed and it was found that 0.05% of cells were the desired 
CD271bright/CD45low cells (Figure 7.4), which is within the SEM recorded from 
the thawed samples (0.04 ± 0.02%, mean ± SEM, n=3, Section 7.3.1). In contrast, 
the total number of desired cells was greater in the fresh sample compared to the 
thawed samples since there was an overall greater number of single cells in the 
fresh sample (500,000 total events collected, then gated for single cells (see 
Chapter 4: Section 4.5)). In the fresh sample there were 84 
CD271bright/CD45low cells recorded from 200,000 events compared to an 
average of 50 ± 15 from three thawed samples. This data is summarised in Table 
7.3. 
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Figure 7.3 Flow cytometry analysis of the viability of BM-MNCs in fresh and 
thawed samples 
Flow cytometry was used to assess the percentage of viable cells in 
samples of BM-MNCs when samples had been thawed or were analysed 
fresh. A gate was set according to an unlabelled sample (left-hand side) and 
compared to a sample labelled with propidium iodide (PI) viability stain 
(right-hand side). It was found that the percentage of viable cells was less 
than 21% when samples had been cryopreserved and then thawed, 
compared to 74% when samples were analysed fresh. 500,000 events were 
collected for the thawed sample and 100,000 events were collected for the 
fresh sample. The red box indicates a population of cells that became 
apoptotic after cryopreservation whereas cells in the orange box appeared 
to be unaffected by cryopreservation.  
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Figure 7.4 The percentage and number of CD271bright/CD45low cells in a 
thawed sample compared to a fresh sample of BM-MNCs 
The percentage and number of CD271bright/CD45low cells in a thawed 
sample was compared to the percentage and number in a fresh sample. 
Samples were labelled with CD271-PE antibody and CD45-FITC antibody 
and 500,000 total events were collected. There were 0.03% cells in the 
CD271bright/CD45low gate in the thawed sample shown here and 0.05% in 
the fresh sample. As well as this, due to the higher percentage of single cells 
in the fresh sample the actual number of CD271bright/CD45low cells was 
greater. The fresh sample was analysed using the same template and 
therefore the same CD271bright/CD45low gate as for the data shown in 
Figure 7.2.  
 
Table 7.3 Summary of results from fresh and thawed samples of BM-MNCs 
Data shown represents the mean ± SEM for thawed samples (n=3). Only 
one replicate was carried out with a fresh sample due to limited sample 
availability. 
 Thawed samples Fresh sample 
Percentage of 
CD271bright/CD45low 
cells (%) 
0.04 ± 0.02 0.05 
Number of 
CD271bright/CD45low 
cells (per 200,000 
events) 
50 ± 15 84 
 
In order to draw accurate conclusions from this data, further analysis of fresh 
samples would be necessary to see if there was a significant difference between 
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the percentage and number of CD271bright/CD45 low cells in thawed and fresh 
samples from a range of different donors or using donor-matched samples. 
However due to limited sample availability, further repeats with fresh samples 
were not carried out and the information gathered from this experiment is taken 
as an indication only. 
Despite this, there is evidence in the literature that supports this preliminary data 
to suggest that cryopreservation does in fact decrease the viability of BMNCs but 
does not affect their function. Yang et al. (2016)(268) observed an overall 
significant decrease in the viability of the BM-MNC population after 
cryopreservation but no significant difference in the progenitor subpopulations 
before and after cryopreservation. Moreover the beneficial effect of fresh and 
frozen BM-MNCs was comparable in an ischemic stroke model. This study and 
further studies (269, 270) verify that cryopreserved BM-MNCs maintain their 
bioactivity in vitro and in vivo and support the data shown here which suggests 
that the functional population are somewhat resistant to cryopreservation – 
possibly due to the small size of the cells. 
Although this information is important for the design of further experiments, in the 
desired application cells would be processed within the same surgery and 
therefore not cryopreserved. The fact that there may be a greater number of 
CD271bright/CD45low cells in fresh samples is beneficial for the final application 
and must be considered as this technology is progressed further.  
 
7.3.3 Comparison of the total cell recovery from MACS and FACS 
and the impact on the number of CD271bright/CD45low cells 
In the first instance, the characterisation of BM-MNCs was carried out by pre-
enriching CD271+ cells using MACS and then analysing or sorting using flow 
cytometry/FACS. However, it was noted that the percentage recovery of total 
cells from the MACS column was low (46 ± 8%) and therefore direct sorting via 
FACS could lead to a greater total cell recovery and consequently a greater 
number of CD271bright/CD45low cells collected from one experiment (avoiding 
the potential loss of cells in the MACS column). 
A direct comparison of two experiments processing a similar number of BM-
MNCs found that there was no apparent advantage of using FACS directly (Table 
7.4). The main reason for this was the fact that cell clumping hindered both 
methods equally. When cells have been exposed to freeze/thawing, 
environmental stresses can accelerate the rate of death resulting in the release 
of ‘sticky’ DNA molecules from dying cells (271). This causes the cells to clump. 
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To counteract this, endonuclease DNase I was used at a concentration of 0.1 
mg/mL in the thawing medium (with a 15 min incubation prior to MACS 
processing) and in the MACS buffer to minimise cell clumping from free DNA 
molecules.  
Although DNase I treatment reduced cell clumping, the problem was not 
eradicated entirely and filtering through a 70 micron filter was required 
immediately prior to FACS. This led to a large loss of cells from the initial cell 
count and equated to a similar final cell count to the recovered cell population 
from the MACS column (also filtered through a 70 micron filter before application 
to the MACS column; numbers highlighted in red in Table 7.4). It is therefore 
unsurprising that a similar number of CD271bright/CD45 low cells were collected 
from the two methods. If cell clumping could be eradicated further, it is possible 
that directly sorting by FACS could lead to a greater number of 
CD271bright/CD45low cells, however, at this point there was no advantage of 
sorting cells via FACS directly. For the final experiments described in this Chapter 
(Sections 7.3.6 and 7.3.8), the DNase I protocol was optimised further to include 
a longer incubation time before any centrifugation steps which eradicated cell 
clumping entirely. It would therefore be interesting to repeat this comparison with 
the optimised protocol, however this was outside the scope of this work. 
In contrast, at this time, there were several disadvantages to using FACS directly; 
to label and sort the entire population of BM-MNCs required 20 times more 
antibody and took four times longer cell sorting time compared to labelling and 
sorting a MACS pre-enriched sample. The longer processing times also 
exacerbated cell clumping issues. It was therefore decided to continue pre-
enriching CD271+ cells using MACS prior to cell sorting using FACS.  
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Table 7.4 MACS and FACS comparison for BM-MNC processing 
A comparison of two experiments processing a similar number of BM-MNCs 
using either MACS and FACS or FACS only.  
Process MACS and FACS FACS only 
Initial cell count 96,900,000 92,400,000 
(40,249,993 counted 
by flow cytometer*) 
Calculated cell recovery 
from MACS 
37% (35,853,000) N/A 
Percentage of captured 
cells (%) 
0.40 N/A 
Total number of 
CD271bright CD45low 
cells collected from 
FACS 
3524 3222 
Number of CD271bright 
CD45low cells collected 
from FACS (per 106 
cells) 
983 800 
Antibody required 8 µL 160 µL 
Time required 1 h 4 h 
*cells filtered through a 70 micron filter immediately prior to FACS causing large 
cell loss 
 
7.3.4 The clonogenic potential of CD271-enriched and depleted BM-
MNC populations 
Once a protocol had been established to enrich CD271+ cells from clinical 
samples of bone marrow aspirate, the clonogenic potential of the different 
populations was assessed via a CFU-F assay (Sections 7.1.1 and 7.2.4). The 
samples were processed in the same way as described in Section 7.2.1 then pre-
enriched using CD271 microbeads (Section 7.2.2). The enriched population was 
sorted using FACS under sterile conditions and the CD271bright/CD45low 
population collected. The CD271bright/CD45low population, the CD271-depleted 
population from the MACS column, and an unseparated population of cells were 
seeded at low densities in well plates and cultured for 14 days. On the 14th day, 
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colonies were stained with Giemsa stain and counted microscopically (Section 
7.2.4).   
It was found that in all but one case, there were no colonies present in the CD271-
depleted cell populations (n=6, where two separate experiments were carried out, 
with three technical replicates for each experiment)(Figure 7.5). This was 
significantly different to an unseparated population of cells which contained a low 
percentage of CD271+ cells (n=6 (same replicates as above); p<0.005, Figure 
7.7). In the CD271bright/CD45low population, three out of five replicates were 
enriched for CFU-F (Figure 7.6) and it was proposed that the two replicates with 
no colonies could be outliers. This was because in the first and second 
experiments (wells 1 and 2 in Figure 7.6) all the CD271bright/CD45low cells 
collected from FACS were seeded in one well and produced several colonies. 
However in the third experiment, the collected CD271bright/CD45low cells were 
seeded in triplicate (wells 3, 4 and 5 in Figure 7.6) and colonies were only visible 
in one well – the well seeded first (well 3). This could suggest that the cells were 
unevenly distributed between the wells leading to anomalous results.  
The outlying results were excluded from statistical analysis and it was found that 
CFU-F were significantly enriched in the CD271bright/CD45low population 
compared to the unseparated populations of BM-MNCs (p<0.05, n=3). On 
average, CFU-F were enriched 220-fold in the CD271high/CD45low populations 
compared to the unseparated populations. Furthermore, from a qualitative 
perspective, colonies from the CD271bright/CD45low population were typically 
larger and more dense than those from the unseparated populations (Figure 7.5 
and Figure 7.6). 
 2
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Figure 7.5 Macroscopic and microscopic images of colonies formed by unseparated and CD271-depleted BM-MNC populations 
after 14 days 
A CFU-F assay was carried out to assess the clonogenic potential of the different cell populations sorted by MACS and FACS. The 
original BM-MNC population (unseparated cells) and CD271-depleted cells from the MACS column were seeded at 50 000 cells/cm2. 
After 14 days in culture, colonies were stained with Giemsa stain and counted microscopically. Three technical replicates were carried 
out for each experiment, with two separate experiments carried out in total. BM-MNC samples from multiple donors were combined 
for each experiment.
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Figure 7.6 Macroscopic and microscopic images of colonies formed by CD271bright/CD45low cells after 14 days 
A CFU-F assay was carried out to assess the clonogenic potential of the different cell populations sorted by MACS and FACS. 
CD271bright/CD45low cells were seeded at 200 - 1600 cells/cm2. After 14 days in culture, colonies were stained with Giemsa stain 
and counted microscopically. Between one and three technical replicates were carried out for each experiment, with three separate 
experiments carried out in total. BM-MNC samples from multiple donors were combined for each experiment.
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Figure 7.7 The number of colony-forming units in enriched and depleted 
populations of CD271+ cells 
The number of colonies formed by different populations of cells sorted by 
MACS and FACS were counted microscopically and normalised according 
to cell seeding density. Significantly less colonies were found in CD271-
depleted populations compared to populations of unseparated cells (where 
CD271+ cells were present at a low percentage)(p<0.005, n=6). 
Significantly more colonies were found in CD271-enriched populations 
(CD271bright/CD45low) compared to unseparated populations of cells 
(p<0.05, n=3). Statistical analysis was carried out using a Mann Whitney U 
test since data was not normally distributed according to the Shapiro Wilk 
test of normality. Bars represent the mean values, dashed lines represent 
median values and error bars represent the SEM. 
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This data is supported by Cuthbert et al. (2012)(180), who investigated the 
clonogenic potential of CD271bright/CD45low cells and found that there was a 
linear relationship between the number of CD271bright/CD45low cells and the 
number of CFU-F. In their study, bone marrow aspirates were examined using a 
single-platform, lyse-no-wash protocol with 25 different donor samples, providing 
a robust analysis of CD271-enriched populations. In addition, Tormin et al. 
(2011)(193) reported that CFU-Fs were exclusively enriched in CD271+ 
populations when compared to CD45+ and CD271- populations.  
In this work, the availability of samples limited the number of replicates carried 
out, and cells in the CD271bright/CD45low population were seeded at densities 
as low as 200 cells/cm2. It was previously discussed that seeding at low densities 
could have lead to inaccuracies between replicates if samples were not 
homogenous, which resulted in what were assumed to be outlier results. In the 
unseparated and CD271-depleted populations, cells were consistently seeded at 
a higher density of 50,000 cells/cm2 which could be why these populations 
demonstrated more reliable results. There was one result in the CD271-depleted 
population that could be suggested as an outlier, however there was no rationale 
to exclude this result and it was still found that the number of colonies in CD271-
depleted populations was significantly different to the number of colonies in an 
unseparated population. In addition to the different seeding densities, increased 
uncertainty arises from the fact that CFU-F counting is subjective and does not 
take into account the different sizes of colonies. In the paper described above 
(180), digital measurements of total colony area were used alongside manual 
counting for a more accurate representation.  
 
7.3.5 Estimating the number of CD271 molecules (antigens) on the 
cell membranes of CD271+ cells 
Once the typical number of CD271+ cells in clinical samples of bone marrow 
aspirate had been estimated and their clonogenic potential determined, the aim 
was to investigate the feasibility of enriching these cells using the prototype 
device. One consideration before doing this was to compare the number of 
CD271 molecules (antigens) on the cell membranes of SH-SY5Y cells (used in 
Chapter 6 to optimise cell capture and release in the device) to the number of 
CD271 molecules (antigens) on the cell membranes of cells in the CD271-
enriched populations of BM-MNCs. This was important because the number of 
antigens on each cell surface could affect how the cells bind and release in the 
device. For example, a high number of antigens on the cell surface may cause 
cells to be bound more tightly to the immobilised antibody due to avidity effects. 
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To estimate the number of CD271 antigens on the different cell surfaces, BD 
Quantibrite™ Beads (BD Biosciences) were used according to the 
manufacturer’s protocol described in Section 7.2.5.  
It was found that cells in the CD271bright/CD45low population of cells had over 
75,000 CD271 antigens per cell assuming a 1:1 binding ratio of monoclonal 
antibody and conjugated PE molecules (Table 7.5). Assuming an average cell 
diameter of 16 µM (272), this estimates the density of antigens to be 93 molecules 
per µM2. The number of CD271 antigens on SH-SY5Y cells was an order of 
magnitude lower than for the CD271bright/CD45low cells, and assuming an 
average cell diameter of 12 µM (272), only 8 molecules per µM2. Although these 
numbers are only estimates, this data would appear logical since the 
CD271bright/CD45low cells display a higher fluorescence signal than SH-SY5Y 
cells. This experiment has helped provide quantitative data in this respect. To 
further confirm these estimates, additional analysis could be carried out using 
ELISA or quantitative real-time PCR, however these methods would also be 
indirect measurements of the number of CD271 molecules. 
Since the number of CD271 antigens reported here is an order of magnitude 
higher for CD271bright/CD45low cells, and 12 times more dense on the cell 
surface, it must be considered that the binding behaviour of these cells could be 
different to SH-SY5Y cells in the device and it is possible different release 
mechanisms may need to be explored. 
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Table 7.5 The number of PE molecules per cell when labelled with a CD271-
PE conjugated monoclonal antibody 
The number of PE molecules per cell was estimated using Quantibrite™ 
Beads and flow cytometry analysis. The CD271bright/CD45low population 
of cells had comparable numbers of PE molecules to the ‘high’ beads. The 
SH-SY5Y cells were comparable to the ‘med-low’ beads. The number of PE 
molecules per cell of SH-SY5Y cells labelled with an isotype control antibody 
has been subtracted from both cell populations.  
Population of cells PE molecules/cell 
CD271bright/CD45low 75861 
SH-SY5Y 3686 
Low beads 474 
Med-low beads 5359 
Med-high beads 23843 
High beads 62336 
 
 
7.3.6 Investigating the enrichment of CD271+ cells from clinical 
samples using the prototype device 
In order to assess the capture of CD271+ cells in the prototype device, BM-MNCs 
were first enriched by MACS. This was necessary due to the low numbers of 
CD271+ cells in whole BM-MNC populations and the current processing 
capabilities of the device. At this stage, the aim was to carry out proof-of-concept 
experiments with cells from clinically relevant samples, however the technology 
would need further development before being capable of processing whole bone 
marrow samples with no pre-enrichment.   
BM-MNCs were pre-enriched for CD271+ cells as described in Section 7.2.2. The 
CD271-enriched and depleted populations from MACS were both fluorescently 
labelled with a live cell stain (calcein AM) so that the low number of captured cells 
could be easily detected above background. The populations were injected into 
the device using the same protocol as described for previous experiments 
(Section 7.2.6) and a photo was taken at four different locations in the centre of 
each branched channel. The number of cells captured at each location for each 
population was compared.  
From this initial trial, no significant difference could be detected between the 
CD271-enriched and CD271-depleted populations (data not shown). This could 
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be because one image only captures the activity in approximately 1/60th of the 
channel and therefore four images still only captures the activity in approximately 
7% of the channel. Further to this, the total volume of the channels is 11 µL and 
the sample loading requires a minimum volume of 200 µL – this means that the 
population is significantly diluted and only a small proportion of the cells can be 
captured in one incubation.  
It was also noted that more non-specific binding was observed when the CD271-
depleted population was used compared to when non-specific fibroblast 
populations were used previously (Chapter 6: Section 6.3.2). Moreover, the cell 
concentrations of CD271-enriched and CD271-depleted populations were 
considerably different as the CD271-enriched population from MACS typically 
consisted of between 200,000 and 400,000 cells whereas the CD271-depleted 
population consisted of between 60 million and 80 million cells. In these initial 
experiments the CD271-depleted population was diluted to a concentration of 20 
million cells/mL according to the optimised protocol in Chapter 6: Section 6.3.3.2. 
However, if non-specific binding is proportional to the number of cells present, 
having considerably different cell concentrations could obscure results. In further 
trials, the CD271-depleted population was diluted to a cell concentration 
comparable to that of the CD271-enriched population (Section 7.3.8).  
 
7.3.7 Optimising a device protocol for the enrichment of CD271+ 
cells from clinical samples using a cell line model 
To develop a protocol which may be able to show a more accurate representation 
of CD271-enriched and CD271-depleted populations in the device, modelling of 
CD271-enriched and CD271-depleted populations was carried out using mixtures 
of SH-SY5Y (CD271+) and fibroblast (CD271-) cells used during the optimisation 
of cell capture and release (Chapter 6: Section 6.3.4). From previous experiments 
carried out in Section 7.3.1, it was expected that in a pre-enriched population of 
BM-MNC CD271+ cells from MACS, there would be between 1000 and 6000 
CD271+ cells and approximately 200,000 non-specific cells (see Figure 7.2, 
panel D for flow cytometry analysis of a pre-enriched population of BM-MNC 
CD271+ cells). Therefore 1000 – 6000 SH-SY5Y cells were mixed with 200,000 
fibroblast cells and compared to CD271-depleted populations of 200,000 
fibroblast cells only.  
Two trials were carried out using the model populations; the first used repeat 
injections of the cell suspension to enable analysis of a greater total volume of 
the sample, and the second approach involved taking images of the entire 
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channel surface area to gain a more accurate assessment of the number of 
captured cells. The results from these trials are described in Section 7.3.7.1 and 
7.3.7.2. 
 
7.3.7.1 Trial one: model CD271-enriched and CD271-depleted populations 
with repeat injections  
The model CD271-enriched population in trial one had 5000 SH-SY5Y cells and 
195,000 fibroblast cells. The model CD271-depleted population had 200,000 
fibroblast cells. The model populations were loaded into a 1 mL syringe in 200 µL 
volumes and injected 10 µL at a time. Each injection was incubated for 2 minutes 
before unbound cells were washed away at 20 µL/min. The subsequent cell 
suspension injections were also injected at 20 µL/min to ensure that already 
captured cells were not released from the channel surface. Photos were taken at 
four different locations (in the centre of each branched channel, as in Section 
7.3.6) after each buffer wash, and the number of cells compared after one 
injection with images acquired after subsequent injections.  
For the model CD271-enriched population, it was found that the cells captured in 
each image ranged from zero to three cells after one injection (Figure 7.8, top 
panel). If the cell suspension was truly homogenous, the number of SH-SY5Y 
cells in one image would be expected to be four or five cells after one incubation 
(25,000 SH-SY5Y cells/mL, 275 SH-SY5Y cells in 11 µL injection volume, four or 
five cells in 1/60th of the channel). Since cells at low concentrations are unlikely 
to be homogenous and due to the inherent error associated with manual cell 
counting, it would be reasonable to suggest the cells observed were in the 
expected range.  
After seven injections, the number of cells captured in each image ranged from 
two to four cells. Although there was a slight increase observed after seven 
injections it was not of the order expected. The largest increase was observed in 
channel 1 – from zero to four cells. This was because after the first incubation, 
the cell suspension of the subsequent cell injection was no longer evenly 
distributed between the four channels. Using the current design of the prototype 
device, a short incubation period is necessary for cells to interact with the channel 
surface. In these circumstances, the incubation with no flow causes cells to also 
sediment in the inlet tubing which affects the distribution of cells when injected 
into the channels. For these reasons, it was decided that repeat injections were 
not an efficient way to analyse CD271-enriched populations in the device at this 
time. 
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For the model CD271-depleted population, it was found that after seven injections 
no cells were captured in the four locations of the channel analysed (Figure 7.8, 
bottom panel). In contrast to the initial trials using BM-MNC CD271-enriched and 
depleted populations, there was a difference observed between model CD271-
enriched and depleted populations with respect to the number of cells captured. 
This supported the hypothesis that the greater amount of non-specific binding 
observed originally (described in Section 7.3.6), could have been obscured due 
to the higher cell concentrations of CD271-depleted populations.    
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Figure 7.8 Model CD271-enriched and CD271-depleted populations were 
analysed using repeated injections into the prototype device 
Model CD271-enriched and CD271-depleted populations were mixed using 
SH-SY5Y cells as CD271+ cells and fibroblasts as non-specific cells. The 
model populations were injected 10 µL at a time for the total available 
volume of sample. In the CD271-enriched population, several cells were 
captured and remained bound to the channel surface throughout repeated 
injections. In channels 1 and 4, the number of cells captured increased with 
the number of injections however this was not observed in channels 2 and 
3. No cells were observed to be captured in the CD271-depleted population. 
All cells are indicated by a red arrow and one image is missing due to 
experimental error. 
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7.3.7.2 Trial two: model CD271-enriched and CD271-depleted populations 
with assessment of entire channel surface area 
The results from trial one (described above) suggested that repeated injections 
were not feasible using the current device design due to cell sedimentation. An 
alternative approach to assess a larger volume of sample was therefore used, 
which was to take photos of the entire surface area of the channel after one 
incubation period. This allowed a more accurate assessment of cell numbers 
given that only 7% of the channel was assessed in previous protocols. 
Two model CD271-enriched populations were investigated in trial two; one with 
2500 SH-SY5Y cells and 200,000 fibroblast cells, and a second with 4000 SH-
SY5Y cells and 200,000 fibroblast cells. These numbers were chosen according 
to the mean and SEM values recorded from three experiments carried out in 
Section 7.3.1, and should result in approximately 138 and 220 cells in the channel 
after one incubation, respectively. The model CD271-depleted population 
comprised of 200,000 fibroblast cells only. Model populations were fluorescently 
labelled as previously described for trial one. The populations were injected into 
the device at 100 µL/min, incubated for 5 min and then unbound cells washed 
away at 20 µL/min. Once all unbound cells had been washed away, photos were 
taken of the entire channel surface area. 
For the CD271-enriched population with 2500 SH-SY5Y cells, it was found that 
ten cells were captured after one incubation (Figure 7.9). For the CD271-enriched 
population with 4000 SH-SY5Y cells it was found that 45 cells were captured after 
one incubation. This means there was a factor of 4.5 difference between the 
number of cells captured from the two model CD271-enriched populations where 
in theory there should have only been a factor of 1.6 difference. In addition, the 
number of cells bound was 14-fold and 5-fold lower than expected according to 
the initial cell concentration injected. It was discussed previously that there are 
inherent issues with manual cell counting and the accuracy of processing low 
numbers of cells that could lead to unexpected results. Further repeats and a 
range of different cell concentrations would need to be analysed to gather more 
reliable quantitative data.   
Importantly, as in trial one, there was a difference observed between the model 
CD271-enriched populations and the model CD271-depleted population. For the 
CD271-depleted population there were five cells in total captured, however three 
of the cells were attached to debris present in the channel (indicated by a red 
dashed box in Figure 7.11). It was therefore decided to use the protocol from trial 
two to analyse clinical samples of BM-MNC CD271-enriched and depleted 
populations. 
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Figure 7.9 Assessment of entire channel surface area after injection of a 
model CD271-enriched population with 2500 SH-SY5Y cells 
A model CD271-enriched population was mixed using 2500 SH-SY5Y cells 
and 200,000 fibroblast cells. Ten microlitres of cell suspension was injected 
and incubated for 5 minutes. After the unbound cells were washed away, 
photos were taken of the entire channel surface area. 10 cells were captured 
in total, marked by red arrows. The top image shows the channel using 
bright field microscopy and the bottom image shows the same view using 
fluorescence microscopy. Cells were stained with a live cell stain (calcein 
AM) to allow easier identification.  
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Figure 7.10 Assessment of entire channel surface area after injection of a 
model CD271-enriched population with 4000 SH-SY5Y cells 
A model CD271-enriched population was mixed using 4000 SH-SY5Y cells 
and 200,000 fibroblast cells. Ten microlitres of cell suspension was injected 
and incubated for 5 minutes. After the unbound cells were washed away, 
photos were taken of the entire channel surface area. 45 cells were captured 
in total, marked by red arrows. The top image shows the channel using 
bright field microscopy and the bottom image shows the same view using 
fluorescence microscopy. Cells were stained with a live cell stain (calcein 
AM) to allow easier identification. 
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Figure 7.11 Assessment of entire channel surface area after injection of a 
model CD271-depleted population 
The model CD271-depleted population consisted of 200,000 fibroblast cells. 
Ten microlitres of cell suspension was injected and incubated for 5 minutes. 
After the unbound cells were washed away, photos were taken of the entire 
channel surface area. Five cells were captured in total however three cells 
were attached to debris in the channel – marked by the dashed red box. 
Captured cells are marked by a red arrow. The top image shows the channel 
using bright field microscopy and the bottom image shows the same view 
using fluorescence microscopy. Cells were stained with a live cell stain 
(calcein AM) to allow easier identification. 
7.3.8 Using the optimised device protocol to assess BM-MNC 
CD271-enriched and CD271-depleted populations 
BM-MNCs were processed as described in Section 7.2.6 and the CD271-
enriched population obtained using MACS. The CD271-enriched population was 
centrifuged, counted and re-suspended in a volume of 200 µL for injection into 
the prototype device. The CD271-depleted population (after MACS separation) 
was centrifuged, counted and diluted to a concentration of 1 million cells/mL in 
200 µL (200,000 cells in 200 µL – comparable to the number of cells in the 
CD271-enriched population from MACS). A third population was prepared in 
which 4000 SH-SY5Y cells were spiked into 200,000 cells from the CD271-
depleted population. This population represented the model CD271-enriched 
population used in Section 7.3.7.2 however with a more accurate representation 
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of non-specific cells. Of course it is important to remember that the model 
populations may not behave in the same way as the BM-MNC populations due 
to the differing number of CD271 molecules on the cell surface (Section 7.3.5). 
However, the model populations provide additional data required since the 
availability of clinical samples was limited.  
It was found that there was a greater number of cells captured in the SH-SY5Y 
spiked population (Figure 7.12) and the BM-MNC CD271-enriched population 
(Figure 7.13) than the BM-MNC CD271-depleted population (Figure 7.14). As 
was previously observed, there was more non-specific binding than when using 
fibroblast cells however when the cell concentrations were normalised there was 
still a clear difference between BM-MNC CD271-enriched and depleted 
populations. The result from trial two (Section 7.3.7.2) and the results from this 
experiment are summarised and compared in Table 7.6. 
The percentage of cells captured in each population was estimated by 
approximating the total number of cells in the channel during the five minute 
incubation period, and comparing this to the number of cells captured after the 
20 µL/min buffer wash. The total number of cells in the channel during the 
incubation period was calculated by: 
1. Counting the number of cells in four representative images from each 
repeat (12 images in total) 
2. Calculating an average from the 12 images (17 ± 2, mean ± SEM) 
3. Multiplying the average by 60 (60 images taken for entire surface area of 
the channel) 
This calculation resulted in an approximation of 1000 ± 90 cells in the channel 
during the five minute incubation period (mean ± SEM, n=12). The percentage of 
cells captured after a 20 µL/min buffer wash could then be estimated. From three 
repeats including two model CD271-enriched populations and one BM-MNC 
CD271-enriched population, the percentage of cells captured was 5.9 ± 1.0%. 
When the number of ‘non-specific’ cells captured from the model CD271-depleted 
and BM-MNC CD271-depleted populations was subtracted from the CD271-
enriched populations, the percentage of cells captured was 4.1 ± 0.6%. These 
numbers are in good agreement with the percentage of CD271bright/CD45low 
cells identified in three sterile FACS repeats (4.7 ± 1.6%)(Table 7.6).
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Figure 7.12 Assessment of entire channel surface area when a BM-MNC CD271-depleted population spiked with 4000 SH-SY5Y 
cells was injected into the prototype device 
A MACS separated BM-MNC CD271-depleted population was spiked with 4000 SH-SY5Y cells and injected into the prototype device. 
After a 5 min incubation, unbound cells were washed away at 20 µL/min and photos were taken of the entire channel surface area. 
Cells were stained with a live cell stain (calcein AM) to enable detection above the channel background and bound cells are marked 
with red arrows. The BM-MNC CD271-depleted population spiked with 4000 SH-SY5Y cells was injected at 1 million cells/mL and the 
number of cells captured (normalised to cell concentration) is reported in Table 7.6.
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Figure 7.13 Assessment of entire channel surface area when a BM-MNC CD271-enriched population of cells was injected into the 
prototype device 
A MACS separated BM-MNC CD271-enriched population was injected into the prototype device. After a 5 min incubation, unbound 
cells were washed away at 20 µL/min and photos were taken of the entire channel surface area. Cells were stained with a live cell 
stain (calcein AM) to enable detection above the channel background and bound cells are marked with red arrows. The BM-MNC 
CD271-enriched population was injected at 1.9 million cells/mL and the number of cells captured (normalised to cell concentration) is 
reported in Table 7.6.
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Figure 7.14 Assessment of entire channel surface area when a BM-MNC CD271-depleted population was injected into the 
prototype device 
A MACS separated BM-MNC CD271-depleted population was injected into the prototype device. After a 5 min incubation, unbound 
cells were washed away at 20 µL/min and photos were taken of the entire channel surface area. Cells were stained with a live cell 
stain (calcein AM) to enable detection above the channel background and bound cells are marked with a red arrow. The BM-MNC 
CD271-depleted population was injected at 1 million cells/mL and the number of cells captured (normalised to cell concentration) is 
reported in Table 7.6. 
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Table 7.6 Summary of results using model CD271-enriched and depleted 
populations and BM-MNC CD271-enriched and depleted populations in the 
prototype device and compared with FACS 
Row  Repeat 1: 
model 
CD271-
enriched 
population 
(Section 
7.3.7.2) 
Repeat 2: 
SH-SY5Y 
spiked BM-
MNC 
CD271-
depleted 
population 
(Section 
7.3.8) 
Repeat 3: 
BM-MNC 
CD271-
enriched 
population 
(Section 
7.3.8) 
Mean ± 
SEM 
(n=3) 
1 Number of cells 
captured from 
enriched population* 
44 55 77 N/A 
2 Number of cells 
captured from 
depleted population* 
2 26 N/A 
3 Row 1 – Row 2 42 29 51 41 ± 6 
5 Percentage of cells 
captured including all 
cells (%) 
4.4 5.5 7.7 5.9 ± 1.0 
4 Percentage of cells 
captured excluding 
‘non-specific’ cells (%) 
4.2 2.9 5.1 4.1 ± 0.6 
5 Percentage of 
CD271bright/CD45low 
cells sorted by sterile 
FACS 
   4.7 ± 1.6 
* Number of cells normalised to cell concentration of 1 million cells/mL 
 
Although the data presented here is based on cell counts only, it has provided an 
early indication of the efficacy of the prototype device using clinically relevant 
populations. From this data it appears that the prototype device captures a similar 
percentage of cells to the percentage of CD271bright/CD45low cells identified by 
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sterile FACS from pre-enriched BM-MNC populations. It must however be noted 
that the method has made multiple assumptions and does not include the errors 
associated with these assumptions. The numbers processed by the prototype 
device need to be greatly increased for a more accurate assessment and to allow 
collection of cells post-enrichment.  
From this preliminary experiment it was found that the cells could be released 
from the antibody-functionalised surface by increasing the flow rate (as previously 
found in Chapter 6: Section 6.3.2 for SH-SY5Y CD271+ cells) however it was not 
possible to elucidate what flow rate would be most suitable with the small number 
of cells captured. In Section 7.2.5, it was estimated that the number of CD271 
antigens on the surface of CD271bright/CD45low cells was an order of magnitude 
higher than for SH-SY5Y cells and therefore higher flow rates may be required 
for the release of cells. Some of the cells captured in this experiment released at 
lower flow rates (<1 mL/min), however to release all cells higher flow rates were 
required (>1 mL/min). Analysis of a greater number of cells is required to optimise 
the release of CD271bright/CD45low cells in the prototype device.  
Post-enrichment analysis of CD271bright/CD45low cells would also need to be 
carried out to ensure that if higher flow rates are required, it does not affect the 
viability or function of cells. Fluidic force has been commonly used for cell 
detachment however there are concerns that the shear stress involved could 
result in cell damage (273). The effects of flow acceleration on cancer cell lines 
adhered to functionalised surfaces was explored by Cheung et al. (2009)(274). 
They found that low acceleration resulted in significant cell deformation, however 
there was negligible deformation under high flow acceleration. It has also been 
found that shear stress can change the cell microenvironment; Wang et al. 
(2005)(275) investigated the relationship between shear stress and endothelial 
differentiation of an murine embryonic cell line, and Chowdhury et al. (2010)(276) 
demonstrated that cell softness dictates the stress-induced spreading of mouse 
embryonic stem cells and could drive the differentiation of cells.  
In this work, post-enrichment analysis was carried out on a SH-SY5Y 
neuroblastoma cell line (Chapter 6: Section 6.3.6) which included assessing the 
viability and proliferation capacity of cells enriched in the device. Here it was 
found that there were no detrimental effects of cell detachment via increased flow 
rates, however, it was previously discussed that more in-depth analysis is 
required to confirm this. Whilst utilising shear stress to detach cells has the 
advantages of being simple and inexpensive, more sophisticated methods could 
result in less harmful methods of detachment. 
Alternative methods have been explored for MSC detachment including; 
temperature-sensitive polymers (277), light-sensitive polymers (278) and 
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electrochemical harvesting and bulk pH decrease on polyelectrolyte monolayers 
(279). Some of the data reported in Chapters 5 and 6 suggested pH-mediated 
release could be used as a release mechanism; pH mediated release was 
observed in SPR analysis of SH-SY5Y cells on a CD271 antibody-functionalised 
surface (Chapter 6: Section 6.3.1.1) and pH-mediated release of Affimers was 
used during phage display selection of CD271-specific Affimers (Chapter 5: 
Section 5.3.1.2). Although there were no CD271-specific Affimers established in 
this work, aptamers such as Affimers have the potential to be selected with 
specific properties which could aid the detachment of cells. Zhu et al. (2012)(280) 
used surface-immobilised aptamers to capture a leukaemia cell line which could 
then be released by a moderate increase in temperature.  
At this time, increased flow rates were used to detach cells from the channel 
surface however as the device is developed further, more work will be required 
to assess if this is the most suitable method of detachment.   
 
7.4 Conclusions 
In this chapter of work, the previously optimised prototype device has been 
evaluated with clinical samples of bone marrow aspirate. The overall aim of the 
device is to be able to enrich a population of cells that could be used in cell 
therapies. A CD271bright/CD45low population of cells has been well 
characterised in the literature and has been shown to have high clonogenic and 
multipotent potential (see Chapter 2: Section 2.6.2.2). The device was therefore 
designed to capture CD271+ cells in an antibody-functionalised microfluidic 
channel. This concept allows controlled fluid flow to wash away undesired cells 
resulting in a therapeutic population of cells with higher purity.  
Clinical bone marrow aspirates were supplied with informed consent from 
patients undergoing orthopaedic surgery, and MACS and FACS were used to 
characterise the CD271bright/CD45low cell population. The percentage and 
number of CD271bright/CD45low cells in BM-MNC populations was very low and 
therefore different protocols were investigated to demonstrate the efficacy of the 
prototype device. At this stage, only preliminary data has been collected, limited 
by the availability of clinical samples and the low number of CD271+ cells. To 
progress this technology further, a number of considerations must be taken into 
account; the number of cells required for cell therapies, the throughput 
capabilities of the device, different sources of MSCs and the possibility of a hybrid 
microfluidic technology. Each of these considerations are discussed in detail in 
Chapter 8.  
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Chapter 8: Future work and thesis conclusions 
8.1 Considerations for future work 
8.1.1 The number of cells required for MSC therapies 
To progress this technology further, the total number of cells required to have a 
clinically beneficial effect in any MSC therapy must be considered, and currently, 
this number is largely unknown. Chapter 2: Section 2.2 summarises the results 
from recent clinical trials to treat a number of different diseases in which the 
number of MSCs used varies from 106 to 108 million cells/mL with no consensus 
on what constitutes an effective dose. Furthermore, these trials use cells that 
have been expanded in vitro or have been concentrated using density gradient 
centrifugation. They therefore comprise of a heterogeneous population of cells 
with unknown therapeutic effect.  
Hernigou et al. (2005)(3) used density gradient centrifugation to concentrate bone 
marrow aspirate for treatment of non-union fractures in 60 patients. They found 
that successful treatments contained an average of 55,000 MSCs (calculated by 
extrapolation of CFU-F results) compared to an average of 19,000 MSCs for 
patients where bone union was not obtained. This study provided an indication of 
the number of MSCs required for the treatment of non-union bone fractures, 
however, a large volume of aspirate was taken from patients (300 mL) and only 
a small fraction of this was assessed for CFU-F potential. This method could 
therefore inaccurately predict the number of MSCs injected into the fracture site.  
In 2018, two studies were published by Petters et al. (4, 5) investigating the use 
of CD271-selected MSCs as a single stage treatment (without prior in vitro 
expansion of cells) for cartilage repair. Recognising the potential of intraoperative 
therapies, Petters first investigated different biomarkers for isolating CFU-Fs from 
ovine bone marrow and then used the population isolated by the defined marker 
to generate a cartilage graft consisting of clinically approved collagen type I 
hydrogel and the non-expanded MSC population (4). They found that CD271 was 
the most effective marker and that CD271-selected cells were capable of 
producing a cartilage graft comparable to a heterogeneous population of 
unseparated BM-MNCs - despite the fact that the CD271-selected cells were 
seeded at a significantly reduced volume (6.25% of the volume used for 
unseparated BM-MNCs). The actual number of CD271-positive MSCs seeded in 
the graft was reported as 4207, demonstrating that a minimal number of CD271+ 
cells were able to populate the graft with viable cells with adequate chondrogenic 
potential. The authors discussed that enriching the CD271 subset of MSCs 
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depletes non-chondrogenic differentiable cells and results in a usable volume of 
cells (4). 
In the second study, the same cartilage grafts were investigated however using 
human bone marrow rather than ovine bone marrow (5). Here it was found that 
at the final time point (day 35) the number of cells in the CD271+ graft was 2.2-
fold higher than in grafts with unseparated BM-MNCs, even though the CD271+ 
grafts were originally seeded with 4% of the cells that were seeded for 
unseparated BM-MNCs (9000 cells per graft vs. 225,000 cells per graft). The 
sulphated glycosaminoglycan (sGAG) content (present in cartilage tissue) was 
also higher in CD271+ grafts compared to unseparated BM-MNC grafts. The 
greater chondrogenic potential of CD271-selected MSCs was also reported by 
Mifune et al. (2013)(281) in both in vitro and in vivo studies however these cells 
were culture-expanded after CD271-selection.  
The studies suggest that if pre-enriched, non-expanded cells are used for MSC 
therapies, the number of cells required is in the thousands rather than the 
millions. Further in vivo proof of concept studies are required for CD271-selected 
cell therapies which could clarify the ideal cell dose.  
 
8.1.2 Increasing the throughput of the device for clinical application 
Evidently, to enrich cell numbers on this scale, the throughput of the device must 
be increased. Currently only a small fraction of the cell suspension was able to 
be analysed in the device due to the laborious methods involved. The most 
effective way to analyse the number of cells captured was to photograph the 
entire surface area of the channel which still resulted in the identification of less 
than 150 cells. The volume of the current channel is 11 µL in total and the 
minimum reliable loading volume (due to sample injection from a 1 mL syringe) 
is ~200 µL. Therefore in one incubation, only ~5% of the cell suspension was 
being analysed. If repeat injections could be successfully employed then the 
number of cells captured could be increased to 1000’s rather than 100’s.  
The current limitation of repeated injections was the fact that the cells sedimented 
during the incubation period in the absence of flow. This meant that the cell 
distribution was not homogenous and led to an inefficient method of cell capture. 
If a mixing mechanism was incorporated into the device, repeat injections would 
become feasible and allow for easier methods of analysis. A mixing mechanism 
could be incorporated where the flow continued in a sample loop away from the 
microfluidic channel so cells remained in a homogenous suspension and were 
available for repeat injections.  
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Moreover, if cell capture could be achieved under continuous flow conditions it 
would be of even greater benefit. Chueng et al. (2009)(274) reported that 
‘although difficult’, it was possible to capture moving cancer cells at low flow rates 
(1 µL/min) in an N-cadherin antibody-functionalised channel, however the capture 
efficiency was ~50% compared to almost 100% when a 5 min incubation with no 
flow was used. Cell capture at low flow rates was not observed in this work 
however with some channel modifications this could become a possibility. To 
improve the capture efficiency of microfluidic devices, microstructures such as 
microposts, micropillar and herringbones mixer have been designed such that the 
flow is changed from streamlined to chaos or vortex (282). This increases the 
contact frequency between cells and the functionalised substrates leading to a 
higher capture efficiency. It must however be noted that increasing contact 
frequency between cells and functionalised substrates could also compromise 
purity due to a greater amount of non-specific binding. The efficiency and purity 
of various devices with incorporated microstructures are discussed below.  
Nagrath and colleagues (283) describe the capture of circulating tumour cells 
(CTCs) on a chip with an array of microposts functionalised with anti-epithelial-
cell-adhesion-molecule (EpCAM) antibodies. At a flow rate of 1-2 mL/hour the 
capture efficiency was 65% with a purity of approximately 50%. Improved capture 
efficiencies have been reported in similar devices – Gleghorn et al. (2010)(284) 
used staggered obstacle arrays that optimised CTC-wall interactions and 
reported a capture efficiency of 85% with 68% purity. Finally, a capture efficiency 
as high as 98% was found by Sheng et al. (2012)(285) who also investigated 
properties such as channel depth as a factor of capture efficiency. They found 
that as the channel depth was increased the capture efficiency decreased, 
however a decreased channel depth compromised purity.  
The decreased capture efficiency was observed to be due to the reduced 
interactions between the cells and the aptamer-functionalised channel top and 
bottom, and the decreased purity was observed to be due to the geometric 
trapping of non-specific cells in channels with a smaller channel depth. For 
example, the channel with the greatest depth (44 µM) had a capture efficiency of 
~92% and a purity of ~80% compared with the smallest channel depth (24 µM) 
which had a capture efficiency of ~98% with a purity of ~20% - clearly 
demonstrating the compromise between capture efficiency and purity with 
increased contact frequency, either due to non-specific capture or trapping of 
cells. 
In devices comprising of herringbones mixers; a study compared the capture 
efficiency of CTCs using a flat device or a herringbones mixer device and found 
that the capture efficiency was <8% in the flat device at 0.48 mL/hour and a 
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maximum of ~30% at the lowest flow rate applied (0.12 mL/hour), compared with 
~40% and ~80% for the herringbones device respectively (286). The 
herringbones device was then enlarged for use with clinical samples and 
compared to a micropost-based device. The herringbones device was still found 
to have superior capture efficiency - ~26% higher than the micropost-based 
device – however both devices achieved purities of <15%. Another herringbones 
device reported 90-92% capture efficiency of CTCs at flow rates as high as 3.6 
mL/hour (287). In this study a high purity of 84% was achieved whilst maintaining 
the capture efficiency of ~90% by increasing the width of herringbone grooves to 
avoid cell trapping. To avoid the complicated microfabrication steps involved in 
the above devices, Cheng et al. (2016)(288) created a 3D scaffold chip fabricated 
from PDMS and found that at flow rates less than 6 mL/hour there was more than 
90% capture efficiency but there was no information on the population purity. 
Affinity-based capture in microfluidic devices has been widely explored for the 
capture of CTCs due to the fact that CTCs ubiquitously express EpCAM and 
blood cells do not, providing a specific biomarker for CTC isolation. There are no 
reports of microfluidic devices with antibody-based capture for MSCs perhaps 
owing to the fact that there is no consensus on a specific biomarker for MSCs. In 
this work CD271 was chosen due to a significant amount of literature evidence 
showing that this biomarker isolates a subset of MSCs with high clonogenic 
potential (Chapter 2: Section 2.6.2.2). However different strategies could be 
explored using this platform technology and the most effective population of 
MSCs for MSC therapies is not yet known.  
A device developed to capture circulating plasma cells (CPCs) in multiple 
myeloma used the plasma cell biomarker CD138 (253). Using a herringbones 
mixer device it was reported that the capture efficiency was between 40–70% 
depending on parameters such as flow rate, antibody concentration and cell 
suspension. The purity was also low at 1–5% necessitating CD138 staining after 
capture for an accurate analysis of CPCs present. This demonstrates the 
challenges involved using different biomarkers and the requirement for 
optimisation in each case. The capture efficiency of the device described in this 
thesis was found to be ~70% for target populations greater than 25% however 
~20% for target populations less than 25% (Chapter 6: Section 6.3.4.1). The 
purity was consistently high at 80 ± 3% for populations higher than 6% initial 
target cell concentration (lower percentage target populations were not 
assessed). With further optimisation of the capture efficiency at lower target cell 
concentrations, this device shows great potential for enriching a high purity MSC 
subpopulation.   
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If the device and protocols could be developed to capture a greater number of 
cells, the throughput could be further optimised by increasing the number of 
parallel channels. In this work the throughput was increased 4.8-fold by changing 
the channel design (Chapter 6: Section 6.3.5.2) therefore this is a relatively 
simple way to reduce the time taken for enrichment, with the final aim to enrich 
cells within an intraoperative timeframe.  
 
8.1.3 Investigating different sources of MSCs to increase the 
number of CD271+ cells available for capture 
Whilst increasing the throughput of the device is essential, the percentage of 
CD271bright/CD45low cells in BM-MNC populations is inherently low. To gain a 
larger therapeutic population of cells, different sources of MSC could be explored. 
Adipose tissue has been suggested as a rich source of MSCs where 1–10% of 
the stromal fraction are MSCs (289). In a comparison of bone marrow and 
adipose tissue it was found that approximately 11% of the stromal vascular 
fraction of adipose tissue (AT-SVF) was CD271+ compared to 2% in BM-MNCs 
(290). However, CFU-Fs were only enriched in the CD271-enriched BM-MNCs 
not the CD271-enriched AT-SVF population. On further analysis it was 
established that a subset of cells with high proliferative and clonogenic abilities 
could be isolated by CD271 selection from adipose tissue however only from 
lipoaspiration samples not abdominoplasty samples.   
Another study investigated the relationship between donor age and CD271 
expression of adipose tissue-derived mesenchymal stem cells (AT-MSCs) from 
cosmetic liposuction patients (191). Here it was found that there was a negative 
correlation with age however even the average lowest proportion of CD271+ cells 
(1.8% for ages 51-65) was higher than that typically found in BM-MNC 
populations. No CFU-F assessment was carried out in the study. In a comparison 
of foetal and adult MSCs from different sources, there was an average of 8.4% 
CD271+ cells from AT-MSCs and 3.7% in BM-MNCs (291). Unfortunately, CFU-
F analysis was reported as adult versus foetal MSCs therefore no direct 
comparison between BM-MNCs and AT-MSCs. Altogether, the evidence does 
suggest a higher proportion of CD271+ cells in adipose tissue removed by 
lipoaspiration, however whether these cells have the same clonogenic potential 
as CD271+ cells from BM-MNCs needs to be confirmed.   
Furthermore, the cryopreservation process was not optimised in this work, which 
was speculated to cause a significant decrease in viability of BM-MNCs (Chapter 
7: Section 7.3.2). The detrimental effects were not able to be fully established 
however it was hypothesised that immediate processing of cells would lead to a 
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higher number of CD271+ cells in BM-MNC populations. Differences in 
membrane permeability and surface to volume ratio causes cells to have varying 
responses to cryopreservation leading to differences in viability when thawed 
(292). This highlights the necessity of protocol optimisation for different cell types.  
 
8.1.4 Developing a hybrid microfluidic technology  
Finally, a microfluidic device based on affinity capture to enrich a specific 
population of MSCs is likely to always require pre-processing steps. In this work, 
the red blood cells were lysed to obtain a mononuclear cell fraction and CD271+ 
cells were pre-enriched from the mononuclear cell fraction using MACS 
technology. The aim of this novel device is to overcome limitations associated 
with MACS such as the attachment of magnetic microbeads and lengthy pre-
labelling steps, therefore this would not suffice as a pre-processing step.  
Instead, the aim is to develop a hybrid microfluidic technology incorporating a 
high throughput, less specific pre-processing step in the first stage of the device 
and a highly specific, affinity-based capture in the second stage of the device. A 
hybrid technology such as this would provide a high purity population of MSCs in 
an enclosed and portable device suitable for use within an operating theatre.  
The proposed technology for the first stage of the device is currently being 
developed within this research group. Smith et al. (2017)(293) describe the 
development of surface acoustic wave–dielectrophoresis (SAW-DEP) technology 
which combines acoustophoresis (a density-based separation method) and 
dielectrophoresis (a separation method based on the dielectric properties of a 
cell) in order to overcome the limitations of each individual method and provide a 
rapid, label-free cell separation method. In the publication the separation of viable 
and non-viable dental pulp stem cells was demonstrated using a SAW-DEP 
device with throughput of 104 cells/minute (293). Current work has increased this 
throughput further and is working towards the separation of individual cell types 
from whole blood. This technology would provide an ideal method of pre-
enrichment in the first stage of a hybrid microfluidic device.  
 
8.2 Thesis conclusions and summary 
In conclusion to this thesis, each of the objectives described in Chapter 3 have 
been completed and the research aim has been achieved. During the completion 
of objective 1 (Section 3.2.1), an appropriate binding molecule for affinity-capture 
of CD271+ cells was established, as well as the identification of a cell line model 
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for use during the proof-of-concept stages of development. These aspects were 
essential to achieving the research aim; reliable and highly specific binding of 
CD271+ cells is fundamental to enriching a population of cells with high purity, 
and since the number of CD271+ cells in clinical samples is extremely low, 
optimising cell capture and release in the device using clinical samples would 
have posed an extraordinary challenge.  
During the completion of objective 2 (Section 3.2.2), a prototype microfluidic 
device was designed and fabricated, and it was discovered that the device could 
effectively capture CD271+ cells from mixed cell populations. Through several 
device iterations, cell capture and release was optimised and allowed the 
collection of enriched CD271+ cell line populations. Post-enrichment analysis 
suggested that cells remained viable, able to proliferate under normal cell culture 
conditions, and had no antibody attached to the cell surface post-release – a 
significant advantage compared to current affinity-based cell sorting methods.  
Finally, the completion of objective 3 (Section 3.2.3) evaluated the feasibility of 
capturing CD271+ cells from clinical samples of bone marrow aspirate. It was 
found that the device captured a comparable number of cells to the number of 
CD271+ cells found in typical bone marrow aspirates analysed using established 
cell sorting methods. This was a significant step towards demonstrating clinical 
utility and progressing the device towards commercialisation.  
In summary, this technology is in the early stages of the development process, 
initial proof-of-concept has been demonstrated using a cell line, and preliminary 
data with clinical samples indicates it is a viable method to enrich CD271+ cells. 
Further development of the device to enable repeat injections into the device, or 
capture under continuous flow, would allow a clinically relevant number of cells 
to be collected for MSC therapies. This technology could be combined with a 
high-throughput microfluidic technology to provide a novel, rapid, highly specific 
and minimally manipulative method of stem cell enrichment. 
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Appendix A: KingFisher Flex Protocol 
“Phage_Display_Competition” 
Protocol Step Plate Volume 
(µL) 
Settings 
Tipcomb  96 deep well tip 
comb 
  
Pick-Up: 
Tipcomb 
KingFisher 96 KF 
plate 
  
Collect Beads Plate: Binding 
Microtiter deep 
well 96 plate 
 Collect count 1 
Collect time (s) 1 
Binding Plate: Binding 
Microtiter deep 
well 96 plate 
300 Beginning of Step 
Release beads [hh:mm:ss]: 
00:00:00 
Mixing/Heating Parameters 
Mix time [hh:mm:ss]: 
00:00:10 
Speed: fast 
Mix time [hh:mm:ss]: 
01:00:00 
Speed: slow 
End of step 
Collect beads, count: 5 
Collect time (s): 30 
Wash 1 Plate: Wash 1 
Microtiter deep 
well 96 plate 
950 Beginning of Step 
Release beads [hh:mm:ss]: 
00:00:00 
Mixing/Heating Parameters 
Mix time [hh:mm:ss]: 
00:01:00 
Speed: slow 
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End of step 
Collect beads, count: 5 
Collect time (s): 30 
Wash 2 Plate: Wash 2 
Microtiter deep 
well 96 plate 
950 Beginning of Step 
Release beads [hh:mm:ss]: 
00:00:00 
Mixing/Heating Parameters 
Mix time [hh:mm:ss]: 
00:01:00 
Speed: slow 
End of step 
Collect beads, count: 5 
Collect time (s): 30 
Wash 3 Plate: Wash 3 
Microtiter deep 
well 96 plate 
950 Beginning of Step 
Release beads [hh:mm:ss]: 
00:00:00 
Mixing/Heating Parameters 
Mix time [hh:mm:ss]: 
00:01:00 
Speed: slow 
End of step 
Collect beads, count: 5 
Collect time (s): 30 
Wash 4 Plate: Wash 4 
Microtiter deep 
well 96 plate 
950 Beginning of Step 
Release beads [hh:mm:ss]: 
00:00:00 
Mixing/Heating Parameters 
Mix time [hh:mm:ss]: 
00:01:00 
Speed: slow 
End of step 
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Collect beads, count: 5 
Collect time (s): 30 
Particle Release Plate: pH elution 
KingFisher 96 KF 
plate 
100 Beginning of Step 
Release beads [hh:mm:ss]: 
00:00:10 
Speed: Fast 
Leave: Tipcomb 96 deep well tip 
comb 
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Appendix B: KingFisher Flex Protocol 
"Phage_Display_Wash_Elute" 
Protocol Step Plate Volume 
(µL) 
Settings 
Tipcomb  96 deep well tip 
comb 
  
Pick-Up: 
Tipcomb 
KingFisher 96 KF 
plate 
  
Collect Beads Plate: Binding 
Microtiter deep 
well 96 plate 
 Collect count 1 
Collect time (s) 1 
Binding Plate: Binding 
Microtiter deep 
well 96 plate 
300 Beginning of Step 
Release beads [hh:mm:ss]: 
00:00:00 
Mixing/Heating Parameters 
Mix time [hh:mm:ss]: 
00:00:10 
Speed: fast 
End of step 
Collect beads, count: 5 
Collect time (s): 30 
Wash 1 Plate: Wash 1 
Microtiter deep 
well 96 plate 
950 Beginning of Step 
Release beads [hh:mm:ss]: 
00:00:00 
Mixing/Heating Parameters 
Mix time [hh:mm:ss]: 
00:01:00 
Speed: slow 
End of step 
Collect beads, count: 5 
Collect time (s): 30 
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Wash 2 Plate: Wash 2 
Microtiter deep 
well 96 plate 
950 Beginning of Step 
Release beads [hh:mm:ss]: 
00:00:00 
Mixing/Heating Parameters 
Mix time [hh:mm:ss]: 
00:01:00 
Speed: slow 
End of step 
Collect beads, count: 5 
Collect time (s): 30 
Wash 3 Plate: Wash 3 
Microtiter deep 
well 96 plate 
950 Beginning of Step 
Release beads [hh:mm:ss]: 
00:00:00 
Mixing/Heating Parameters 
Mix time [hh:mm:ss]: 
00:01:00 
Speed: slow 
End of step 
Collect beads, count: 5 
Collect time (s): 30 
Wash 4 Plate: Wash 4 
Microtiter deep 
well 96 plate 
950 Beginning of Step 
Release beads [hh:mm:ss]: 
00:00:00 
Mixing/Heating Parameters 
Mix time [hh:mm:ss]: 
00:01:00 
Speed: slow 
End of step 
Collect beads, count: 5 
Collect time (s): 30 
pH Elution Plate: pH elution 100 Beginning of Step 
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KingFisher 96 KF 
plate 
Release beads [hh:mm:ss]: 
00:00:00 
Mixing/Heating Parameters 
Mix time [hh:mm:ss]: 
00:07:30 
Speed: slow 
Post mix[hh:mm:ss]: 
00:00:05 
Speed: Bottom mix 
End of step 
Collect beads, count: 5 
Collect time (s): 30 
Triethylamine 
Elution 
Plate: 
Triethylamine 
KingFisher 96 KF 
plate 
100 Beginning of Step 
Release beads [hh:mm:ss]: 
00:00:00 
Mixing/Heating Parameters 
Mix time [hh:mm:ss]: 
00:03:30 
Speed: slow 
Post mix[hh:mm:ss]: 
00:00:05 
Speed: Bottom mix 
End of step 
Collect beads, count: 5 
Collect time (s): 30 
Leave: Tipcomb 96 deep well tip 
comb 
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Appendix C: KingFisher Flex Protocol 
“Phage_Display_Standard” 
Protocol Step Plate Volume 
(ul) 
Settings 
Tipcomb  96 deep well tip 
comb 
  
Pick-Up: 
Tipcomb 
KingFisher 96 KF 
plate 
  
Collect Beads Plate: Binding 
Microtiter deep 
well 96 plate 
 Collect count 1 
Collect time (s) 1 
Binding Plate: Binding 
Microtiter deep 
well 96 plate 
300 Beginning of Step 
Release beads [hh:mm:ss]: 
00:00:00 
Mixing/Heating Parameters 
Mix time [hh:mm:ss]: 
00:00:10 
Speed: fast 
Mix time [hh:mm:ss]: 
01:00:00 
Speed: slow 
End of step 
Collect beads, count: 5 
Collect time (s): 30 
Wash 1 Plate: Wash 1 
Microtiter deep 
well 96 plate 
950 Beginning of Step 
Release beads [hh:mm:ss]: 
00:00:00 
Mixing/Heating Parameters 
Mix time [hh:mm:ss]: 
00:01:00 
Speed: slow 
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End of step 
Collect beads, count: 5 
Collect time (s): 30 
Wash 2 Plate: Wash 2 
Microtiter deep 
well 96 plate 
950 Beginning of Step 
Release beads [hh:mm:ss]: 
00:00:00 
Mixing/Heating Parameters 
Mix time [hh:mm:ss]: 
00:01:00 
Speed: slow 
End of step 
Collect beads, count: 5 
Collect time (s): 30 
Wash 3 Plate: Wash 3 
Microtiter deep 
well 96 plate 
950 Beginning of Step 
Release beads [hh:mm:ss]: 
00:00:00 
Mixing/Heating Parameters 
Mix time [hh:mm:ss]: 
00:01:00 
Speed: slow 
End of step 
Collect beads, count: 5 
Collect time (s): 30 
Wash 4 Plate: Wash 4 
Microtiter deep 
well 96 plate 
950 Beginning of Step 
Release beads [hh:mm:ss]: 
00:00:00 
Mixing/Heating Parameters 
Mix time [hh:mm:ss]: 
00:01:00 
Speed: slow 
End of step 
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Collect beads, count: 5 
Collect time (s): 30 
pH Elution Plate: pH elution 
KingFisher 96 KF 
plate 
100 Beginning of Step 
Release beads [hh:mm:ss]: 
00:00:00 
Mixing/Heating Parameters 
Mix time [hh:mm:ss]: 
00:07:30 
Speed: slow 
Post mix[hh:mm:ss]: 
00:00:05 
Speed: Bottom mix 
End of step 
Collect beads, count: 5 
Collect time (s): 30 
Triethylamine 
Elution 
Plate: 
Triethylamine 
KingFisher 96 KF 
plate 
100 Beginning of Step 
Release beads [hh:mm:ss]: 
00:00:00 
Mixing/Heating Parameters 
Mix time [hh:mm:ss]: 
00:03:30 
Speed: slow 
Post mix[hh:mm:ss]: 
00:00:05 
Speed: Bottom mix 
End of step 
Collect beads, count: 5 
Collect time (s): 30 
Leave: Tipcomb 96 deep well tip 
comb 
  
 
